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Abstract 
The lipid-modifying qualities of nicotinic acid, a B3 vitamin, have been exploited for 
many years to prevent cardiovascular disease and its associated mortality. Despite its 
widespread availability and clinical use, the clinical target and precise molecular 
mechanism by which nicotinic acid acts remains elusive. In order to maximise 
nicotinic acid’s full potential as a lipid-modulating drug, overcome its related side 
effects and further develop novel and more potent drugs it is vital to understand its 
molecular mechanism of action. Fifty years on from its arrival on the market, 
receptors which this drug acts upon have recently been identified as the G protein-
coupled ‘nicotinic acid receptors’. 
A family of three highly homologous receptors, HM74, HM74A and GPR81 are 
characterised by their differing affinities for nicotinic acid. Comparison of these 
homologues revealed a high degree of similarity between them, with the greatest 
similarity between HM74 and HM74A.  The main structural difference between these 
receptors is the longer C-terminal tail of HM74. As the C-terminal tail of GPCRs is 
often implicated in receptor regulation it was hypothesised that the differences in this 
region may result in differential regulation of HM74 and HM74A. This hypothesis 
was tested by examining the regulation and desensitisation characteristics of each 
receptor in a heterologous expression system. Both HM74 and HM74A failed to 
interact with β-arrestin 2 or internalise in response to nicotinic acid. However, both 
receptors were phosphorylated in an agonist-dependent manner. HM74 but not 
HM74A was demonstrated to desensitise as result of prolonged nicotinic acid 
exposure. The importance of the C-terminal region was further analysed by the use of 
chimeric nicotinic acid receptors, in which the C-terminal tail of HM74 and HM74A 
were exchanged. It was shown that the C-terminal tail of HM74 may be implicated in 
the desensitisation characteristics of this receptor. Furthermore, it was shown that 
HM74 and HM74A display differential characteristics with respect to ERK1/2 
phosphorylation. 
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1.  Introduction 
With obesity now accepted as a global issue, the occurrence of obesity related 
diseases, such as cardiovascular diseases, have become a major concern and strain on 
health services around the world. A constant race exists amongst pharmaceutical 
companies to develop ‘miracle’ drugs to treat affected individuals, recently of all 
ages. However, in order to aid drug discovery there is an imminent need to identify 
the mechanisms of action of existing ‘successful’ drugs on the market.  
Many risk factors for cardiovascular disease have been identified, dislipidaemia, for 
example, is a condition where the plasma levels of one or more lipoproteins is 
abnormally high or low. A dislipidaemic patient most at risk from cardiovascular 
disease would likely exhibit raised levels of low density lipoprotein (LDL) cholesterol 
and triglycerides while at the same time also displaying low levels of high density 
lipoproteins (HDL). A dislipidaemic patient is also at high risk of suffering from 
atherosclerosis. Atherosclerosis is characterised by accumulation of cholesterol, other 
lipids, extracellular matrix and various inflammatory cells which results in the 
narrowing of the vessel lumen. If the atherosclerotic lesion becomes unstable it can 
lead to arterial thrombosis. High levels of LDL cholesterol are therefore a risk factor. 
However, HDL cholesterol is thought to have anti-atherogenic properties due to its 
role in reverse cholesterol transport (Lewis & Rader, 2005). 
Nicotinic acid, also known as niacin, is a B3 vitamin abundant in red meat, fish, 
poultry and green leafy vegetables. Its vitamin effects, including promoting the health 
of the nervous system, skin, hair and eyes, were demonstrated in the early 20th 
century. As little as 20 mg/day is sufficient to benefit from its vitamin properties. In 
1955 the lipid-lowering qualities of nicotinic acid were published by Altschul and 
colleagues (Altschul et al., 1955). Since its arrival on the market as the first lipid-
based intervention proven to prevent cardiovascular disease and associated mortality, 
it has been available both over the counter and by prescription in various 
formulations. When given in gram doses nicotinic acid produces many desirable 
effects in patients, such as lowering of total plasma levels of cholesterol, LDL 
cholesterol and total triglycerides and it is the only available drug that also decreases 
 21
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lipoprotein involved in cholesterol transport (Parsons, Jr. & Flinn, 1959; Altschul et 
al., 1955; Malik & Kashyap, 2003). Nicotinic acid is also known to selectively 
increase HDL cholesterol and apolipoprotein AI-only containing HDL particles (Lp 
AI) – which are believed to be implicated in reverse cholesterol transport ( Shepherd 
et al., 1979; Sakai et al., 2001). Nicotinamide, also a B-complex vitamin, however 
does not display any of these lipid-modifying qualities. These observations led to 
much more interest in the beneficial effects of nicotinic acid in humans and on going 
research into the mechanism by which this vitamin successfully modifies lipid levels 
to more favourable concentrations. The biological effects of nicotinic acid as a 
vitamin and lipid-modifying drug have been summarised in Tables 1.1 and 1.2. 
1.1.  Early studies 
Not long after the lipid-modifying effects of nicotinic acid were reported, Carlson and 
co-workers demonstrated that nicotinic acid was able to inhibit a noradrenaline-
stimulated increase in plasma levels of free fatty acid (FFA) (Carlson & Oro, 1962). 
In later studies it was shown that nicotinic acid was able to reduce FFA levels by 
inhibiting lipolysis in adipose tissue (Carlson, 1963). The uptake of nicotinic acid by 
adipose tissue was very neatly established with the use of [3H]-labelled nicotinic acid 
(Carlson & Hanngren, 1964). The mechanism by which nicotinic acid is thought to act 
has been illustrated in Figure 1.1.  
With respect to clinical studies, the Coronary Drug Project was the first study to show 
that nicotinic acid monotherapy of 3 g/day prevented cardiovascular disease and its 
associated mortality (Canner et al., 1986; Coronary Drug Project Research Group, 
1975). This study also demonstrated the long lasting effects of nicotinic acid therapy. 
Patients who had stopped taking nicotinic acid for 9 years still experienced an 11 % 
decrease in total mortality compared to those on placebo (Canner et al., 1986).  
Around this time, in the late 1980s, cholesterol synthesis inhibitors (statins) were 
introduced. Although they have been shown to effectively reduce elevated levels of 
LDL cholesterol they have only little or no effects on HDL cholesterol and 
triglyceride levels. To take advantage of nicotinic acid’s ability to increase HDL 
cholesterol levels, studies were then conducted to examine the combined use of 
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nicotinic acid with a statin called simvastin (Brown et al., 2001). The HDL 
Atherosclerosis Treatment Study (HATS) demonstrated that combined treatment was 
more beneficial than monotherapy with statin alone. Compared to placebo, a reduction 
of around 60 % in clinical cardiovascular events was recorded.  
1.2.  Introduction to nicotinic acid therapy 
As is the case with many drugs, the use of nicotinic acid is associated with side effects 
which are relatively harmless but often limit patient compliance. The so called ‘niacin 
flush’, being the prime culprit, is the flushing of the skin due to a prostaglandin D2-
mediated vaso-cutaneous reaction (Morrow et al., 1989). Flushing of the face and 
upper body can be induced within minutes of administering as little as 50 mg of 
nicotinic acid. Higher doses of 1 g of nicotinic acid can result in pronounced 
cutaneous vasodilation over the whole body lasting around half an hour. Starting in 
the upper body around the face and neck region, the patient experiences intense 
feelings of warmth and itching. It can then spread to the arms and chest and 
occasionally the legs and feet. Although this nicotinic acid-induced flushing can be 
substantially reduced by continuous treatment and/or the administration of 
cyclooxygenase inhibitors, for example aspirin, many patients discontinue their 
treatment due to severe discomfort (Kaijser et al., 1979). During the time of absence, 
the patient loses the tolerance developed to the flushing response and if treatment is 
commenced again the flushing will also develop. Although tolerance to the nicotinic 
acid-induced flushing is observed, patients do not develop tolerance to its lipid-
modifying effects. Hepatotoxicity, ranging from minor elevation in liver enzymes to 
hepatic necrosis and death, is another complication associated with nicotinic acid 
treatment. Other reported side effects include gastrointestinal upset (such as 
heartburn, indigestion, nausea, diarrhoea and stomach pain) and hyperuricemia 
(McKenney, 2004).  
Early studies indicated that nicotinic acid treatment was not safe for diabetic patients. 
It had been reported that diabetic patients were at risk of developing insulin resistance 
as a result of long-term treatment (Kahn et al., 1989; Garg & Grundy, 1990). An 
initial increase in FFA levels following nicotinic acid treatment was blamed for the 
insulin resistance. However, recent studies are now concluding that when given in 
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moderate doses under strict monitoring, nicotinic acid is not only safe but also 
effective in diabetic patients (Elam et al., 2000; Grundy et al., 2002).  
The severity of these niacin-induced side effects depends greatly on the specific 
formulation given to patients. These formulations fall under three categories outlined 
below (McKenney, 2004; Mills et al., 2003). 
Unmodified/Immediate Release 
Available over-the-counter, immediate release nicotinic acid has been used 
therapeutically for 50 years in doses as high as 12 g a day. For optimum effects this 
formulation needs to be taken three times a day. Unmodified niacin is often associated 
with higher occurrences of skin flushing, gastrointestinal symptoms and elevated 
blood glucose levels.  
Modified/Sustained Release 
Originally designed to reduce flushing in patients, this formulation is metabolised 
slowly. It has been associated with liver toxicity and hence abandoned in clinical 
trials. 
Extended Release 
Available by prescription for a single daily dose, the absorption rate of this 
formulation is an intermediate of the two previously described forms. It is associated 
with fewer episodes of flushing, gastrointestinal symptoms and hepatotoxicity. 
1.3.  Nicotinic acid: Molecular mechanism of action? 
As statins do not display the side effects associated with nicotinic acid, statins were 
widely welcomed by medical practitioners and nicotinic acid therapy was largely 
‘neglected’. However, unlike nicotinic acid, statins have no effect on elevated levels 
of Lipoprotein (a) (Lpa) or low levels of HDL. With increasing awareness of the 
importance of the levels of different lipids in plasma as risk factors for cardiovascular 
disease, the past few years has witnessed a new interest in this vitamin. 
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Despite the widespread availability and clinical use of nicotinic acid, the exact 
mechanism by which it acts is not fully understood. In order to maximise the full 
potential of nicotinic acid as a lipid-modulating drug, overcome niacin-related side 
effects and further develop novel and more potent drugs to treat cardiovascular 
disease, it is vital to elucidate the molecular mechanism of action of nicotinic acid. 
This has only become possible with the recent identification of the G protein-coupled 
nicotinic acid receptors as the molecular target for nicotinic acid (Soga et al., 2003; 
Tunaru et al., 2003; Wise et al., 2003). 
 25
Sanam Mustafa, 2008  
 
 
Nicotinic acid   
Use Vitamin 
Physiological role 
precursor for NAD+, 
NADP+ 
Anti-dislipidaemic drug 
Pharmacological use 
Required dose > 15 – 20 mg/day in the 
diet 
500 – 2000 mg/day 
Required plasma level 100 – 400 nM 4 -16 μM 
Peak concentration: 50 – 300 
μM 
Nicotinamide Equivalent to nicotinic 
acid as a vitamin 
No anti-dislipidaemic effects 
Table 1.1 Summary of the biological effects of nicotinic acid 
Abbreviations: NAD, nicotinamide adenine dinucleotide (major electron acceptor in 
the oxidation of fuel metabolites; NADP, nicotinamide adenine dinucleotide 
phosphate. Table adapted from (Offermanns, 2006).  
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Lipid/Lipoprotein Effects on plasma concentrations 
VLDL ↓ 25 – 40 % 
LDL cholesterol ↓ 6 – 22 % 
HDL cholesterol ↑ 18 -35 % 
Total cholesterol ↓ 4 – 16 % 
Triglyceride ↓ 21 – 44 % 
Lipoprotein Lp(a) ↓ 16 – 36 % 
Table 1.2 Effects of nicotinic acid on plasma concentrations of lipids and lipoproteins 
The above effects are summarised for nicotinic acid treatment in excess of 1.5 g/day. 
VLDL, very low density lipoprotein. Table adapted from (Gille et al., 2008). 
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Nicotinic acid 
Figure 1.1 Proposed mechanism of nicotinic acid action 
Plasma FFA act as precursors of liver triglycerides which in turn are precursors for 
VLDL and so forth as illustrated above. By inhibiting FFA mobilisation in adipocytes, 
nicotinic acid is thought to reduce the flow of FFA into the liver. This reduces the 
synthesis of VLDL and therefore also LDL. Figure adapted from (Carlson, 2005). 
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1.4.  Introduction to G protein-coupled receptors 
G protein-coupled receptors (GPCRs) make up the largest family of cell-surface 
receptors. By responding to a vast array of stimuli, known as ligands, such as sensory 
messages (photons and odours) and messenger molecules (lipids, nucleotides, and 
peptides), GPCRs allow cells to communicate with each other and their surroundings 
(Kristiansen, 2004). As their name suggests, these receptors transduce extracellular 
signals via guanine nucleotide binding proteins (G proteins) to intracellular effectors. 
Widely expressed in the human body, GPCRs are implicated in a wide range of 
disease pathways including pain, arthritis, cancer and schizophrenia (Lundstrom, 
2006). It is estimated that 50 % of all drugs on the market regulate GPCR function, of 
which 30 % directly target GPCRs (Jacoby et al., 2006). Despite this, however, out of 
the 800 or so receptors that make up this superfamily, drugs directed at these 
receptors act on approximately only 30 receptors (Wise et al., 2004). This knowledge, 
taken together with their diverse physiological and pathological roles, highlights the 
potential for drug discovery in this field. 
1.4.1. Brief history 
Although physiological techniques had been used to study the effects of drugs on 
receptors since the early 20th century, the understanding of receptors as discrete 
molecular entities did not exist until the development of radioligand binding studies in 
the late 1960s. The first such pioneering studies demonstrated the binding of [3H] 
atropine to endogenously expressed muscarinic receptors in guinea-pig ileum smooth 
muscle (Paton & Rang, 1965). Despite this, the existence of molecular receptors was 
only widely accepted when purified and reconstituted β2-adrenergic receptor was 
demonstrated to respond to catecholamines in systems not normally responsive to β-
adrenergic agonists (Cerione et al., 1983). The eventual cloning of hamster β2-
adrenergic receptor revealed sequence and structural homology to rhodopsin, a seven 
transmembrane spanning light receptor protein that resides inside cell membranes of 
retinal rod cells (Dixon et al., 1986). Homology approaches were then adopted to 
clone several members of the GPCR family. For example, low stringency Southern 
blotting utilising β2-adrenergic receptor cDNA as a probe identified the first orphan 
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receptor (a receptor with an unknown function and/or ligand) (Kobilka et al., 1987). 
This receptor was later recognised as 5-HT1A, the first serotonin receptor to be cloned 
(Fargin et al., 1988). In an independent attempt, again employing the  β2-adrenergic 
receptor as a probe in low stringency hybridization experiments, rat dopamine D2 
receptor was isolated (Bunzow et al., 1988). Thereafter, rapid progress in the search 
for new GPCRs was the result of the exploitation of the relatively new PCR 
technology. DNA probes were designed to conserved sequences in the third and sixth 
transmembrane domains of cloned GPCRs (Libert et al., 1989). In a similar approach 
the use of degenerate primers, based on the dozen or so receptors cloned by then, 
allowed the cloning of a large family of olfactory receptors (Buck & Axel, 1991).  
1.4.2. GPCR classification 
Members of the GPCR superfamily can be divided into five major subfamilies, which 
show considerable sequence conservation within members of one family but not 
between families. The major differences between the GPCR subfamilies are the 
variability in the length and function of the N-terminus and the location of the ligand-
binding domain. The GPCR superfamily can be divided into the following five 
groups/families (Lagerstrom & Schioth, 2008). 
1.4.2.1.  Rhodopsin family/class A 
The Rhodopsin family is the largest of the GPCR superfamily. Although members of 
this family contain residues that are highly conserved, the primary structure is diverse.   
Conserved motifs, E/DRY (Glu/Asp-Arg-Tyr) motif in TM III and the D/NPXXY 
(Asp/Asn-Pro-X-X-Tyr) motif in TM VII, are hallmarks of receptors belonging to this 
family. Class A receptors also often contain cysteine residues which form a disulphide 
bond connecting the first and second extracellular loops. 
These receptors characteristically have short extracellular N-terminal tails and for this 
reason are primarily activated by interactions between the ligand and the TM regions 
and the extracellular loops. Based on their ligand binding properties, class A receptors 
can be further sub-divided into four groups. Group Aα is composed of GPCRs with 
small ligands, such as rhodopsin and the β–adrenergic receptors, which have binding 
sites within the seven transmembrane region. Peptide-binding receptors form group 
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Aβ. Ligands bind to these receptors at the N-terminal tail or the extracellular loops. 
Receptors in group Aγ bind to peptides and lipid-like compounds and include opioid, 
angiotensin and chemokine receptors. The final group, Aδ, contain nucleotide- and 
glycoprotein-binding receptors and are characterised by large extracellular domains 
containing the ligand binding sites. 
1.4.2.2. Secretin receptor family/class B 
A family of around 15 receptors, they share a similar morphology to class A receptors 
but generally have a larger extracellular N-terminal tail which is involved in ligand 
binding. The N-terminal region of these receptors contains several cysteine residues 
which form a network of disulphide bridges. These receptors are activated by high 
molecular weight peptide hormones such as glucagon and secretin. 
1.4.2.3.  Adhesion receptor family/class B 
The second largest GPCR family with 33 members is characterised by long N-
terminus regions. The endogenous ligands for many receptors from this family are not 
known. However, the few deorphanised receptors bind extracellular matrix molecules. 
1.4.2.4.  Glutamate receptor family/class C 
The smallest family of GPCRs contains metabotropic glutamate receptors, GABA-B 
receptors, calcium sensing receptors and the sweet and umami taste receptors. These 
receptors are characterised by a long N-terminus tail, which folds to incorporate a 
separate ligand-binding domain.  
1.4.2.5.  Frizzled/Taste2 receptors 
This group includes the frizzled/smoothened receptors that are known to be involved 
in embryonic development. The 25 bitter taste receptors also belong to this family of 
receptors and can be further divided due to the sequence diversity between the 
receptors. 
1.4.3. GPCR structure 
Insight into the structure of GPCRs can aid understanding of the mechanisms of 
ligand binding and receptor activation. This knowledge can then be exploited to 
 31 
Sanam Mustafa, 2008  
 
design novel ligands but also to predict novel receptor binding sites. However, due to 
the inherent flexibility of GPCRs, especially in the third intracellular loop, these 
receptors are difficult to crystallise. Until recently the only high resolution crystal 
structure, at 2.8 Å, available was for bovine rhodopsin in its inactive state (Palczewski 
et al., 2000). In 2007, published reports presented two crystal structures of the human 
β2-adrenergic receptor (Cherezov et al., 2007; Rasmussen et al., 2007; Rosenbaum et 
al., 2007). The third intracellular loop was stabilised by either binding to an antibody 
fragment, Fab5, (Rasmussen et al., 2007) or by replacing it with T4 lysozyme, a small 
soluble protein (Cherezov et al., 2007; Rosenbaum et al., 2007). In both cases, 
carazolol, an inverse agonist was also present. As carazolol only suppresses around 50 
% of basal activity of β2-adrenergic receptor, the crystal structures therefore do not 
represent a fully active or inactive receptor.  
Crystal structures confirmed data generated from hydrophobicity analysis and 
electron microscopy that GPCRs share a heptahelical structure where a single 
polypeptide chain spans the membrane seven times, resulting in an extracellular N-
terminus and an intracellular C-terminus. The seven transmembrane helices (TM I – 
TM VII) vary in length and are linked by three alternating intracellular (ICL) and 
extracellular loops (ECL), as shown in Figure 1.2. From sequence homology of 
members of the GPCR family, it is clear that TM domains are the most highly 
conserved regions amongst GPCRs. Unsurprisingly, the extra- and intracellular 
regions are more divergent as these domains allow the receptors to interact with a 
myriad of structurally different ligands and couple to different intracellular effectors 
respectively.  
When viewed from the extracellular surface, the seven helices are arranged in an 
anticlockwise manner and although TM IV and VI are roughly perpendicular to the 
membrane, due to the presence of certain amino acids such as prolines, the remaining 
helices are slightly tilted and kinked. This results in the receptor being split into three 
functional domains; an extracellular region for ligand binding, an intracellular region 
for intracellular interactions and a linking region in between the two allowing signal 
transduction (Madabushi et al., 2004). Within the transmembrane region, the C-
terminal end of TM III contains a highly conserved DRY motif which has been 
implicated in the stabilisation of the inactive state by allowing the formation of an 
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‘ionic lock’ between R135 (R in DRY motif) and E247 in TM VI (Ballesteros et al., 
2001). The constitutive activity of β2-adrenergic receptor may be partly due to the 
absence of the ‘ionic lock’ observed in the rhodopsin crystal structure. The NPXXY 
motif which is highly conserved in TM VII has also been shown to be important in 
stabilising the inactive state of the receptor by allowing TM VII to interact with TM 
VI. 
From the rhodopsin crystal structure, the extracellular domain forms a compact 
structure, often referred to as a ‘lid’. It is thought this plays a role in preventing rapid 
dissociation of rhodopsin’s ligand (Sakmar, 2002; Palczewski, 2006). However, with 
respect to the β2-adrenergic receptor, the crystal structure obtained suggests a more 
open conformation allowing it to interact with diffusible ligands. The extracellular 
loops of rhodopsin also contain two conserved cysteine residues which form a 
disulphide bond stabilising the receptor structure. Virtually all GPCRs possess one or 
more N-linked glycosylation sites (Asn-X-Ser/Thr) in the extracellular region, where 
X can be any amino acid except proline or asparagine (Kristiansen, 2004). For several 
GPCRs, prevention of glycosylation results in reduced cell surface expression of the 
receptor but has a limited effect on ligand binding or the function of the receptors that 
are successfully delivered to the cell surface (Davidson et al., 1995; Ray et al., 1998).  
The intracellular domains of GPCRs display flexibility allowing these regions to 
undergo conformational changes following receptor activation and interact with 
various intracellular effectors. Due to this high degree of flexibility this region is 
poorly defined in the crystal structures. However, studies have shown that the serines 
and threonines in this region can form recognition sites for protein kinases and 
therefore play a role in receptor regulation.  
1.4.4. GPCR oligomerisation 
In the past few years a new phenomenon of GPCR dimerisation/oligomerisation has 
been described. Challenging traditional models of GPCRs as monomeric signalling 
units, initial evidence supporting oligomerisation was obtained over twenty-five years 
ago but largely ignored (Salahpour et al., 2000). These experiments typically reported 
the identification of molecular species with molecular mass consistent with the 
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presence of dimers not monomers. These results were overlooked until 1993 when 
Maggio and co-workers explored this idea further. Complementation experiments 
were set up using two chimeric α2-adrenergic–m3-muscarinic receptors which when 
expressed alone failed to induce any signals. However, when expressed together 
agonist-dependent activation of phospholipase C was detected (Maggio et al., 1993). 
This observation was explained by intermolecular interactions between the two 
mutant receptors.  
The discovery by different groups that the GABAb receptor was in fact a heterodimer 
of two distinct subunits, GABAbR1 and GABAbR2, further strengthened the faith of 
followers of the dimerisation theory (Jones et al., 1998; Kaupmann et al., 1998; White 
et al., 1998). It was shown that the GABAbR1 subunit was unable to bind ligand or 
traffic to the cell surface when expressed in a heterologous system due to the presence 
of an endoplasmic reticulum retention motif identified within the C-terminal tail of 
the GABAbR1. The interaction of GABAbR1 with the C-terminal tail of the 
GABAbR2 subunit masks the retention signal, allowing the heterodimer to be 
exported and trafficked to the cell surface (Margeta-Mitrovic et al., 2000; Pagano et 
al., 2001). The importance of heterodimerisation for receptor function was 
demonstrated in studies with mutant GABAbR1 subunits that displayed cell surface 
expression (Margeta-Mitrovic et al., 2000). These subunits were not functional 
despite expression at the plasma membrane. 
Despite the generation of experimental evidence supporting dimerisation, there are 
many sceptics among the scientific community who dismiss the results as artefacts. 
Concerns are mainly due to the shortcomings of the experimental techniques used to 
detect dimerisation. For example, co-immunoprecipitaton is a biochemical technique 
commonly used to detect protein-protein interactions between two differentially 
tagged receptors. Both tagged receptors are expressed in a single heterologous 
expression system and cell lysates are prepared. Using an antibody specific to one tag, 
one receptor is immunoprecipitated and the resulting samples are analysed by 
immunoblotting with a primary antibody to detect the second tag. Immunoreactivity 
suggests the presence of both receptors, possibly as a dimer. This detection method 
has been criticised as the high levels of receptors expressed and also the hydrophobic 
nature of GPCRs may cause artificial aggregation. For example, Salim and colleagues 
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reported that the 5-HT-1A receptor interacted with any GPCR it was co-expressed with 
(Salim et al., 2002). Although negative controls have been developed, where lysates 
prepared from cells separately expressing each tagged receptor are mixed prior to 
immunoprecipitation, critics argue over the use of recombinant systems with high 
levels of expressed receptors and not native tissues.  
Addressing the issue of using heterologous systems, atomic force microscopy was 
used to investigate the organisation of rhodopsin in native mouse disc membranes 
(Fotiadis et al., 2003; Liang et al., 2003). These studies showed the rhodopsin 
receptors arranged in an oligomeric array of closely packed dimers, as shown in 
Figure 1.3. However, these results have also been challenged. Firstly, it was argued 
that the tissue chosen for this study naturally expresses the rhodopsin receptor at very 
high densities, so therefore it can be argued that close proximity does not necessarily 
mean there are any physical interactions between the receptors. Also, Chabre and co-
workers have argued that the oligomer-like arrangements seen by Fotiadis’ and 
Liang’s research groups are due to the segregation of proteins and lipids at low 
temperatures (Chabre et al., 2003). They strongly dismiss the results as rows of 
proteins packed in partially ordered microcrystalline arrays and refer back to the 
original X-ray crystal structure determined by Palczewski and colleagues, which gave 
no indication of rhodopsin existing as a dimer (Palczewski et al., 2000).  
GPCR dimerisation with other GPCRs or unrelated receptors has the potential to 
make a significant contribution to the diversity and specificity of GPCR signalling.  
As there is a divide in the scientific community with regards to the existence of 
higher-order oligomeric complexes, much more research is needed in this field before 
any firm conclusions can be made firstly about their authenticity and then their 
functional significance.  
1.4.5. Introduction to G proteins and classical signal 
transduction 
Upon ligand binding, the cytoplasmic domain of the receptor undergoes a 
conformational change; rotation of TM VI uncovers the G protein binding sites 
causing it to acquire a high affinity for G proteins (Javitch et al., 1997). Consisting of 
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three separate polypeptides, these heterotrimeric G proteins are made up of highly 
conserved α, β and γ subunits. Based on sequence homology of the Gα subunit, G 
proteins are typically divided into four main classes; Gi/0, Gs, Gq/11, G12/13. In the 
inactive state, the guanine diphosphate (GDP) bound α subunit is tightly associated 
with the βγ complex. The GPCR acts as a guanine nucleotide exchange factor and 
promotes the release of GDP from the α subunit, which is then replaced with guanine 
triphosphate (GTP). Historically the exchange of GDP for GTP was thought to result 
in the dissociation of the α subunit from the β and γ subunits. However, fluorescence 
resonance energy transfer (FRET)-based studies have suggested that a conformational 
re-arrangement, not a separation, of the α and βγ subunits may occur (Bunemann et 
al., 2003). These subunits are then able to associate with various effectors, such as 
adenylyl cyclase, phospholipase C, calcium (Ca2+) and potassium (K+) channels, to 
transduce the signal from the receptor. G protein subunits and their effectors have 
been summarised in Figure 1.4. The intrinsic GTPase activity of the α subunit 
terminates this signalling cascade by hydrolysing GTP back to GDP and re-uniting the 
α subunit with the βγ complex, thus completing the cycle, as shown in Figure 1.5 
(Brink et al., 2004). This GTP-GDP exchange is accelerated by proteins known as 
regulators of G protein signalling (RGS). RGS proteins are defined by a so called 
RGS domain which binds directly to activated Gα subunits to enhance their intrinsic 
GTPase activity (Berman et al., 1996; Hollinger & Hepler, 2002). More than 30 RGS 
and RGS-like proteins have been identified and, based on amino acid sequence and 
protein structure, can be divided into six distinct families. 
1.4.6. Regulation of GPCR signalling 
Many mechanisms have evolved for regulating receptor signalling. These mechanisms 
can operate at the level of the GPCR, G protein or further down the signalling 
cascade. For example, as mentioned previously, the RGS proteins involved in halting 
signals that have already been generated, provide a negative regulatory mechanism.  
1.4.6.1.  Desensitisation of GPCR signalling 
At the receptor level, one of the most studied regulatory mechanisms is 
desensitisation. As a result of prolonged or repeated exposure to an agonist, signal 
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transduction can be either completely or partially abolished. This prevents the 
receptor from over-stimulating and is important in both physiological and 
pharmacological settings. Desensitisation can be classed as either homologous or 
heterologous. Homologous desensitisation refers to the situation where only the 
activated GPCR is desensitised, whereas in heterologous desensitisation, activation of 
one GPCR can lead to the desensitisation of other unrelated and often inactivated 
GPCRs. Many mechanisms of desensitisation exist, however GPCR phosphorylation 
plays a crucial role in the classical model of desensitisation (Krupnick & Benovic, 
1998).  
GPCR phosphorylation by second messenger-dependent protein kinases such as 
cAMP-dependent protein kinase A (PKA) and protein kinase C (PKC) were regarded 
as the principal mechanisms of receptor desensitisation (Benovic et al., 1985). It was 
only when the β2-adrenergic receptor was shown to be phosphorylated in cells lacking 
functional PKA that the existence of other relevant kinases was acknowledged 
(Strasser et al., 1986). This led to the identification of β-adrenergic receptor kinase (β-
ARK), which was later renamed G protein-coupled receptor kinase (GRK) 2 (Benovic 
et al., 1986). 
GRKs are a family of serine/threonine protein kinases which preferentially 
phosphorylate residues of the third intracellular loop or C-terminal domain of agonist-
occupied receptors. It is thought agonist binding causes the receptor to undergo a 
conformational change, unmasking the substrates for phosphorylation (Pitcher et al., 
1998). The seven members of this family can be grouped into subfamilies based on 
sequence and functional similarities (Pitcher et al., 1998). The first group, comprising 
of GRK 1 and 7, are found exclusively in retinal rods and cones, respectively. They 
regulate rhodopsin and the colour opsins. The second group consists of GRK 2 and 3. 
These GRKs are distributed throughout the body and are responsible for 
phosphorylating a variety of receptors. Finally, GRK4, 5 and 6 make up the last 
subfamily. GRK4 is expressed at significantly high levels in testes and is the only 
GRK known to date that undergoes alternative splicing (Sallese et al., 1994). GRK5 is 
expressed at high levels in the heart, lung and retina. GRK6 is widely expressed 
throughout the body. Generally GRKs are considered to be cytosolic proteins, 
however both GRK5 and 6 are constitutively associated with membranes through 
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various mechanisms. For example, electrostatic interactions are thought to play a role 
in membrane association of GRK5, but in the case of GRK6, palmitoylation of the 
kinase is necessary (Stoffel et al., 1994; Kunapuli et al., 1994; Premont et al., 1994). 
GRKs are made up of three domains, where the catalytic domain is flanked by two 
regulatory domains (Figure 1.6). The N-terminal region is thought to be important for 
recognition and binding of the activated receptor and the C-terminal domain is 
responsible for interacting with inositol phospholipids and the Gβγ subunit of G 
proteins (Inglese et al., 1993). It is thought that the cytosolic proteins are recruited to 
the plasma membrane, at least partly, by the disassociated Gβγ subunits (Daaka et al., 
1997b). 
In the classical model of desensitisation, phosphorylation by GRK marks the receptor 
for further desensitisation by arrestin proteins. However, recently GRK2 and 3 have 
been reported to mediate phosphorylation-independent desensitisation of Gq coupled 
GPCRs. By binding to both the GPCR and Gq protein it prevents the receptor and G 
protein from interacting (Ferguson, 2007). It is also worth mentioning that arrestins 
can associate in an agonist-dependent manner with receptors that are not 
phosphorylated. This was first demonstrated in a study where phosphorylation 
deficient leukotriene B4 receptors were able to interact with β-arrestin and hence were 
desensitised and internalised (Jala et al., 2005).  
Arrestins are a class of soluble proteins, which also play an important role in 
regulating receptor signaling. The evolutionary conservation of the arrestins in all 
mammals highlights their importance as ‘housekeeping’ proteins (Miller & 
Lefkowitz, 2001). The members of the arrestin family can be divided into two groups 
based on their sequence, function and tissue distribution. The visual arrestins make up 
the first group. Visual arrestin, also known as arrestin 1, was the first arrestin 
identified. It is the major protein constituent of the rod outer segments, localised 
primarily in the retina, where it was demonstrated to bind rhodopsin (Pfister et al., 
1985; Smith et al., 1994). Subsequently, cone arrestin which shared a high degree of 
homology (around 50 %) with visual arrestin was identified and therefore was also 
placed into this group (Murakami et al., 1993; Craft et al., 1994). Cone arrestin is 
highly enriched in both the retina and the pineal gland but is mainly localised within 
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the cone photoreceptors of the retina (Craft et al., 1994). Both arrestins are implicated 
in the regulation of photoreceptor function. 
The β-arrestins are expressed outside the retina, and are highly expressed in neuronal 
tissue and in the spleen (Attramadal et al., 1992). Their ubiquitous expression 
suggests they have relatively broad receptor specificity. β–arrestin 1 was originally 
identified as a co-factor required for GRK-mediated β2-adrenergic receptor 
desensitisation in vitro and shares 59 % sequence homology with visual arrestin 
(Benovic et al., 1987; Lohse et al., 1990). β–arrestin 2 was cloned from bovine and rat 
brain (Sterne-Marr et al., 1993; Attramadal et al., 1992). Recent evidence indicates 
that β-arrestins can form both homo- and heterodimers (Storez et al., 2005). Evidence 
suggests that monomeric β-arrestin 1 displays nuclear localisation whereas oligomeric 
β-arrestin 1 is cytoplasmic (Milano et al., 2006). However, β-arrestin 2 does not 
display nuclear localisation and co-expression with β-arrestin 1 also prevents β-
arrestin 1 accumulation in the nucleus. 
The arrestin proteins are present in all mammals and share a highly conserved 
structure. With respect to receptor binding, mutagenesis studies on visual arrestin 
allowed it to be divided into two main domains; the N and C domains. These can be 
further subdivided into three functional and two regulatory domains (Gurevich et al., 
1995). The functional domains are comprised of a receptor activation recognition 
domain (residues 24 -180), a secondary receptor binding domain (residues 180 – 330), 
and phosphate sensor domain (residues 163 – 182). The regulatory domains are at the 
N- and C-terminus, (residues 1 -24 and 330 – 404 respectively). The structure of 
arrestins has been summarised in Figure 1.7 (Ferguson, 2001). Crystal structure 
analysis of visual arrestin suggest the domains are composed largely of anti-parallel 
β-sheets (Hirsch et al., 1999). The N and C domains are connected by a hinge region 
and the C domain is also connected to the C-terminal tail by a flexible linker. The C-
terminus also forms various interactions with parts of the N and C domains which 
results in a rigid structure. Splice variants of visual, β-arrestin 1 and β-arrestin 2 exist. 
However, these are not reported to possess any differences in their functional activity. 
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Following agonist stimulation of the receptor, arrestin proteins undergo a substantial 
conformational change into a high affinity receptor-binding state and translocate 
rapidly to the plasma membrane where they selectively bind GRK phosphorylated 
agonist-bound GPCRs (Lohse et al., 1990; Gurevich & Benovic, 1993). It has been 
proposed that the intramolecular interactions which stabilise the inactive arrestin are 
broken by an active phospho-receptor, thus allowing the transition of the inactive 
arrestin into a high affinity receptor binding state (Hirsch et al., 1999; Schleicher et 
al., 1989). By binding to the receptor the arrestin protein prevents G protein coupling 
by steric hindrance (Kuhn & Wilden, 1987; Krupnick et al., 1997). This in turn 
prevents the signalling cascade from initiating. The arrestin protein can then interact 
with various other proteins of the endocytotic machinery and internalise the GPCR 
(Goodman, Jr. et al., 1996). 
1.4.6.2.  GPCR internalisation 
In addition to their classical role in GPCR desensitisation, β-arrestins have additional 
roles differentiating them from the visual arrestins. In 1996, Ferguson and colleagues 
reported that the rapid recruitment of β–arrestins to the phosphorylated β2-adrenergic 
receptor was vital for the receptor to internalise into intracellular vesicles (Ferguson et 
al., 1996). Internalisation, or sequestration, is the physical process by which the 
receptor moves from the plasma membrane into the intracellular membrane 
compartments of the cell upon agonist activation – this is essential for down 
regulation of the signal and receptor resensitisation (the process by which internalised 
receptors are dephosphorylated and recycled back to the cell surface). Although 
GPCR internalisation is generally considered to be a result of agonist-stimulation, a 
number of published studies suggest some GPCRs are constitutively internalised in 
the absence of agonist binding. This constitutive internalisation was first reported for 
the δ opioid receptors (Costa & Herz, 1989). Our understanding of the role of β–
arrestins in internalisation and the fate of internalised GPCRs has been greatly 
advanced by the use of fluorescently tagged β–arrestins, which allow the visualisation 
of β–arrestin and receptor trafficking in live cells (Barak et al., 1997).  
Studies by von Zastrow and Kobilka in 1994 proposed that the internalisation of the 
β2-adrenergic receptor was mediated via the clathrin-coated vesicle pathway (von 
 40 
Sanam Mustafa, 2008  
 
Zastrow & Kobilka, 1994). In 1996, it was determined that β–arrestin is able to bind 
to clathrin with high affinity, which reinforced the idea that the β–arrestins were 
acting as adapter proteins by targeting GRK phosphorylated ligand-activated GPCRs 
to clathrin coated-pits for endocytosis (Goodman, Jr. et al., 1996). 
β–arrestins 1 and 2 have two recognition sites which allow them to link GPCRs with 
at least two components of the endocytic machinery; clathrin (the major structural 
component of the clathrin-based endocytic machinery) and the β2-adaptin subunit of 
the clathrin adapter protein 2 (AP-2) complex (Goodman, Jr. et al., 1996; Laporte et 
al., 1999). The AP-2 complex is responsible for linking many receptors to the clathrin 
endocytic machinery by binding to clathrin and dynamin (Kirchhausen, 1999). The 
heterotetrameric AP-2 complex is composed of two large α- and β2-adaptin subunits 
of 100 kDa, μ2 subunit (50 kDa) and a small 17 kDa subunit named σ2 (Kirchhausen, 
1999). Dynamin, a GTPase that forms the neck of clathrin-coated pits, is essential for 
pinching off the vesicles from the plasma membrane (Urrutia et al., 1997). It’s 
importance was demonstrated in studies where the presence of a dominant-negative 
mutant of dynamin impaired the endocytosis of β2-adrenergic receptor (Zhang et al., 
1996). Figure 1.8 is a schematic illustration showing the molecular mechanisms 
involved in GRK and β–arrestin-dependent desensitisation and internalisation. 
Internalised receptors bound to β–arrestin are either retained in large endosomes for 
recycling back to the membrane (resensitisation) or targeted for degradation by 
lysosomes (downregulation). 
The functions of both β–arrestin 1 and 2 are regulated by post-translational 
modifications. The endocytic function of β–arrestin is regulated by phosphorylation. 
Despite sharing around 80 % amino acid identity each arrestin is phosphorylated by a 
different kinase. β-arrestin 1 is phosphorylated by extracellular signal regulated 
kinase (ERK) enzymes whereas β-arrestin 2 is phosphorylated by casein kinase II 
(Attramadal et al., 1992; Lin et al., 1999; Lin et al., 2002). Cytosolic β-arrestin 1 is 
phosphorylated at S412 and upon translocation to the membrane the arrestin protein is 
rapidly dephosphorylated where it can then bind with high affinity to both the 
receptor and clathrin ( Lin et al., 1999). The importance of this post-translational 
modification was demonstrated in a study where a S412 β-arrestin 1 mutant, 
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mimicking the phosphorylated state of the protein, was introduced into cells 
expressing the β2-adrenergic receptor. Although the mutant protein was able to 
mediate desensitisation it was only able to bind poorly to clathrin and therefore 
inhibited receptor sequestration. Hence it can be concluded that dephosphorylation is 
only required for its function in receptor-β-arrestin-mediated endocytosis but not for 
receptor binding and desensitisation (Lin et al., 1997). 
1.4.6.3. GPCR downregulation and resensitisation 
Downregulation of GPCRs is caused by long term exposure of the receptor to an 
agonist and is characterised by a persistent loss of receptors from cells. This results in 
the attenuation of signal transduction. In contrast to receptor desensitisation or 
internalisation, agonist removal only slowly or incompletely reverses this process. 
Downregulation is the least understood mechanism involved in receptor regulation. 
However, one thing is certain, the control of cell surface receptor density not only 
occurs at the transcriptional level but also by ‘sorting’ of sequestered GPCRs to either 
degradation or recycling pathways (Whistler et al., 2002).  
The physiological importance of receptor resensitisation is logical, as irreversible 
desensitisation would result in cells becoming unable to respond to extracellular 
stimuli – key to its survival. However, an example where reversible desensitisation is 
detrimental to the cell is also known. The protease-activated receptors (PAR) are 
‘self-activated’ receptors, such that once cleaved by thrombin, the N-terminal tail 
folds over to act as a ligand. In this case, resensitisation would mean that the receptor 
would be delivered back to the cell surface in its activated form. To prevent this from 
occurring, in the case of the PAR receptors, all activated receptors are degraded and 
new receptors are synthesized (Hein et al., 1994). It is becoming clear that β-arrestins 
are highly involved in many aspects of receptor trafficking – resensitisation is no 
exception. A study by Zhang and colleagues, reported that unless β-arrestins were 
overexpressed in COS7 cells (which naturally only produce low levels of these 
proteins), no resensitisation of β2-adrenergic receptors was observed (Zhang et al., 
1997). It can therefore be presumed that β–arrestins maybe responsible for delivering 
receptors back to the plasma membrane in their inactivated and dephosphorylated 
state. Generally, dephosphorylation of the GPCRs is known to occur in an acidified 
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endosomal vesicle compartment (Krueger et al., 1997). However, an example where 
receptor internalisation is not necessary for dephosphorylation or resensitisation is the 
thyrotropin-releasing hormone receptor, which can undergo dephosphorylation at the 
cell membrane (Jones & Hinkle, 2005). 
The rate at which GPCRs traffic from the plasma membrane to the endosomal 
compartment and back again to the cell surface varies depending on the subtype of the 
receptor. Depending on their interactions with β–arrestins, GPCRs are classed as 
either A or B receptors (Oakley et al., 1999; Oakley et al., 2000). Class A, including 
the β2 adrenergic receptor, bind preferentially to β–arrestin 2 in a transient manner, 
such that the receptor-β–arrestin complex dissociates rapidly when the receptor is 
internalised (Pierce & Lefkowitz, 2001; Luttrell & Lefkowitz, 2002). This allows the 
receptor to be rapidly dephosphorylated and recycled back to the plasma membrane. 
Receptors designated as class B, such as vasopressin 2, bind equally to β–arrestin 1 
and 2 to form more stable receptor-β–arrestin complexes, thus allowing the targeting 
of the whole complex to the endosomes (Luttrell & Lefkowitz, 2002). As a result of 
this, class B receptors, therefore, recycle back to the plasma membrane slowly 
suggesting the stable receptor-β–arrestin complexes may favour receptor degradation. 
The fates of both classes of receptors is illustrated in Figure 1.9 (Pierce & Lefkowitz, 
2001). It is worth mentioning, however, that evidence exists for a class B receptor (the 
mutant S363A-V2R vasopressin receptor) to efficiently recycle back to the cell 
surface despite its stable interaction with β–arrestin (Innamorati et al., 2001). It is has 
therefore been proposed that other ‘receptor intrinsic’ or protein determinants must 
also exist.  
The covalent attachment of ubiquitin, known as ubiquitination, was originally 
discovered in the context of cellular protein degradation. Now ubiquitination of β-
arrestin has also been shown to play an important role in regulating GPCR 
internalisation and resensitisation. This was demonstrated in a study where 
internalisation of β2-adrenergic receptor was inhibited in the absence of β-arrestin 
ubiquitination (Shenoy et al., 2001). Protein ubiquitination is mediated by the action 
of three enzymes, E1, E2 and E3. The first two enzymes are responsible for activating 
and escorting the activated ubiquitin. The third enzyme is then able to recognise and 
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modify the protein of interest. It is thought that the transient ubiquitination of arrestins 
results in an unstable GPCR-arrestin complex. In this case, the GPCR exhibits fast 
recycling to the plasma membrane. Conversely, prolonged arrestin ubiquitination 
equates to a stable GPCR-arrestin complex and therefore slow recycling of the GPCR 
to the membrane. Although GPCR ubiquitination is not thought to play a role in 
receptor endocytosis it is, however, implicated in lysosomal sorting and degradation 
of the activated receptor. An example of this is where a mutant β2-adrenergic receptor 
unable to be ubiquitinated, was demonstrated to internalise but unable to be efficiently 
degraded (Shenoy et al., 2001).  
The persistent degradation of cell surface receptors, due to long-term exposure to an 
agonist, is one of the most poorly understood regulatory mechanisms. This course of 
action can occur in a period of hours to days. What is certain, however, is that the role 
of β–arrestins is of paramount importance during this process. In 2001, Kohout and 
co-workers observed that downregulation of the β2 adrenergic receptors failed to take 
place in mouse embryo fibroblasts (MEF) cells lacking both β–arrestin 1 and 2 
(Kohout et al., 2001). To summarise, the three β-arrestin-mediated regulatory 
mechanisms discussed in this chapter are illustrated in Figure 1.10 taken from 
(McDonald & Lefkowitz, 2001). 
1.4.6.4. Arrestin-independent desensitisation and internalisation 
pathways 
The exact consensus sequence dictating phosphorylation by a GRK or second 
messenger-dependent protein kinase is not known. It has recently been suggested that 
the negative charge introduced by phosphorylation is important for arrestin binding 
rather than the precise position (Gurevich & Gurevich, 2006). However, an increasing 
amount of evidence suggests that all phosphorylation events are not equal. For 
example, published studies suggest PKC or PKA phosphorylated receptors are not 
good substrates for arrestin binding (Pitcher et al., 1992). This has been demonstrated 
with the β2-adrenergic receptor where phosphorylation by both PKA and GRK has 
been shown to result in desensitisation (Roth et al., 1991). However, only GRK-
mediated phosphorylation results in arrestin binding (Lohse et al., 1992). In another 
independent study utilising FRET, the rapid disassociation of arrestin from β2-
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adrenergic receptor was observed when the agonist was removed but the receptor 
remained phosphorylated (Krasel et al., 2005). This is likely to be the case as 
evidence suggests both agonist occupancy and phosphorylation of a GPCR is 
necessary for arrestin recruitment. Unlike GRK phosphorylation, agonist occupancy 
of receptors is not a prerequisite for PKA or PKC phosphorylation. Taken together, 
these observations would go some way to explaining the lack of arrestin recruitment. 
Nevertheless, both PKA and PKC phosphorylated receptors can undergo 
desensitisation and internalisation. Desensitisation of the D3 dopamine receptor, for 
example, is mediated almost exclusively by the second messenger-dependent protein 
kinase, PKC (Cho et al., 2007). Earlier evidence suggesting phosphorylation by PKA 
is sufficient to impair receptor-stimulated GTPase activity has been published for the 
β2-adrenergic receptor (Benovic et al., 1985). It is thought that receptor 
phosphorylation in a G protein coupling region by a second messenger-dependent 
protein kinase, but not a GRK, can sterically inhibit receptor/G protein interactions 
(Benovic et al., 1985). With respect to receptor internalisation, β-arrestin independent 
pathways have been identified. 
This was first observed when the overexpression of dominant-negative β–arrestin 
proteins did not affect the internalisation of the vasoactive intestinal peptide type 1 
(VIP 1) receptor or the endothelin type B (ETB) receptor (Claing et al., 2000). These 
studies suggested that the VIP 1 and ETB receptors internalised by a β–arrestin-
independent mechanism. Evidence suggests that in the case of the ETB receptor 
internalisation is via the caveolar pathway (Teixeira et al., 1999). 
Caveolae are small flask-shaped invaginations of the plasma membrane, rich in 
proteins and lipids. The shape and structural organisation of caveolae are due to the 
presence of caveolin proteins 1, 2 and 3. These proteins self-assemble in high mass 
oligomers to form a cytoplasmic coat on the membrane invaginations. Recent 
evidence associates caveolae with GPCR endocytosis and signalling. Initial evidence 
supporting the role of caveolae in receptor internalisation came from studies of the 
GPI-anchored folate receptor by Anderson and colleagues (Anderson et al., 1992). 
Since this initial discovery many receptors are now known to be present in caveolae, 
including the M2 muscarinic receptor, the β2 adrenergic receptor and the endothelin 
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ETA receptor (Feron et al., 1997; Dupree et al., 1993; Chun et al., 1994). Evidence 
supporting their role in signal transduction comes from the observation that G proteins 
and other signalling molecules are also present (and enriched) in caveolae (Anderson, 
1993; Lisanti et al., 1994). Not much is known about the precise mechanism by which 
caveolae-mediated pathways operate besides the knowledge that there is a 
requirement for cholesterol. Studies have shown treatment with inhibitors of 
cholesterol such as cholesterol-binding drugs inhibit endocytosis by caveolae 
(Anderson et al., 1996; Kiss & Geuze, 1997; Schnitzer et al., 1994). As caveolae are 
rich in lipids, presumably removal of cholesterol would affect the caveolar structure 
and hence function. In 1995, Roettger and co-workers looked at the internalisation of 
the cholecystokinin (CCK) receptors and their preferred internalisation pathways. It is 
known that approximately 80 % of these receptors internalise via the clathrin-coated 
pit pathway, whilst the remaining 20 % or so prefer internalising via caveolae 
following receptor stimulation (Claing et al., 2002). Roettger and co-workers 
demonstrated that when the clathrin-coated pit pathway was inhibited, surprisingly, 
nearly all the CCK receptors internalised (Roettger et al., 1995). These results not 
only confirmed that the caveolar pathway is another means for receptor internalisation 
but also suggested that CCK receptors (and possibly other GPCRs) can internalise via 
both pathways if the need ever arises.  
The GTPase dynamin has also been implicated in the caveolae pathway as well as in 
clathrin-mediated endocytosis – it has been shown to be present at the neck of 
caveolar structures (Claing et al., 2002). Claing and colleagues have shown that 
overexpression of a dynamin dominant negative mutant reduces internalisation of the 
endothelin ETB and VIP 1 receptors (Claing et al., 2000). Internalisation pathways 
independent of both β–arrestin and dynamin have also been suggested (Claing et al., 
2000; Gilbert et al., 2001; Lamb et al., 2001). 
1.4.7. Novel mechanisms of GPCR signalling: signal 
specificity 
The vast number of receptors that make up the GPCR superfamily respond to a 
diverse array of stimuli, however, they rely on a limited number of intracellular 
effectors, second and third messengers to convey highly specific physiological 
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responses. In recent years it has become clear that signal transduction is not a simple 
linear pathway transferring information from the cell membrane to the nucleus, but a 
more intricate network of signalling dependent on a multitude of factors such as 
biased agonism, receptor oligomerisation, receptor density and cell type. This 
introduces novel aspects of GPCR signalling and regulation. The classical model of 
GPCR regulation has been described in section 1.4.6. Although a few examples which 
differed from the classical model were introduced, below is a somewhat limited 
summary of the current understanding of GPCR regulation and its complexities.  
1.4.7.1. Biased agonism 
It is now generally acknowledged that the ‘two state’ model where a receptor adopts 
either an active or inactive conformation is not entirely accurate. Instead it is thought 
the receptor can undergo a variety of conformational changes that can lead to different 
downstream signalling pathways. Biased agonism or agonist-directed trafficking 
describes the phenomenon where different ligands can act on the same receptor but 
induce different conformations and therefore different physiological responses 
(Kenakin, 1995). An example of differential signalling by different agonists via the 
same receptor is the serotonin 5-HT2C receptor (Berg et al., 1998; Backstrom et al., 
1999). In the study by Berg and co-workers, it was demonstrated that some agonists 
preferentially activate the phospholipase C (PLC) pathway to mediate inositol 
phosphate (IP) accumulation or the phospholipase A2 (PLA2) pathway resulting in 
arachidonic acid (AA) release (Berg et al., 1998). In a separate study it was 
demonstrated that, unlike serotonin, LSD was unable to promote calcium release 
(Backstrom et al., 1999). 
1.4.7.2. G protein-coupling 
Although little is known about the selectivity of this process as no consensus motif to 
predict G protein-coupling has been identified, in general, intracellular sequences 
closest to the plasma membrane appear to be crucially involved in G protein 
specificity (Ostrowski et al., 1992). It is now widely accepted that GPCRs can couple 
to more than one class of G proteins and therefore specificity of a cellular response 
can be achieved due to the existence of molecular variability within the G proteins 
(Hermans, 2003). The β2-adrenergic receptor, for example, which is well documented 
to couple to Gαs can also couple to Gαi following receptor phosphorylation by PKA 
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(Daaka et al., 1997a). It has been suggested that PKA phosphorylation is mainly 
important at low agonist concentrations (Tobin, 1997). This provides an interesting 
example of where an agonist can control G protein specificity in a dose-dependent 
manner. Other examples of G protein promiscuity are the M2 muscarinic and S1P2 and 
S1P3 sphingosine-1-phosphate receptors, which have been shown to couple to three 
different classes of G proteins (Michal et al., 2007; Siehler & Manning, 2002). 
1.4.7.3. β-arrestin-mediated signalling 
Increasing evidence suggests that β–arrestins play a more prominent role in cellular 
signalling than initially envisaged. They have been shown to play a critical role in the 
signalling complexes that ultimately lead to activation of members of the mitogen-
activated protein kinase family (MAPK).  
The best characterised members of the MAPK family are extracellular signal 
regulated kinases (ERK) 1 and 2, c-Jun N-terminal kinase (JNK) and p38 MAPK. 
These proteins have key roles in the regulation of many biological processes, 
including cell growth, proliferation, differentiation and apoptosis. MAPKs represent a 
key step in the signalling cascades that relay signals from the plasma membrane to the 
nucleus. The core unit of a MAPK signalling complex is made up of a three-tiered 
protein kinase family – activation of each MAPK requires the phosphorylation of 
tyrosine and threonine by an upstream protein kinase as illustrated in Figure 1.11 
(Miller & Lefkowitz, 2001; Pierce & Lefkowitz, 2001). ERKs are primarily 
cytoplasmic but their activation leads to their dissociation from cytoplasmic anchoring 
proteins, such as MEK. They can then translocate to the nucleus where they can 
phosphorylate substrates such as transcription factors. Initial evidence suggesting β–
arrestins can function as transducers of GPCR signals came from a study where β2-
adrenergic receptor activation of MAPK was inhibited by the expression of a 
dominant-negative β-arrestin mutant (Daaka et al., 1998). Then the discovery that β–
arrestins can interact with Src, a non-receptor tyrosine kinase involved in the Ras-
dependent activation of MAPK, in an agonist-dependent manner lead to the 
conclusion that β-arrestins can act as scaffolds, linking receptors to downstream 
signalling pathways (Luttrell et al., 1999). This activation of signalling pathways by 
β-arrestin is often referred to as a ‘second wave of signal transduction’. β–arrestin 
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appears to directly interact with Src via the Src homology 3 (SH3) and the catalytic 
domains of Src (Luttrell et al., 1999; Miller et al., 2000). Recently, β–arrestins have 
been shown to regulate two MAPK family members; ERK 1/2 and JNK3 (DeFea et 
al., 2000; McDonald et al., 2000). By binding to JNK3, β-arrestin can recruit 
upstream kinases such as apoptosis signal-regulating kinase 1 and form scaffolding 
complexes to transduce signals from the cell membrane. It has been suggested that the 
recruitment of Src to GPCRs is essential for both the activation of the ERK cascade 
and for receptor internalisation – possibly Src may be involved in the phosphorylation 
of a key component involved in both pathways (Miller & Lefkowitz, 2001).  
The angiotensin receptor system has provided a good model for studying β-arrestin-
mediated signalling. A mutated angiotensin octapeptide, SII angiotensin, which is 
unable to stimulate G protein-mediated effects such as calcium mobilisation but 
retained the ability to recruit β-arrestin to the receptor and thereby induce receptor 
internalisation, was utilised to study β-arrestin-dependent ERK1/2 activation. It was 
demonstrated that angiotensin II type 1A receptor was able to activate ERK1/2 via G 
protein- and β-arrestin 1-dependent pathways in an independent manner (Ahn et al., 
2004). The kinetics of ERK activation were also deduced, where G protein-mediated 
activation was rapid and transient. However, β-arrestin-mediated activation was 
slower but more prolonged. In general, G protein-mediated ERK activation results in 
the translocation of ERK to the nucleus. β-arrestin-mediated ERK activation is 
usually restricted to the cytoplasm (DeFea et al., 2000). In this case, ERK can 
phosphorylate cytosolic substrates, including transcription factors, which then 
translocate to the nucleus (Ebisuya et al., 2005). 
Recent evidence suggests both β-arrestins can translocate to the nucleus and induce 
transcription of various genes by recruiting co-factors such as p300 and increasing 
histone acetylation (Kang et al., 2005). One such example is the translocation of β-
arrestin 1 to the nucleus in response to the activation of the δ-opioid receptor. By 
translocating to the nucleus it increased the transcription of p77 and FOS genes and 
thereby regulated the cell cycle. In a similar manner, activation of an odorant receptor 
can translocate β-arrestin 2 to the nucleus (Neuhaus et al., 2006). With respect to the 
‘new’ roles of arrestin, Figure 1.12 is an updated diagram of the β-arrestin domain 
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structure illustrating binding sites, nuclear localisation and nuclear export (NES) (Ma 
& Pei, 2007). Also, a model for β-arrestin-mediated regulation of transcription has 
been illustrated in Figure 1.13 (Ma & Pei, 2007).   
1.4.7.4. Signalling by intracellular GPCRs 
Increasing amounts of evidence exist which strongly suggests the existence of 
functional intracellular GPCRs. Recently an example of a receptor, GPR30, which is 
exclusively targeted to the endoplasmic reticulum has been reported (Revankar et al., 
2005). This fully functional estrogen receptor demonstrated intracellular calcium 
mobilisation upon agonist activation.  
Challenging textbook understanding, published studies suggest that GPCRs and G 
proteins may be pre-assembled and then targeted to the plasma membrane (Dupre et 
al., 2006). This has further supported the idea of intracellular GPCR signalling, as 
intracellular receptor/G protein complexes have been shown to be sensitive to agonist 
(Rebois et al., 2006). It has been proposed that these intracellular receptors may 
activate signalling pathways that are distinct from those activated by cell surface 
receptors. One such example comes from receptors that signal from 
compartmentalised lipid rafts. Lipid rafts are planar domains of cell membranes and, 
like caveolae, are enriched in lipids and proteins, in particular cholesterol. G proteins 
and many GPCRs have been shown to localise in lipid rafts (Oh & Schnitzer, 2001). 
Via the Gq coupled-oxytocin receptor, oxytocin inhibits cell growth. However, fusion 
of this receptor with caveolin-2 localised this receptor to lipid rafts where it was then 
able to activate distinct pathways which resulted in the opposite response and 
promotion of cell proliferation (Guzzi et al., 2002). As oxytocin can stimulate and 
inhibit cell growth via a single receptor, this finding goes a long way to demonstrate 
how the differential localisation of a receptor can achieve signal specificity. 
Clearly GPCR signalling is not as simple as first envisioned. In order to appreciate the 
complexities of this signalling cascade, it is becoming increasingly important to study 
these receptors in their native systems. The willingness of researchers to think 
‘outside the box’ and the development of more sensitive experimental techniques are 
likely to uncover more surprises. To summarise, Figure 1.14 is an updated version of 
Figure 1.4 incorporating G protein-independent signalling pathways. 
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Figure 1.2 Schematic diagram illustrating the main structural features of a GPCR 
The seven transmembrane (TM) helices are linked by three extracellular (e) loops and 
three intracellular (i) loops. GPCRs have an extracellular N-terminus tail and an 
intracellular C-terminus tail. 
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Figure 1.3 Organisation of rhodopsin in native mouse membranes 
The atomic force microscopy image is presented to support the conclusion that the 
rhodopsin receptor is arranged in an oligomeric array of closely packed dimers in 
native mouse rod-outer segment disc membranes. A single rhodopsin dimer is 
indicated by a broken ellipse and the white arrowheads indicate a rhodopsin 
monomer. Image from (Liang et al., 2003). 
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Figure 1.4 Summary of G protein subunits and intracellular effectors 
Activation of GPCRs can mediate a variety of cellular responses via various 
intracellular effectors. PLCβ, phospholipase Cβ 
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Figure 1.5 The G protein activation cycle 
A: In the inactive state the GDP bound G protein α (Gα) subunit associates with the 
β/γ complex to form an inactive heterotrimeric G protein. Upon ligand activation the 
GPCR undergoes a conformational change resulting in increased affinity for the G 
protein; this results in the exchange of GDP for GTP on the Gα subunit, which 
reduces the affinity of the Gα subunit for the β/γ complex and therefore leads to 
dissociation of the heterotrimeric G protein. Both the Gα subunit and the β/γ complex 
can then interact with effectors, transducing the signal. B: The activated state lasts 
until the GTP is hydrolysed to GDP by the intrinsic GTPase activity of the Gα 
subunit. 
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N-terminal GPCR binding Catalytic domain C-terminal domain 
Figure 1.6 Schematic representation of the domain structure for GRK 
The catalytic domain is flanked by two regulatory domains. The N-terminal domain 
plays a role in the recognition and binding of activated receptors. The C-terminal 
domain is responsible for interacting with intracellular effectors and Gβγ subunit of G 
proteins.
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Figure 1.7 Structure of arrestins 
The functional domains are comprised of a receptor activation recognition domain 
(A), a secondary receptor binding domain (S) and phosphate sensor domain (P). The 
regulatory domains (R1 and R2) are at the N- and C-terminus. The clathrin- and β-
adaptin-binding domains are represented by the black box at the extreme C-terminus. 
Figure from (Ferguson, 2001).
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Figure 1.8 Schematic illustration of GRK- and β-arrestin-dependent desensitisation and 
internalisation 
β–arrestin proteins translocate to the cell surface and bind to the GRK phosphorylated 
receptor. β–arrestins then associate with clathrin and the AP-2 complex and target the 
bound GPCR to clathrin-coated pits, where the GPCR is internalised. (Ferguson, 
2001). H, hormone; G, G protein; E, effector; βArr, β arrestin. 
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Figure 1.9 Diagram illustrating fates of internalised class A and class B receptors 
Class A GPCRs preferentially internalise via β–arrestin 2 in a transient manner, where 
the interaction between the GPCR and the β–arrestin is not stable. It is has been 
suggested that the transient ubiquitination of arrestin results in an unstable GPCR-
arrestin complex. In this case β–arrestin does not localise with the GPCR in 
endosomes and the GPCRs are rapidly dephosphorylated and recycled back to the cell 
surface. GPCRs belonging to class B have been shown to internalise with either β–
arrestin 1 or 2 via a more stable interaction. In this case ubiquitination of arrestin is 
more prolonged. The whole GPCR-β–arrestin complex is targeted to endosomes. 
Class B receptors are more likely to be recycled slowly if not degraded. (Pierce & 
Lefkowitz, 2001). A, agonist; βARR, β arrestin. 
 58 
Sanam Mustafa, 2008  
 
 
 
 
 
 
 
 
 
Figure 1.10 Schematic diagram summarising the three β–arrestin-mediated regulatory 
mechanisms 
As discussed in the main text desensitisation of the GPCR by GRK phosphorylation 
and binding of β–arrestin is followed by β–arrestin-mediated internalisation via 
clathrin-coated vesicles. Receptors are then either targeted for degradation or 
resensitisation, where the whole process starts again upon ligand (L) activation. 
(McDonald & Lefkowitz, 2001). NSF, N-ethylmaleimide-sensitive fusion protein. 
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A B
       
Figure 1.11 MAPK cascades 
A: GPCR activation of MAPK cascades proceeds by the sequential activation of a 
MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAPK. (Pierce 
& Lefkowitz, 2001). B: Examples of members involved in each specific pathway 
(Miller & Lefkowitz, 2001).  
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Figure 1.12 Updated domain structure of β-arrestin annotated for binding sites 
Domain structure of β-arrestin 1 and 2 incorporating binding sites, nuclear 
localisation and nuclear export (NES) signals (Ma & Pei, 2007). 
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Figure 1.13 A model for β-arrestin-mediated regulation of transcription 
a) Direct pathway: In response to receptor activation, β-arrestins (βarr) translocate 
from the cytoplasm to the nucleus and associate with transcription cofactors such as 
p300 and CREB at the promoters of target genes to promote transcription directly. b) 
Indirect pathway: β-arrestins interact with regulators of transcription factors such as 
IκBα and MDM2 in the cytoplasm, which results in changes in activity and the 
subcellular distribution of these binding partners, and thus exert regulatory effects on 
the activation of transcription factors indirectly. Ub, ubiquitylation. From (Ma & Pei, 
2007).
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Figure 1.14 Summary: Diversity of GPCR signalling 
Activation of GPCRs can mediate a variety of cellular responses via various 
intracellular effectors in a G protein-dependent or -independent manner. 
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1.5.  Nicotinic acid mediates it response via G protein-
coupled receptors 
It is believed that nicotinic acid lowers the high levels of lipids in blood by inhibiting 
lipolysis, the process of mobilisation of stored fat from adipocytes. This would 
involve the regulation of the rate-limiting enzyme, hormone-sensitive lipase. In 
general, anti-lipolytic agents act by inhibiting adipocyte adenylyl cyclase and thus 
lowering the cellular levels of cAMP, which in turn hinders the normal processes that 
lead to the release of non-esterified fatty acids (NEFA) into the circulation. In 1983, 
Aktories and colleagues presented the first evidence that the inhibition of adenylyl 
cyclase occurred via a functional Gi G protein (Aktories et al., 1983a). Further studies 
by Aktories’ and Green’s research groups supported the role of an inhibitory GPCR 
(Aktories et al., 1983b; Green et al., 1992). Based on these findings a schematic 
diagram of the possible metabolic mechanism is shown in Figure 1.15 (Pike & Wise, 
2004). 
In 2001, Lorenzen and co-workers confirmed specific binding of nicotinic acid to 
adipose tissue and spleen and reported that nicotinic acid acts on a specific 
membrane-bound receptor (Lorenzen et al., 2001). Interestingly, this data nicely 
corresponded to that obtained by Carlson and colleagues where nicotinic acid uptake 
was greatest by adipose tissue (Carlson & Hanngren, 1964). Based on the tissue 
expression profiles generated by Lorenzen and co-workers and the responses to 
nicotinic acid, in 2003 various groups published reports identifying the nicotinic acid 
receptor as protein upregulated in macrophages by IFNγ (PUMA-G) or HM74 (Soga 
et al., 2003; Tunaru et al., 2003; Wise et al., 2003). Nomura and colleagues had 
originally cloned this HM74 receptor from a cDNA library derived from human 
monocytes for a separate study (Nomura et al., 1993). Both Soga’s and Wise’s 
research groups further went on to report the existence of a high affinity receptor, 
(HM74A or HM74b) identified by a bioinformatics approach exploiting their highly 
homologous amino acid sequence. It is interesting to note that out of these three 
groups two have a commercial interest, highlighting the potential therapeutic 
significance of this discovery. 
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1.5.1.  Introduction to nicotinic acid receptors 
Nearly fifty years on from its arrival on the market, the receptors on which nicotinic 
acid acts have recently been identified as the ‘nicotinic acid receptors’. A family of 
three receptors, HM74 (GPR109B) and HM74A (GPR109A) are co-located with 
another orphan GPCR, GPR81, on chromosome 12q24.31 (Wise et al., 2003). 
Comparison of these homologues revealed a high degree of similarity between them. 
HM74 and HM74A are both single exon genes that differ by only 15 base changes at 
the DNA sequence level (Zellner et al., 2005). HM74A also has a 5 base-pair 
insertion at the 3’ end of the gene changing the 3’ coding sequence and ultimately 
resulting in HM74A possessing a shorter C-terminal tail (Wise et al., 2003). With 96 
% identity at the protein level, these receptors differ by only 17 amino acids out of a 
total of around 400 amino acids (Zellner et al., 2005). As HM74 is present in humans 
but not in rodents it is thought that it is the result of a recent gene duplication event. 
GPR81 has 57 and 58% amino acid sequence identity with HM74 and HM74A 
respectively. Recently, hamster and guinea pig HM74A receptors were cloned and 
characterised, however there was no evidence of a HM74 homologue (Torhan et al., 
2007). They have around 80 % sequence identity with human HM74A. HM74A is 
primarily expressed in adipose tissue, spleen and the lung in humans (Pike & Wise, 
2004). Hamster and guinea pig HM74A have a similar expression pattern (Torhan et 
al., 2007). Both HM74A and HM74 are expressed in lymphocytes, but HM74 is more 
highly expressed.  
To confirm that the receptors were indeed Gi coupled, receptor-expressing cell lines 
were pre-treated with pertussis toxin. This abolished signalling via the receptors and 
therefore it was concluded that the signal was transduced via Gi (Wise et al., 2003). 
When these receptors were individually expressed in a mammalian cell line, 
measurement of a functional response by [35S] guanosine 5’-(γ-thio) triphosphate 
(GTPγS) binding following nicotinic acid treatment found it to be an agonist for all 
three GPCRs. However, nicotinic acid was more potent at HM74A (μM range), 
followed by HM74 (mM range) and then GPR81 (> mM) (Wise et al., 2003). Wise 
and co-workers were also able to reproduce [3H] nicotinic acid binding studies 
conducted by Lorenzen and colleagues to determine the affinity of HM74A for 
nicotinic acid (Lorenzen et al., 2001; Wise et al., 2003). [3H] nicotinic acid binding 
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was around 30 % higher in membranes prepared from adipocytes than those generated 
from spleen (Lorenzen et al., 2001). Due to the low affintiy of HM74 and GPR81 
radioligand binding studies were not conducted and expression levels of these 
receptors have not been determined. 
A patent application detailing the molecular identification of a novel nicotinic acid 
receptor has been published by Arena Pharmaceuticals (Arena Pharmaceuticals.Inc., 
2008; Soudijn et al., 2007). Named RUP25, it is reported to be 99 % identical to 
HM74A. RUP25 has one amino acid difference where phenylalanine replaces glycine 
at position 65. It has been reported to possess similar affinities for nicotinic acid and 
its analogs as HM74A. Whether this is a novel receptor or a polymorphism of 
HM74A is questionable. 
1.5.2.  Ligands for nicotinic acid receptors 
Lorenzen and co-workers were the first to publish the pharmacological profile of a 
number of compounds that were structurally related to nicotinic acid (Lorenzen et al., 
2001). These were tested in various assays including [35S] GTPγS and [3H] nicotinic 
acid binding studies on rat adipocytes or spleen. In hindsight, activity of the 
compounds tested represents activity at HM74A, as we now know HM74 does not 
have a rodent orthologue. Out of the compounds described in this report, only acifran 
activated both HM74A and HM74 (Wise et al., 2003). In [35S] GTPγS binding assays 
nicotinamide has been shown to be inactive at HM74A (Wise et al., 2003; Lorenzen et 
al., 2001). Nicotinic acid and nicotinamide are nutrionally equivalent and structurally 
similar; in nicotinamide, an amine group replaces the carboxyl group in nicotinic acid, 
as shown in Figure 1.16. This suggests that the carboxyl group is important for 
receptor activation and therefore lipid-modifying qualities. Acifran, which displays 
similar anti-lipolytic characteristics as nicotinic acid, also contains a carboxyl group 
(Figure 1.16). Not only is the presence of the carboxylic acid group essential but its 
position in the heterocyclic structure dictates activity levels (Soudijn et al., 2007). 
Synthetic analogs of acifran have been developed and demonstrated to be at least as 
active as acifran, if not more so, at both receptors (Jung et al., 2007; Mahboubi et al., 
2006). Although a series of selective agonists at HM74A and HM74 have been 
identified, to date no antagonists have been reported. 
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1.5.2.1. HM74A 
The doses of nicotinic acid required to produce a pharmacological response are in 
excess of those achieved naturally. Therefore, it is unlikely that nicotinic acid is the 
endogenous ligand for either HM74 or HM74A. In 2006, β-hydroxybutyrate, a ketone 
body, was reported to selectively activate HM74A at relatively high concentrations 
(EC50 = 750 μM) (Taggart et al., 2005). The ability of the ketone body to inhibit 
lipolysis in mouse adipocytes demonstrated its role in a more physiological context. 
Although under normal conditions β-hydroxybutyrate levels in plasma range from 50 
– 400 μM, in conditions of starvation these levels can increase to 6 – 8 mM. 
Therefore, β-hydroxybutyrate may be the endogenous ligand for HM74A, allowing a 
negative feedback mechanism during starvation to achieve metabolic homoeostasis, as 
illustrated in Figure 1.17 (Gille et al., 2008). 
Many selective agonists have been described for HM74A, some of which are not 
structurally related to nicotinic acid have been developed by pharmaceutical 
companies and are patented (Skinner et al., 2007c; Bodor & Offermanns, 2008; 
Soudijn et al., 2007). Interestingly, many of these ligands lack the carboxylic acid 
group which was thought to be important for receptor activation (Bodor & 
Offermanns, 2008). Partial agonists for this receptor have also been described (van 
Herk et al., 2003). Recently, a cAMP-based high throughput assay was described for 
identifying agonists at HM74A (Gharbaoui et al., 2007). The interest in identifying 
more potent and physiologically relevant ligands has clearly not declined. 
1.5.2.2. HM74   
The endogenous ligand for HM74 has not been identified. Based on the high sequence 
homology between HM74 and HM74A, it is a possiblity that a ketone body may be 
the natural ligand for this receptor. In the meantime selective HM74 agonists have 
been identified (Semple et al., 2006; Skinner et al., 2007a). In the case of 1-Alkyl-
benzotriazole-5-carboxylic acids, they are some 20-fold less potent than nicotinic acid 
but nevertheless inhibit isoprenaline-stimulated glycerol production in human 
adipocytes (Semple et al., 2006).  
To date no ligands have been described for GPR81. There is potential, therefore, to 
identify the natural ligand by screening against tissue extracts and bioactive 
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molecules. The molecular structures and the pharmacological profiles of compounds 
that act on the nicotinic acid receptors have been summarised in Figure 1.18 and 
Table 1.3 (Offermanns, 2006; Gille et al., 2008). 
1.5.2.3. Biased agonism? 
Many studies have reported ERK1/2 activation by nicotinic acid and related 
compounds via HM74A (Richman et al., 2007; Tunaru et al., 2003; Mahboubi et al., 
2006). Published reports by Richman and co-workers also suggest these compounds 
cause internalisation of HM74A (Richman et al., 2007). In these studies Richman and 
colleagues presented evidence to support their hypothesis that compounds that cause 
flushing also induce receptor internalisation and ERK1/2 activation. A number of 
HM74A pyrazole-based agonists have been reported as ‘non-flushing’ agonists which 
do not cause receptor internalisation or ERK1/2 activation (Richman et al., 2007). 
These compounds were also demonstrated to inhibit isoproterenol-stimulated lipolysis 
in adipocytes.  
1.5.3. Homology modelling and structural determinants of 
ligand binding 
The nicotinic acid receptors contain conserved cysteine residues, at positions 100 and 
177, which form a disulphide bridge between extracellular loops I and II. They also 
contain a DRY motif at the interface between TM III and the second intracellular 
loop. These are characteristics of receptors belonging to the class A family of GPCRs. 
Based on shared characteristics with the rhodopsin receptor, Tunaru and colleagues 
generated a structural model for the nicotinic acid receptors (Figure 1.19).  
As mentioned earlier, in addition to a shorter C-terminal tail, HM74A differs from 
HM74 by 17 amino acids which cluster around the extracellular loops 1 and 2. Of 
these amino acids, 14 are conserved across different species and are thought to be 
implicated in ligand binding. Tunaru and co-workers determined the ligand binding 
site by systematically mutating each of the 14 amino acids (Tunaru et al., 2005). They 
also took advantage of the high degree of homology shared by HM74 and HM74A to 
generate receptor chimeras. Pharmacological profiling of these recombinant receptors 
was achieved by the use of nicotinic acid, which is nearly 1000 fold more potent at 
 68 
Sanam Mustafa, 2008  
 
HM74A than HM74 and acifran, a synthetic compound, which displays similar 
potency at both receptors and lipid-modifying effects. From these studies, TM helices 
II, III and VII, extracellular loop II and the junction of TM II/ECL I of HM74A were 
demonstrated to be directly involved in nicotinic acid binding. This differs from 
traditional binding sites of class A receptors which is formed by TM helices III, V and 
VI. With respect to key amino acid players in nicotinic acid binding, Asn86/Trp91 at 
the junction of TM II/ECL I and Ser178 in ECL II are essential (Tunaru et al., 2005). 
Also, Arg111, which is conserved in both HM74 and HM74A, is thought to be 
implicated in forming a salt bridge with the carboxylic acid group found in many 
agonists for the nicotinic acid receptors. Key amino acids in ligand binding have been 
highlighted in Figure 1.19 and an interaction model of nicotinic acid at the binding 
site of HM74A is shown in Figure 1.20. 
1.6.  Clinical targets for nicotinic acid 
With the identification of the nicotinic acid receptors there was much speculation with 
regards to the clinical target for nicotinic acid. In mice it was clearly demonstrated 
that nicotinic acid-mediated its effects through HM74A (PUMA-G) (Tunaru et al., 
2003). Mice lacking HM74A were unable to decrease FFA and triglyceride plasma 
levels when administered with nicotinic acid (Tunaru et al., 2003). β-hydroxybutyrate 
was also unable to inhibit lipolysis in adipocytes from HM74A knock-out mice 
(Taggart et al., 2005). However, in humans due to the presence of both HM74A and 
HM74, deduction of the clinical target is more complicated. Taking into consideration 
the high doses of nicotinic acid required to produce a pharmacological response, 
HM74 seemed like a reasonable target to mediate the anti-lipolytic effects. However, 
studies in which human HM74 or HM74A cDNA was transfected and expressed in 
3T3 L1 cells, nicotinic acid was only able to inhibit lipolysis in cells expressing 
human HM74A (Zhang et al., 2005). To address the gram doses required to generate 
therapeutic effects of nicotinic acid, it has been reported that 90 % of nicotinic acid 
administered is eliminated from the body as unchanged nicotinic acid or nicotinuric 
acid (Gille et al., 2008). The half-life of nicotinic acid in the plasma ranges from 20 – 
45 minutes, so there is a possibility that the vitamin may not be able to maintain the 
concentrations required to activate HM74. 
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Although the above supports the role of HM74A as the clinical target for nicotinic 
acid, only studies conducted in native cell lines in a physiologically relevant context 
can be conclusive. For example, Zellner and co-workers have reported non-
synonymous nucleotide changes that are predicted to fall within the transmembrane 
domains of HM74 (Zellner et al., 2005). Non-synonymous changes result in amino 
acid replacements and therefore can potentially impact receptor function. Therefore, 
there is the possibility that an individual’s response to nicotinic acid may be 
dependent on which HM74 and HM74A haplotype they carry. Studies examining 
receptors in isolation do not allow for these types of issues to be addressed. 
1.7.  Mechanism of ‘niacin flush’  
It has been known for many years that cyclooxygenase inhibitors can reduce the 
flushing experienced in patients taking nicotinic acid. This was the first indication that 
prostanoids are involved in nicotinic acid-induced flushing (Kaijser et al., 1979). The 
increase in levels of vasodilatory prostanoids (prostaglandin I2 (PGI2), prostaglandin 
E2 (PGE2) and prostaglandin D2 (PGD2)) and their metabolites after nicotinic acid 
administration provided further evidence of their involvement (Eklund et al., 1979; 
Morrow et al., 1989). Decrease in levels of PGI2 and PGD2 after continuous treatment 
with nicotinic acid corresponding with the development of tolerance to the nicotinic 
acid-induced flushing was also reported (Stern et al., 1991). It was not then a surprise 
when Benyo and co-workers reported that receptors for both PGI2 and PGD2 were 
important for nicotinic acid-induced flushing (Benyo et al., 2005). In mice lacking 
these receptors reduced flushing was observed. Supporting this murine data, Cheng 
and colleagues demonstrated with the use of selective agonists and antagonists that 
the PGD2 receptor was important in the nicotinic acid-induced flushing response in 
humans (Cheng et al., 2006). Further progress in deciphering the mechanism of the 
flushing response was made when HM74A was identified as the mediator of the 
nicotinic acid-induced flush (Benyo et al., 2005). It was nicely demonstrated that mice 
deficient in HM74A did not display flushing in response to nicotinic acid. As 
mentioned earlier, there is no rodent HM74 homologue. So there is a possibility that 
although HM74A may be the mediator of this nicotinic acid-induced flush in mice, it 
may not be the sole mediator in humans. 
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In the study conducted by Benyo and co-workers, mice deficient in HM74A were able 
to display the flushing response after transplantation of bone marrow from wild type 
mice (Benyo et al., 2005). This, taken together with the observation of HM74A 
expression on immune cells, suggested their involvement in the flushing response. It 
was hypothesised that arachidonic acid in immune cells was mobilised by nicotinic 
acid and converted to prostaglandins and thus caused the flushing response. With the 
recent report of HM74A signalling enhancing the arachidonic acid signalling pathway 
the arguments supporting this hypothesis were strengthened (Tang et al., 2006). 
Around the same time two independent groups reported epidermal Langerhans cells 
were crucial for the cutaneous flushing response induced by nicotinic acid 
(Maciejewski-Lenoir et al., 2006; Benyo et al., 2006). Benyo and co-workers 
demonstrated the flushing response can be abrogated by depleting mice of these cells 
(Benyo et al., 2006). The approach adopted by Maciejewski-Lenoi and co-workers, 
involved assaying PGD2 release in various cells in response to nicotinic acid. 
Langerhans cells were the only cells to respond in this manner (Maciejewski-Lenoir et 
al., 2006). 
1.8.  Other effects? 
It has been suggested that nicotinic acid receptors expressed in macrophages may play 
a role in increasing HDL cholesterol and therefore a role in preventing atherosclerosis 
(Schaub et al., 2001).  Recently, nicotinic acid has been reported to induce 
peroxixome proliferator-activated receptor γ (PPARγ), CD36 and ATP-binding 
cassette A1 (ABCA1) expression and transcriptional activity in macrophages 
(Knowles et al., 2006; Rubic et al., 2004). These are key players in the reverse 
cholesterol transport pathway and therefore any increase in expression would result in 
an enhancement of cholesterol removal. The mechanism by which the nicotinic acid 
receptors regulate PPARγ is currently not known. However, it provides an interesting 
link to understanding how the nicotinic acid receptors are involved in reverse 
cholesterol transport.  
The nicotinic acid-induced flushing response and expression of PPARγ are examples 
demonstrating how cell type specific expression of receptors can achieve signal 
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specificity and diverse physiological responses. The differential responses mediated 
by the nicotinic acid receptors have been summarised in Figure 1.21 (Pike, 2005). 
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Figure 1.15 Schematic diagram of the possible lipid-modifying mechanism of action of 
nicotinic acid via a Gi coupled GPCR 
Abbreviations: CETP: cholesteryl ester transfer protein, Gi: inhibitory G protein, 
NEFA: non-esterified fatty acids. Figure adapted from (Pike & Wise, 2004). 
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Figure 1.16 Molecular structures: Highlighting role of carboxyl group 
The carboxyl group conserved in nicotinic acid and acifran is thought to be important 
for receptor activation. Nicotinamide, which does not display anti-lipolysis 
characteristics, does not share this structural feature. From (Gille et al., 2008). 
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HM74A 
Figure 1.17 Physiological role of the nicotinic acid receptors: Negative feedback 
mechanism during starvation? 
Under conditions of starvation, β-adrenergic receptor (β-AR) can mediate an increase 
in intracellular cAMP levels that stimulate lipolysis. FFAs that are released from fat 
cells are then metabolised in the liver to ketone bodies, including β-hydroxybutyrate 
(β-OHB). β-OHB can inhibit lipolysis via activation of HM74A. HM74A-mediated 
inhibition of adenylyl cyclase (AC) activity and therefore the decrease in cAMP 
synthesis would counteract the increased β-AR-mediated cAMP formation and the 
decreased cAMP degradation by phosphodiesterase 3B (PDE-3B) under starvation 
conditions. I-R, insulin-receptor (Gille et al., 2008). 
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Figure 1.18 Molecular structures of ligands at HM74A 
Examples of molecular structures of ligands that act on HM74A (Gille et al., 2008). 
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Compound HM74A 
EC50 (μΜ) 
HM74 
EC50 (μΜ) 
Nicotinic acid 0.1 > 100 
Acifran 1.2 7 
Acipimox 5.1 > 100 
β-hydroxybutyrate 750 25,000 
Table 1.3 Pharmacological profile of ligands that act on the nicotinic acid receptors 
Summary of the potencies of the best described ligands of the nicotinic acid receptors. 
Acifran has similar potency at both HM74A and HM74. Other compounds described 
here are more potent at HM74A than HM74. Table adapted from (Offermanns, 2006).  
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HM74 
 
Figure 1.19  Predicted structure of the human nicotinic acid receptor HM74A 
Extracellular, transmembrane, and cytoplasmic regions are based on the structure of 
rhodopsin. Straight line indicates the disulphide bond found in the extracellular part of 
the receptor. HM74 has a C-terminus that is extended by 24 amino acids. White 
amino acid symbols on black circles and squares indicate residues in HM74A that 
differ from HM74. The arrows point to the corresponding amino acid in HM74. 
Squares represent residues that showed a significant difference in nicotinic acid 
binding when mutated in HM74A (Tunaru et al., 2005). 
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Figure 1.20 Interaction model of nicotinic acid at the binding site of HM74A 
A: The binding site of nicotinic acid is located between TM II, III, and VII 
(pink/yellow ribbon). B: Close-up view of the binding site. Acidic group of nicotinic 
acid (orange) interacts with the basic anchor point Arg111 at TM III, whereas the 
pyridine ring is embedded between Trp91 at the junction TM II/ECL1, Phe276, and 
Tyr284 at TM VII. The pyridine nitrogen is also bound to Ser178 in ECL2 via an H 
bond. Asn86 (TM II) restrains the orientation of Trp91 by hydrogen bond, and 
Phe180 (ECL2) restrains the orientation of Phe276 by aromatic interactions leading to 
a suitable and rigid binding cleft. Figure from (Tunaru et al., 2005). 
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HM74A 
Figure 1.21 Activation of HM74A  
Activation of HM74A can produce differential responses depending on the location of 
the receptor. TG, triglyceride. From (Pike, 2005). 
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1.9. Project aims 
It has been a long journey since the lipid-modulating benefits of nicotinic acid were 
first described in the late 1950s. In the past 50 years, small but definitive steps have 
led to a greater understanding of the mechanism by which this vitamin acts. There are, 
however, many unanswered questions. The recent identification of the nicotinic acid 
receptors has now further intensified research in this field and in the past few years 
many informative reports describing the action of these receptors have been 
published. Despite this, the exact molecular mechanism by which nicotinic acid 
regulates lipid levels via the nicotinic acid receptors is still not fully understood. Little 
is known about the regulation of these receptors with respect to desensitisation or 
resensitisation.  
As mentioned previously, HM74 and HM74A are highly homologous except in the C-
terminal region. HM74 has a 24 amino acid longer C-terminal tail than HM74A. As 
the C-terminal region of GPCRs often plays an important role in the regulation of 
receptor signalling, it was hypothesised that these receptors may be regulated 
differentially. The aim of the study was to study the regulation of these receptors and 
identify any potential differences.  
First, the tools required for this project were generated and the [35S] GTPγS binding 
assay was optimised to study these receptors. The tools included generation of epitope 
and fluorescent-tagged receptors to allow visualisation of the receptors in live and 
fixed cells. These recombinant receptors where then characterised first in transient 
then stable cell expression systems to confirm native pharmacology. The effects of 
agonist treatment on receptor internalisation, β-arrestin interaction and receptor 
phosphorylation were examined in stable cell lines expressing either the native or 
recombinant receptors. The kinetics of ERK1/2 activation were also studied to 
identify any potential differences between the two receptors. Nicotinic acid pre-
treatment studies to examine the desensitisation characteristics of HM74 and HM74A 
were also conducted. To further examine the role of the C-terminal tail in the 
regulation of the nicotinic acid receptors, C-terminal tail chimeras were generated and 
the pre-treatment studies were repeated. 
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2.  Materials and Methods 
2.1.  Materials 
2.1.1. General reagents, enzymes and kits 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Full range RainbowTM molecular weight markers, 1st strand DNA synthesis kit, 
protein G Sepharose, wheatgerm agglutinin coupled polystyrene imaging beads 
BDH, Lutterworth, Leicestershire, UK 
22 mm coverslips, microscope slides, sodium di-hydrogen orthophosphate 
(Na2HPO4), potassium hydroxide (KOH), potassium chloride (KCl), methanol, 
isopropanol 
Chemicon Europe Ltd., Chandlers Ford, UK 
ReBlot Plus solution 
Duchefa, Haarlem, The Netherlands 
Bactotryptone, yeast extract, bactoagar 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
Sodium chloride (NaCl), sodium hydroxide (NaOH), potassium di-hydrogen 
orthophosphate (KH2PO4), Tris base, HEPES, EDTA, SDS, calcium chloride (CaCl2), 
D-glucose, DTT, urea, glacial acetic acid, sucrose, potassium acetate (C2H3O2K), 
manganese chloride (MnCl2), glycerol, glycine, MOPS, ethylene glycol, ethanol, 
scintilliation vials (7 ml) 
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Flowgen Bioscience Ltd., Nottingham, UK 
Agarose 
Invitrogen Ltd., Paisley, UK 
NuPage Novex pre-cast 4-12 % Bis-Tris gels, NuPage MOPS SDS running buffer, 
deoxyribonuclease, Gel-Dry Drying solution 
Konica Europe, Hohenbrunn, Germany 
X-ray film 
KPL, Inc., Gaithersburg, MD 
SureBlue TMB substrate 
New England Biolabs, MA, USA 
Restriction endonucleases 
Pierce, Perbio Science UK Ltd., Tattenhall, Cheshire, UK 
Supersignal West Pico chemiluminescent substrate, EZ-Link Sulfo-NHS-SS Biotin, 
immobolised streptavidin beads 
Promega UK Ltd., Southampton, UK 
Pfu DNA polymerase, restriction endonucleases, T4 DNA ligase 
Qiagen, Crawley, West Sussex, UK 
QIAfilter maxiprep kit, QIAprep Spin miniprep kit, QIAQuick gel extraction kit, 
QIAQuick PCR purification kit, RNeasy kit 
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Roche Applied Science, Lewes, East Sussex, UK 
DNA molecular weight marker X, shrimp alkaline phosphatase, bovine serum 
albumin (BSA), fatty acid free (BSA), complete EDTA-free protease inhibitor tablet, 
deoxyribonucleotide triphosphates (dNTPs), N-Glycosidase-F, DOTAP transfection 
agent 
Semat International, Hatfield, UK 
GF/C fibreglass filters 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Triton X-100, Na-deoxycholate, magnesium chloride (MgCl2), bromophenol blue, 
BCA solution A, copper sulphate (CuSO4), rubidium chloride (RbCl2), ampicillin, 
kanamycin, Tween-20, ascorbic acid, sodium fluoride (NaF), guanosine diphosphate 
(GDP), deoxycholic acid (sodium salt), sodium azide (NaN3), DL-β-hydroxybutric 
acid sodium crystalline, paraformaldehyde (PFA), dimethyl sulfoxide (DMSO), 
Hoechst stain, ethylene glycol, sodium acetate (CH3COONa), di-sodium 
orthophosphate, ethidium bromide, forskolin, phorbol 12-myristate 13-acetate (PMA), 
nicotinic acid, H 89 dihydrochloride hydrate, RO 31-8220 methanesulfonate salt, 
guanosine 5’-diphosphate sodium salt, UK 14304 
Stratagene, Amsterdam, The Netherlands 
QuikChange site directed mutagenesis kit 
Tocris Bioscience, Northpoint, Avonmouth, UK 
Acifran 
ThermoElectron, Ulm, Germany 
All oligonucleotides used for PCR reactions  
 85 
Sanam Mustafa, 2008  
 
2.1.2. Tissue culture plastic ware and reagents 
Amaxa Biosciences 
MEF nucleofector Kit 
American Tissue Culture Collection, Rockville, USA 
HEK293T cells 
BD Bioscience, Cowley, UK 
75 cm2 and 125 cm2 Falcon vented tissue culture flasks 
Costar, Cambridge, MA, USA 
5 ml, 10 ml and 25 ml pipettes, 75 cm2 and 125 cm2 vented tissue culture flasks, 6 
well plates, and 10 cm dishes 
Invitrogen, Paisley, UK 
DMEM/F12 (minus L-glutamine), MEM non-essential amino acids, foetal bovine 
serum, dialysed foetal bovine serum, lipofectamine 2000 transfection agent, optimem-
1, L-glutamine (200 mM), zeocin, blasticidin, penicillin-streptomycin, geneticin 
G418, hygromycin B, new born calf serum, 2-mercaptoethanol, CHO K1 cell line, 
Flp-In CHO KI cell line, TrypLE Select animal origin free, CHO K1 cells, Flp-In 
CHO-K1 cells 
Greiner Bio-One, Kremsmünster, Austria  
384-well clear low volume plates 
GlaxoSmithKline, Harlow, UK 
Acipimox, MPCA and all GSK compounds were synthesised by GSK 
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MP Biomedicals, Solon, Ohio 
Phosphate-free DMEM 
Roche Applied Science, Lewes, East Sussex, UK 
Hygromycin B 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
DMEM (plus glucose plus L-glutamine minus pyruvate, L-glutamine), DMEM 
powder, 0.25 % trypsin-EDTA, poly-D-lysine, doxycycline, pertussis toxin, 
puromycin, poly-D-Lysine coated multiwell plates 
2.1.3. Radiochemicals 
Perkin-Elmer Life and Analytical Sciences, Beaconsfield, Buckinghamshire, UK  
[35S] GTPγS (1250 Ci/mmol) 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
[32] P orthophosphate 
2.1.4. Antisera 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Donkey anti mouse IgG-HRP conjugate, donkey anti rabbit IgG-HRP conjugate 
Abcam plc, Cambridge Science Park, Cambridge, UK 
Anti GAPDH, anti phospho-CREB ser 133  
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Cell Signaling Technologies, Danvers, MA, USA 
Anti p42/44 MAP kinase, anti phospho-p42/44 MAP kinase 
Santa Cruz Biotechnology, INC 
Anti GRK 2 (C-15), anti tubulin 
Anti VSV-G and all G protein antibodies were produced in-house.  
Refer to Tables 2.2 and 2.3 for details. 
2.1.5. Molecular Probes, Eugene, Oregon, USA 
Anti-mouse Alexa® 594 IgG conjugate, anti-rabbit Alexa® 594 IgG conjugate 
2.2.  Buffers 
2.2.1. General buffers 
Phosphate Buffered Saline (PBS) (10 x) 
137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4 
Diluted 1 in 10 prior to use and stored at 4 oC 
Tris Buffered Saline (TBS) (10 x) 
20 mM Tris-base, 150 mM NaCl pH 7.4 
Diluted 1 in 10 prior to use and stored at room temperature 
Tris-EDTA (TE) Buffer 
10 mM Tris, 0.1 mM EDTA pH 7.4 
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Stored at 4 oC 
Radioimmune precipitation assay (RIPA) Buffer (2x) 
100 mM HEPES (pH7.4), 300 mM NaCl, 2 % (v/v) Triton X-100, 1 % (w/v) Na-
deoxycholate, 0.2 % (w/v)  SDS 
Stored at 4 oC 
Diluted 1:2 prior to use with: 
0.5 M NaF, 0.5 M EDTA, 0.2 M Na4P2O7, 10 % (v/v) ethylene glycol, complete 
EDTA free protease inhibitor tablet 
Physiological Saline Solution pH 7.4 
130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, 10 mM D-
glucose 
Laemelli Buffer (2 x) 
0.4 M DTT, 0.17 M SDS, 50 mM Tris, 50 % (v/v) glycerol, 0.01 % (w/v) 
bromophenol blue 
Stored in aliquots at -20 oC 
2.2.2. Molecular biology solutions 
TAE Buffer (50 x) pH 8.0 
40 mM Tris base, 5 mM EDTA, 5.71 % (v/v) glacial acetic acid 
Diluted 1 in 50 prior to use and stored at room temperature 
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DNA Gel Loading Buffer (5 x) 
0.25 % (w/v) bromophenol blue, 40 % sucrose (w/v) in distilled H2O 
LB Media (Luria-Bertani Medium) 
1 % (w/v) bactotryptone, 0.5 % (w/v) yeast extract, 1 % NaCl (w/v), pH 7.4   
Sterilised by autoclaving at 126 oC 
LB Media containing agar (LBA) 
As above, with the addition of bactotryptone at 15 g/L prior to autoclaving  
Competent Bacteria Buffers 
Competent Bacteria Buffer 1: 
1 M KAc, 1 M RbCl2, 1 M CaCl2, 1 M MnCl2, 80 % glycerol 
pH 5.8 with acetic acid 
Filter sterilised and stored at 4 oC 
Competent Bacteria Buffer 2: 
100 mM MOPS pH 6.5, 1 M CaCl2, 1 M RbCl2, 80 % glycerol 
pH 6.5 with concentrated HCl 
Filter sterilised and stored at 4 oC 
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2.3.  Molecular biology protocols 
All reactions were performed using sterile techniques. 
2.3.1. Preparation of LB agar plates 
LBA medium was prepared as detailed in section 2.2.2. After autoclaving, the 
medium was allowed to cool to 50 oC prior to the addition of a selective antibiotic; 
ampicillin (50 μg/ml) and kanamycin (25 μg/ml). Approximately 25 ml of the LBA 
medium was poured per 10 cm Petri dish. The plates were left to set at room 
temperature before being stored at 4 oC. 
2.3.2. Preparation of competent bacterial cells 
DH5α E.coli cells were streaked onto an LB agar plate in the absence of selective 
antibiotics and incubated overnight at 37 oC. A single colony was inoculated into a 5 
ml culture of LB broth and grown in a shaking incubator for 16 hours at 37 oC. The 
culture was used to inoculate 100 ml of LB broth; this was grown with aeration at 37 
oC until the optical density at 550 nm reached 0.48. The culture was chilled on ice for 
5 minutes then spun at 805 g for 10 minutes at 4 oC. All traces of LB broth were 
removed and the pellet re-suspended in 20 ml of competent bacteria buffer one. The 
suspension was chilled on ice for 5 minutes prior to centrifugation at 805 g for 10 
minutes at 4 oC. The supernatant was removed and the cell pellet was re-suspended in 
2 ml of competent bacteria buffer two. The resulting cell suspension was chilled on 
ice for 15 minutes before being stored at -80 oC in aliquots until required. 
2.3.3. Transformation of competent bacterial cells 
Competent bacteria were allowed to thaw on ice for 30 minutes prior to use. 50 μl of 
competent bacteria was added to a chilled microfuge tube containing 1 – 10 ng of 
DNA. The reaction was chilled on ice for 15 minutes. The cells were heat shocked at 
42 oC for 90 seconds and chilled on ice for 2 minutes. 450 μl of LB broth was added 
to the cells and incubated at 37 oC for 45 minutes in a shaking incubator. 100 – 250 μl 
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of the reaction was plated onto a LB plate containing the appropriate selective 
antibiotic and incubated overnight at 37 oC.  
2.3.4. Preparation of plasmid DNA 
2.3.4.1. Mini-preps 
A single colony of transformed bacteria was used to inoculate a 5 ml LB culture 
containing the appropriate selective antibiotic. The culture was grown overnight at 37 
oC in a shaking incubator. Miniprep purification was carried out using a Qiagen 
miniprep kit as per manufacturer's instructions. 
2.3.4.2. Maxi-preps 
The Qiagen Qiafilter kit was used for larger scale DNA sample preparations. A single 
colony of transformed bacteria was used to inoculate a starter culture of LB 
containing the appropriate selective antibiotic. The culture was grown for 8 hours at 
37 oC in a shaking incubator. This culture was then used to inoculate 100 ml of LB 
media also containing the selective antibiotic. This was grown, in a vessel 4 times the 
volume of the culture, at 37 oC for 12-16 hours. Purification of DNA was carried out 
as per manufacturer's instructions.  
2.3.5. Quantification of DNA 
DNA samples, diluted 1:100, were quantified by measuring the absorbance of light at 
260 nm in a spectrophotometer. An A260 value of 1 unit relates to 50 μg/ml of double 
stranded DNA. Sample concentration is determined by: 
Sample concentration = A260 x dilution factor (100) x 50 μg/ml 
The purity of the DNA sample was determined by measuring the absorbance of light 
at 280 nm. Samples of adequate purity typically have A260:A280 ratio of between 1.5 
and 2.0.   
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2.3.6. Digestion of DNA with restriction endonuclease 
Diagnostic digests were prepared with 1 – 2 units of the appropriate restriction 
enzyme, buffer as specified by the manufacturer, and 1 μg of DNA, in a final volume 
of 20 μl. Reactions were incubated at the recommended temperature for 1 hour. For 
cloning purposes, 3 μg of DNA was digested, with 2 – 3 units of the appropriate 
restriction enzyme, overnight at the recommended temperature. Where appropriate 
restriction enzymes were heat inactivated at the recommended temperature. 
2.3.7. DNA gel electrophoresis 
Digested DNA samples or PCR reactions were analysed using gel electrophoresis. A 
1 % agarose gel was prepared in 1 x TAE and 0.5 μg/ml ethidium bromide. The gels 
were set in a horizontal gel tank (Life technologies, Gibco, Horizon 58 model) and 
once set immersed in 1 x TAE. Samples were diluted in 5 x DNA loading buffer and 
loaded along with the DNA molecular marker X. A voltage of between 75 – 120 mA 
was applied to separate the samples. The DNA fragments were visualised using an 
UV transilluminator. (BioRad transilluminatior).  
2.3.8. DNA purification from agarose gels 
DNA fragments of interest were excised from the gel and purified using the QiaQuick 
gel extraction kit as per the manufacturer’s instructions. DNA was eluted from the 
purification column using 30 μl sterile water. It is generally accepted around 20 % of 
the DNA sample is lost in purification steps. 
2.3.9. Alkaline phosphatase treatment of plasmid vectors 
Digestion by restriction enzymes result in exposed 5’-monophosphate groups in the 
nucleic acid strands. The 5´-monophosphate groups of the vector DNA can be 
hydrolysed by phosphatases to minimise vector re-ligation. Digested vector DNA was 
incubated with two units of shrimp alkaline phosphatase for 15 minutes (cohesive-end 
cloning) and 60 minutes (blunt-end cloning) at 37 oC. The enzyme was either heat 
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inactivated at 65 oC for 15 minutes or isolated by resolving on an agarose gel by 
electrophoresis and then extracted as previously described in section 2.3.8. 
2.3.10. Ligation of DNA 
Vector and insert DNA fragments were quantified by ethidium bromide fluorescence 
quantification. Vector and insert DNA fragments were ligated using T4 DNA ligase in 
a 1:3 ratio. The reaction was set up in a volume of 10 μl containing 1 unit of ligase 
and the supplied buffer. Cohesive-end ligations were performed at room temperature 
for 4 hours. Blunt-end ligations were performed overnight at 4 oC. The ligation 
reactions were transformed as detailed in section 2.3.3. 
2.3.11. Polymerase chain reaction 
2.3.11.1. Standard PCR 
PCR reactions were carried out to amplify DNA sequences and introduce sequences, 
such as new restriction sites and epitope tags. Pfu DNA polymerase was used due to 
its high fidelity and its ability to withstand higher temperatures.  
The PCR reactions contained;  
Pfu polymerase buffer (10 x)    5 μl 
DMSO (optional)     5 μl 
Deoxynucleotide tri-phosphates (dNTPs)  5 μl 
(0.2 mM of each dATP, dCTP, dGTP, dTTP) 
Primer sense: 25 pmol/μl     1 μl 
Primers antisense: 25 pmol/μl   1 μl 
DNA template: 50 ng/μl    1 μl 
Pfu enzyme: 1 unit     1 μl 
dH2O to a final volume of     50 μl 
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Reactions were carried out on an Eppendorf gradient Thermocycler. PCR cycles used 
were as follows and the annealing temperatures were dependent on the melting 
temperature (Tm) of primers used; 
1. Preheating   95 oC  5 min 
2. Denaturation   95 oC  1 min 
3. Annealing   50 - 60 oC  1 min 
4. Extension   72 oC  2.30 min 
5.  Repeat from step 2.     29 x 
6. End    72 oC  10 min 
7. Hold    4 oC 
2.3.11.2. QuikChange mutagenesis PCR 
The QuikChange site-directed mutagenesis method was used to make point mutations 
(either single or multiple residues). Manufacturer's instructions were followed when 
designing primers and carrying out the PCR reactions. 
PCR reactions were compiled with the following components: 50 ng DNA template, 
15 pM of both sense and anti-sense primers, 1 μl of dNTP mix (0.2 μM of each dATP, 
dCTP, dGTP and dTTP) and 2.5 units Pfu DNA polymerase, total volume of 50 μl 
with reaction buffer. Samples were cycled 30 times in an Eppendorf Thermocycler 
system under the following conditions: 
 Cycle 1:  95 oC for 30 seconds 
 Cycles 2-30:  95 oC for 30 seconds,  
50 oC for 1 minute  
68 oC for 1 minute per kbp of plasmid length 
The product was treated with 10 units DpnI restriction enzyme and incubated for 60 
minutes at 37 oC. Control reactions contained 50 ng DNA, 1 μl of dNTP mix and 1 μl 
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Pfu, total volume of 30 μl with reaction buffer. This allows the digestion of parental 
methylated dsDNA. The digested mutated DNA and control were then transformed 
into DH5α cells following the protocol described in section 2.3.3. 
2.3.11.3. RT-PCR 
Total RNA was extracted from 3T3 LI cells using the RNeasy miniprep procedure as 
per manufacturer’s instructions. Prior to reverse transcription, RNA was treated with 
deoxyribonuclease to ensure that there was no contamination with genomic DNA. 
First strand cDNA was produced using the first Strand cDNA synthesis kit. Detection 
of HM74A mRNA transcripts was carried out by PCR using 50 ng cDNA and 200 nM 
oligonucleotides corresponding to mouse HM74A. The primers used for the PCR 
were as follows;  
Murine HM74A  Sense  5’ – CTGCTGTGTGTTCCG – 3’,  
Anti-sense 5’ – CCAGATAAGGGG – 3’,  
cDNA was amplified using the conditions detailed in section 2.3.11.2. Samples were 
resolved on a 1 % agarose gel as described in section 2.3.7. 
2.3.12. DNA sequencing 
DNA sequencing was performed by The Sequencing Service (School of Life 
Sciences, University of Dundee, Scotland) using Applied Biosystems Big-Dye Ver 
3.1 chemistry on an Applied Biosystems model 3730 automated capillary DNA 
sequencer. 
2.4.  Cell Culture 
Sterile techniques were used for cell culture. 
2.4.1. Cell recovery 
Cells were recovered from liquid nitrogen storage by rapid thawing in a waterbath set 
at 37 oC. Cells were transferred to a 15 ml falcon tube already containing 10 ml of 
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pre-warmed growth medium and centrifuged at 290 g for 5 minutes. The resulting 
pellet was re-suspended in 10 mls of fresh medium and plated onto a 75 cm2 flask for 
recovery. Media was changed after 24 hours and as required thereafter. 
2.4.2. Cell maintenance 
2.4.2.1. CHO-K1 
Chinese hamster ovary cells (CHO-K1) were grown in F12-HAMS Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 % (v/v) foetal bovine 
serum (FBS) and 2 mM L-glutamine. Cells were grown in a humidified incubator of 
95 % air/5 % CO2 at 37 oC. 
2.4.2.2. Flp-In CHO-K1 
Cells were maintained in F12-HAMS DMEM supplemented with 10 % (v/v) FBS, 2 
mM L-glutamine, 1 % (v/v) penicillin and streptomycin and 100 μg/ml zeocin. Cells 
were grown in a humidified incubator of 95 % air/5 % CO2 at 37 oC.   
2.4.2.3. CHO-K1 stably expressing receptor 
Cells stably expressing the receptor were maintained in F12-HAMS DMEM 
supplemented with 10 % (v/v) dialysed FBS, 2 mM L-glutamine and 1 mg/ml G418.  
Cells were grown in a humidified incubator of 95 % air/5 % CO2 at 37 oC.  
2.4.2.4. Flp-In CHO-K1 stably expressing receptor 
Flp-In CHO-K1 cells were grown in F12-HAMS DMEM supplemented with 10 % 
(v/v) dialysed FBS, 2 mM L-glutamine, 1 % (v/v) penicillin and streptomycin and 200 
μg/ml hygromycin. Cells were grown in a humidified incubator of 95 % air/5 % CO2 
at 37 oC.   
2.4.2.5. HEK293T 
Human embryonic kidney cells stably expressing the SV40 large T-antigen 
(HEK293T) were grown in DMEM supplemented with 10 % (v/v) newborn calf 
serum and 2 mM L-glutamine. Cells were grown in a humidified incubator of 95 % 
air/5 % CO2 at 37 oC. 
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2.4.2.6. 3T3 L1 
Cells were maintained in DMEM supplemented with 10 % (v/v) newborn calf serum 
and 1 % (v/v) penicillin and streptomycin. Cells were grown in a humidified incubator 
of 95 % air/10 % CO2 at 37 oC. 
2.4.3. Passage of cells 
2.4.3.1. CHO-K1 and HEK293T 
Cells 80 – 90 % confluent were washed once with sterile PBS, and then incubated 
with 3 mls of sterile 0.25 % trypsin-EDTA for 3 minutes at 37 °C in a humidified 
incubator. Once detached, 5 ml of fresh media was added and the cells centrifuged at 
290 g for 5 minutes. The resulting pellet was re-suspended in fresh media and the 
cells plated into flasks, dishes, plates or coverslips as required. 
2.4.3.2. 3T3 L1 
Cells 50 – 60 % confluent were washed once with sterile PBS and incubated with 7 
mls of sterile 0.25 % trypsin-EDTA for 3 minutes at room temperature. Appropriate 
volume of fresh media was added to the trypsinised cells and they were plated into 
flasks or dishes as required. 
2.4.4. Liquid nitrogen storage 
Cells were trypsinised as described above, transferred to a 15 ml falcon tube and 
centrifuged at 290 g for 5 minutes. The supernatant was removed carefully and the 
pellet was re-suspended in 10 % (v/v) DMSO in FBS. Cells were aliquoted into 1 ml 
cryovials and cooled at a rate of -1 °C/minute. After 24 hours the cells were 
transferred to liquid nitrogen for long term storage. 
2.4.5. Differentiation of 3T3 L1 
Cells were grown to confluency, media was replaced with fresh growth media and left 
for 2 days. Media was then replaced with DMEM supplemented with 10 % (v/v) 
Myoclone FBS, 1 μg/ml insulin, 5 μM dexamethasone, 112 μg/ml IBMX. After two 
days, the media was very carefully aspirated so that the loosely attached cells were 
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not disturbed. DMEM supplemented with 10 % (v/v) myoclone FBS and 1 μg/ml 
insulin. Thereafter, every 2 days the cells were fed with DMEM supplemented with 
10 % (v/v) myoclone FBS. Following treatment with differentiating medium cells 
accumulated lipids and acquired adipose cell morphology. Cells were ready for use 
between day 8 and 12 post differentiation. 
2.4.6. Pertussis toxin treatment 
Cells were treated with 25 ng/ml pertussis toxin for 16 hours at 37 oC. 
2.4.7. Transient transfection 
2.4.7.1. Cationic lipid-based transfection 
Transfection of CHO-KI and HEK293 cells was performed with Lipofectamine 2000 
(Invitrogen) in accordance with the manufacturer’s instructions.  
2.4.7.2. Nucleofection 
Mouse embryo fibroblast (MEF) cells were nucleofected with Amaxa nucleofection 
kit in accordance with the manufacturer’s instructions (Amaxa nucleofector 1). 
2.4.8. Stable transfection 
2.4.8.1. DOTAP  
Fresh media was replaced on CHO-K1 cells that were 50 % confluent in a 10 cm dish. 
In a sterile microfuge tube, 5 μg of DNA and 40 μl DOTAP was added to a final 
volume of 200 μl of sterile Hepes Buffered Saline (20 mM HEPES, pH 7.4 150 mM 
NaCl) and left at room temperature for 15 minutes. This was then added to the cells in 
a dropwise manner and the cells were incubated in a humidified incubator of 95 % 
air/5 % CO2 at 37 oC for 48 hours. The cells were then plated onto four fresh 10 cm 
dishes and allowed to attach overnight. The following day the media was changed to 
DMEM containing 1 mg/ml G418. Controls of untransfected and mock transfected 
cells containing basal or G418 media were also set up and cell death was compared. 
Media was changed as required until single colonies appeared. These were then 
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transferred into 12 well plates and allowed to grow before being tested for receptor 
expression by immunoblotting and immunocytochemistry 
2.4.8.2. Lipofectamine 2000  
Transfection of CHO-KI cells was performed with Lipofectamine 2000 in accordance 
with the manufacturer’s instructions and cells were put on antibiotic selection as 
outlined as above. 
2.4.9. Generation of stable Flp-In CHO-K1 cell line 
Flp-In CHO-K1 cells were transfected with a mixture containing the desired receptor 
cDNA in the pcDNA5/FRT/TO vector and the Flp recombinase pOG44 vector in a 
1:9 ratio using Lipofectamine 2000 in accordance with the manufacturer’s 
instructions. After 48 hours, the medium was changed to medium supplemented with 
200 μg/ml hygromycin to initiate selection of stably transfected cells. Resistant clones 
were screened by immunoblotting and immunocytochemistry. 
2.4.10. siRNAi 
Transfection of CHO-K1 cells with siRNAi was performed with Lipofectamine 2000 
in accordance with the manufacturer’s instructions.  
2.4.11. Cell harvesting 
The media was discarded and cells washed 3 times in ice cold 1 x PBS. Cells were 
scraped from the dish using a disposable cell scraper and transferred to a 15 ml 
centrifuge tube.  The detached cells were centrifuged for five minutes at 805 g at 4 oC. 
After discarding the supernatant, the cell pellet was frozen at -80 oC until required. 
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2.5.  Biochemical assays and other methods of 
analysis 
2.5.1. Preparation of cell membranes 
2.5.1.1. Teflon homogeniser 
Harvested pellets were thawed and re-suspended in ice-cold Tris/EDTA (T.E.) buffer 
containing protease inhibitor tablets. The cells were homogenised by 50 passes of a 
glass-on-Teflon homogeniser. The resulting suspension was centrifuged at 153 g for 
10 minutes to remove unbroken cells and nuclei. The supernatant was subsequently 
ultracentrifuged at 89,000 g for 30 minutes in a Beckman Optima TLX 
Ultracentrifuge (Palo Alto, CA). The resulting pellet was re-suspended in T.E. buffer 
and passed 10 times through a 25 gauge needle. The protein concentration was 
determined as detailed in section 2.5.3 and the membranes diluted to 1 μg/μl and 
stored at -80 oC until required. 
2.5.1.2. Covaris acoustic cell disrupter 
Harvested pellets were thawed and re-suspended in 3 ml ice-cold T.E. buffer 
containing protease inhibitor tablets as above. Samples were transferred to Covaris 
tubes and placed in the Covaris acoustic cell disrupter (Covaris model S2) and pulsed 
(pulse 1) using the power tracking setting. 7 ml of T.E. was added to the sample and 
centrifuged at 200 g for 10 minutes at 4 oC to remove unbroken cells and nuclei. The 
supernatant was subsequently centrifuged at 88,900 g for 35 minutes. The supernatant 
was discarded and the pellet was re-suspended in 500 μl of T.E. buffer and pulsed 
again (pulse 2 and pulse 3). Settings for the pulses are summarised in table 2.1. The 
protein concentration was determined and the membranes diluted to 1 μg/μl and 
stored at -80 oC until required. 
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 Pulse 1 Pulse 2 Pulse 3 
Duty cycle 20 % 20 % 20 % 
Cycles/burst 500 500 500 
Cycles 1 2 1 
Intensity 6 6 2 
Time 30 sec 20 sec 40 sec 
Table 2.1 Covaris acoustic cell disrupter settings 
 
2.5.2. Preparation of cell lysates 
Cells were washed 3 times with ice cold 1 x PBS. An appropriate volume of 1 x RIPA 
buffer supplemented with an EDTA-free protease inhibitor tablet was added to the 
cells before scrapping. The lysates were rotated for 1 hour at 4 oC on a rotating wheel. 
After 1 hour, the samples were centrifuged at 21,000 g for 10 minutes. The 
supernatant was carefully removed into fresh eppendorf tubes and the protein 
concentrations of the samples were determined as detailed in section 2.5.3. The 
protein concentration of the samples was equalised to 1 μg/μl using 1 x RIPA and 2 x 
Laemmli buffer was added to the samples before storage. Cell lysates were then 
subjected to SDS-PAGE and Western blotting. 
2.5.3. BCA protein quantification 
The protein concentration in samples was quantified using the BCA assay.  This assay 
utilises bicinchoninic acid (BCA) and copper sulphate solutions, in which proteins 
reduce the Cu(II) ions to Cu(I) ions in a concentration dependent manner and the 
reduced Cu(I) can be bound by BCA. When BCA binds Cu(I) a colour change from 
green to purple occurs which has an absorption maximum of 562 nm. Using solutions 
of known protein concentrations (0 – 2 mg/ml) a standard curve was constructed, 
which allows the concentrations of unknown samples to be established. Solutions 
used in this assay consisted of: Reagent A – 1 % (w/v) BCA, 2 % (w/c) Na2C03, 0.16 
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% (w/v) sodium tartrate, 0.4 % NaOH, 0.95 % NaHCO3, pH 11.25 and Reagent B – 4 
% CuSO4.  One part reagent B was mixed with 49 parts reagent A and 200 μl of this 
solution added to 10 μl of protein standard or unknown sample in a 96 well ELISA 
plate. The assay was incubated at 37 oC for 20 minutes before the absorbance was 
measured at 492 nm.    
2.5.4. Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
Protein samples were resolved using sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples and full range Rainbow molecular weight 
markers were loaded onto pre-cast NuPage Novex bis-tris gels with 4-12 % 
acrylamide concentration. NuPage MOPS SDS buffer was used for electrophoresis at 
200 V using the XCell Surelock mini-cell gel tank until the dye front reached the foot 
of the gel. 
2.5.5. Western blotting 
Following separation of samples by SDS-PAGE as detailed in section 2.5.4, proteins 
were electrophoretically transferred onto a nitrocellulose membrane using the XCell II 
blot module. Proteins were transferred at 30 V for at least 1 hour in transfer buffer 
(0.2 M glycine, 25 mM Tris and 20 % (v/v) methanol). Efficient transfer was 
monitored using Ponceau stain (0.1 % (w/v) Ponceau S, 3 % (w/v) trichloroacetic 
acid). To block non-specific binding sites, the nitrocellulose membrane was incubated 
in 5 % (w/v) low fat milk in TBS/0.1 % (v/v) Tween 20 at room temperature on a 
rotating shaker for 2 hours. The membrane was incubated with primary antibody 
overnight in 5 % (w/v) low fat milk, TBS/0.1 % (v/v) Tween 20 containing the 
required antibody (Table 2.2) at 4 oC.  After overnight incubation, the membrane was 
washed (four 5 minute washes) in TBS/0.1 % (v/v) Tween 20. The horseradish 
peroxidase conjugated (HRP) secondary antibody (Table 2.2) in 5 % (w/v) low fat 
milk, TBS/0/1 % (v/v) Tween 20 was incubated at room temperature for 20 minutes.  
The membrane was washed as before in TBS/0.1 % (v/v) Tween 20. The 
nitrocellulose membrane was then incubated for 5 minutes with an enhanced 
chemiluminescent ECL substrate solution. Exposure and development of blue Kodak 
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film allowed visualisation of the protein of interest. To determine equal loading of 
samples, the blot was stripped and re-probed using different antibodies. To strip the 
antibodies from the nitrocellulose membrane, the membrane was washed for 15 
minutes in TBS/0.1 % (v/v) Tween 20 and then incubated for 15 minutes in 10 % 
(v/v) ReBlot Plus solution. The above process was repeated after blocking with 5 % 
(w/v) low fat milk in TBS/0.1 % (v/v) Tween 20. 
Primary antibody 
Dilution 
factor 
Secondary 
antibody 
Dilution 
factor 
Anti VSV-G 1:4000 Anti rabbit 1:5000 
Anti GFP 1:10000 Anti goat 1:10000 
Anti tubulin 1:10000 Anti mouse 1:5000 
Anti p44/42 MAP kinase 1:1000 Anti rabbit 1:5000 
Anti phospho p44/42 MAP kinase 1:1000 Anti mouse 1:5000 
Anti Gαi1,2 1319G 1:5000 Anti rabbit 1:5000 
Anti Gαq/G11 1:10000 Anti rabbit 1:20000 
Anti GRK 2 (C-15) 1:1000 Anti rabbit 1:5000 
Anti GAPDH 1:20000 Anti mouse 1:1000 
Anti phospho CREB ser 133 1:500 Anti rabbit 1:1000 
Table 2.2 Primary and secondary antibody dilutions for immunoblotting 
2.5.6. Endoglycosidase treatment 
Membrane preparations (50 μg) were treated with 1.5 units of Roche N-Glycosidase-F 
overnight at 32 oC. 
2.5.7. Nicotinic acid preparation 
DMEM solution was prepared from powder form and nicotinic acid stock solution 
was made up in this media. The pH was altered to pH 7.0 and the solution was filter 
sterilised, aliquoted and stored at 20 oC. 
2.5.8. ERK1/2 activation phosphorylation assay 
CHO-K1 cells grown to confluency in six well dishes were washed 2 times with 2 
ml/well basal media (CHO-K1 media described before containing no supplements) 
and serum starved overnight with the same media. The following day the media was 
changed to fresh basal media and the cells were serum starved for a further 2 hours. 
Unless specified the cells were stimulated for 5 minutes with the drug at 37 °C in a 
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humidified incubator of 95 % air/5 % CO2. Foetal bovine serum was utilised as a 
positive control. Cell lysates were prepared and samples were resolved and analysed 
by SDS-PAGE and immunoblotting. 
2.5.9. Cell surface biotinylation assay 
CHO-K1 cells, grown to 80 – 90 % confluency in six well dishes, were washed and 
treated with drug/vehicle for 30 minutes in a humidified incubator of 95 % air/5 % 
CO2 at 37 °C. The reaction was terminated by placing cells on ice and washing twice 
with 2 ml/well of ice-cold borate buffer (10 mM boric acid, 154 mM NaCl, 7.2 mM 
KCl, 1.8 mM CaCl2, pH 9.0). Unless otherwise stated, all subsequent procedures were 
performed at 4 °C. Cell surface glycoproteins were conjugated with biotin by 
incubation with freshly prepared one ml of 0.8 mM EZ-Link Sulfo-NHS-SS Biotin in 
borate buffer for 15 minutes at 0 °C in the dark. Cells were quenched by rinsing twice 
with 2 ml/well of glycine buffer (0.192 M glycine, 25 mM Tris, pH 8.3). The second 
wash was left on ice for five minutes before removing. Cells were lysed with 500 μl 
of 1 x RIPA buffer containing an EDTA-free protease inhibitor tablet. Insoluble 
material was removed by centrifugation for 30 minutes at 21,000 g and the soluble 
extracts were equalised for protein content and volume. A sample of the total extract 
was saved at this point. Cell surface biotinylated proteins were isolated using100 μl of 
ImmunoPure immobilized streptavidin beads. To avoid damaging the beads, the tip of 
a p200 pipette tip was cut and then used to dispense the streptavidin beads. After 1 
hour constant rotation, samples were centrifuged at 153 g for 2 minutes and the beads 
were washed 3 times with 1 x RIPA buffer and the residual supernatant was removed 
with a fine (30 gauge) needle. The biotinlyated proteins were eluted from the beads 
with 200 μl of 2 x Laemmli buffer containing 5 % beta-mercaptoethanol for 1 hour at 
37 °C. To pellet the beads, the samples were then centrifuged at 153 g for 2 minutes. 
A Hamilton syringe was used to remove the samples into a fresh microfuge tube. 
Laemmli buffer was added to the total and unbound extracts and the samples were 
analysed by SDS-PAGE and Western blotting. 
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2.5.10. eYFP fluorescence measurement 
Whole cell lysates prepared from cell lines stably expressing eYFP fusion receptors 
were equalised for protein concentration. 50 μl of cell lysates were then loaded into 
black-walled multiwell plates in triplicates and eYFP fluourscence was measured at 
490 nm with a Victor2 plate reader. Host cells not expressing the fusion protein and 
readings from blank wells served as negative controls. 
2.5.11. [32P] Orthophosphate incorporation into receptors 
CHO-K1 cells grown to confluency in six well dishes were washed twice with 2 
ml/well phosphate-free DMEM supplemented with 2 mM L-glutamine, 1 % (v/v) 
penicillin and streptomycin. Media was then replaced with 0.75 ml/well of the same 
medium supplementated 0.2 mCi/ml [32P] orthophosphate and the cells incubated for 
90 minutes at 37 °C in a humidified incubator of 95 % air/5 % CO2, in order to label 
the intracellular ATP pool with [32P]. After stimulation for 15 minutes at 37 °C with 
0.75 ml/well of 2 x concentrated drug/vehicle, the reaction was stopped by placing the 
cells on ice and washing the cells twice with 3 ml/well of ice-cold PBS. Unless 
otherwise stated, all subsequent procedures were performed at 4 °C. Cells were lysed 
with 500 μl of 1 x RIPA supplemented with an EDTA-free protease inhibitor tablet 
and 100 μM sodium orthovanadate and the samples were rotated for 1 hour. Insoluble 
material was removed by centrifugation for 15 minutes at 21,000 g and the soluble 
extracts were equalised for protein content and volume prior to receptor 
immunoprecipitation. Using a cut p200 tip, 20 μl of protein G was centrifuged at 130 
g for 30 seconds. Residual supernatant was removed with a 1 ml syringe. To this, 1 μl 
of the appropriate antibody and 100 μl of 2 % (w/v) IgG-free BSA in 1 x RIPA 
(supplemented with an EDTA-free protease inhibitor tablet and 100 μM sodium 
orthovanadate) was added and briefly vortexed. This antibody mixture was then added 
to the protein samples and rotated for 1 hour. The immune complexes were isolated 
by brief centrifugation (25 seconds at 153 g), and washed 3 times with 1 ml of 1 x 
RIPA, the residual supernatant was removed with a 1 ml syringe, and the immune 
complexes eluted from the beads by the addition 30 μl of 2 x Laemmli buffer. The 
samples were incubated overnight at room temperature. To pellet the beads, the 
samples were then centrifuged at 153 g for 25 seconds. A Hamilton syringe was used 
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to remove the samples into a fresh microfuge tube. The samples were resolved by 
SDS-PAGE and the gel dried overnight using Invitrogen’s Gel-Dry. The 
phosphoproteins were visualised by autoradiography after 72 hours exposure at -80 
°C. 
2.5.12. Cell surface receptor measurement and Enzyme-
linked Immunosorbent assay (ELISA) 
50, 000 CHO-K1 cells expressing recombinant receptors (100 μl/well) were plated 
onto poly-D-lysine treated 96 well plates and allowed to attach overnight. The next 
day the cells were treated with drug/vehicle for 30 minutes in a humidified incubator 
of 95 % air/5 % CO2 at 37 oC. Four replicates per sample were included in each assay. 
2.5.12.1. Live cells 
Media was removed and the primary anti VSV-G antibody (1:1000 dilution, made up 
in growth media) was added 100 μl/well and incubated for 30 minutes at 37 °C. The 
primary antibody was then removed and the cells were washed once with 100 μl/well 
of sterile DMEM/20 mM HEPES pH 7.4. In a final volume of 100 μl/well, a mixture 
of HRP-conjugated secondary antibody (anti-rabbit HRP 1:5000 dilution) and 
Hoechst nuclear stain (1:1000 dilution), made up in growth media, was added to the 
cells and incubated for a further 30 minutes at 37 oC. The secondary antibody mixture 
were removed and the cells were washed twice with pre-warmed 1 x PBS. During the 
second wash, cell number was determined by measuring Hoechst staining (excitation, 
355 nm and emission 460 nm). After the reading, the PBS was completely removed 
and 100 μl/well of SureBlue TMB substrate was added and the cells incubated in the 
dark for 5 – 10 minutes before the absorbance was measured at 620 nm. Victor2 plate 
reader was used for both readings (PerkinElmer Life Sciences). 
2.5.12.2. Fixed and permeabilised cells 
Media was removed and the cells were washed 3 times with 100 μl/well room 
temperature 1 x PBS. The cells were then fixed with 4 % (w/v) PFA/5 % (w/v) 
sucrose in 1 x PBS for 10 minutes at room temperature. Cells were then permeabilised 
with 5 % (w/v) BSA/0.15 % (v/v) Triton X-100/1 x PBS for 10 minutes at room 
temperature. Cells were then washed 3 times with 100 μl/well room temperature 1 x 
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PBS and the primary anti VSV-G antibody (1:1000 dilution, made up in 5 % (w/v) 
BSA/1 x PBS) was added 100 μl/well and incubated for 30 minutes at room 
temperature. The primary antibody was then removed and the cells were washed once 
with 100 μl/well 1 x PBS. In a final volume of 100 μl/well, a mixture of HRP-
conjugated secondary antibody (anti-rabbit HRP 1:5000 dilution) and Hoechst stain 
(1:1000 dilution), made up in 5 % (w/v) BSA/1 x PBS, was added to the cells and 
incubated for a further 30 minutes at room temperature. The secondary antibody 
mixture was removed and the cells were washed twice with pre-warmed 1 x PBS. 
During the second wash, Hoechst staining was measured (excitation, 355 nm and 
emission 460 nm). After the reading, the PBS was completely removed and 100 
μl/well of TMB substrate was added and the cells incubated in the dark for 5 – 10 
minutes before the absorbance was measured at 620 nm. Victor2 plate reader was 
used for both readings (PerkinElmer Life Sciences). 
2.6. Immunocytochemistry 
2.6.1. Immunostaining 
CHO-K1 cells expressing recombinant receptors were plated onto sterile poly-D-
lysine coated coverslips and allowed to attach overnight. Cells were treated with the 
primary antibody diluted in sterile DMEM/20 mM HEPES pH 7.4 for 40 minutes in a 
humidified incubator of 95 % air/5 % CO2 at 37 oC.  Following this drug/vehicle was 
added to the antibody/DMEM/HEPES mix for a further 30 minutes. The cells were 
washed three times with 2 mls/coverslip ice cold 1 x PBS (each wash was left on for 5 
minutes). The cells were then fixed with 1.5 mls/coverslip of 4 % (w/v) PFA/5 % 
(w/v) sucrose in 1 x PBS for 10 minutes at room temperature. Cells were washed 
three times again with 1 x PBS, as before. The cells were then permeablised with 2 
mls/coverslip of 3 % (w/v) low fat milk/0.15 % (v/v) Triton X-100/1 x PBS for 10 
minutes at room temperature. The secondary antibody was then diluted in 3 % (w/v) 
low fat milk/0.15 % (v/v) Triton X-100/1 x PBS. The antibody solution was then 
centrifuged for 1 minute at 130 g to pellet undissolved antibody aggregates and 200 μl 
of the supernatent was spotted onto nescofilm. Coverslips were incubated cell side 
down for 1 hour at room temperature. Coverslips were carefully returned to the six 
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well dishes and washed 3 times with 3 % (w/v) low fat milk/0.15 % (v/v) Triton X-
100/1 x PBS for 5 minutes each time. The cells were then washed with 3 times with 1 
x PBS, again for 5 minutes each time. The last wash was not removed and 8 μl of 40 
% (v/v) glycerol in 1 x PBS was spotted onto microscope slides. The excess PBS was 
removed from the coverslips by brief drying and the coverslip was placed slowly on 
the spotted glycerol, cell side down avoiding air bubbles. Cells were analysed by 
confocal microscopy straight away or covered in foil and stored at 4 oC until required. 
Primary antibody Dilution factor Secondary antibody Dilution factor 
Anti-c-myc 1:100 Anti-rabbit alexa 594 1:400 
Anti-flag M2 1:1000 Anti-mouse alexa 594 1:400 
Anti-vsv 1:1000 Anti-rabbit alexa 594 1:400 
Table 2.3 Primary and secondary antibody dilutions for immunocytochemistry 
 
2.6.2. Confocal microscopy: Fixed cells 
Cells expressing recombinant receptors were plated onto sterile poly-D-lysine coated 
coverslips and allowed to attach overnight. Cells were treated with drug/vehicle for 30 
minutes in a humidified incubator of 95 % air/5 % CO2 at 37 oC. The cells were 
washed 3 times with 2 mls/coverslip room temperature 1 x PBS and fixed with 1.5 
mls/coverslip of 4 % PFA 5 % sucrose in 1 x PBS for 10 minutes at room 
temperature. Cells were washed 3 times again with 2 mls/well room temperature 1 x 
PBS. The last wash was not removed and 8 μl of 40 % (v/v) glycerol in 1 x PBS was 
spotted onto microscope slides and the coverslips mounted as described before. Cells 
were analysed by confocal microscopy straight away or covered in foil and stored at 4 
oC until required. 
Cells were observed using a laser scanning confocal microscope (Zeiss LSM 5 Pascal, 
Carl Zeiss Inc., Thornwood, NY) with a 63 x 1.40 numeric aperture oil-immersion 
Plan Fluor Apochromat objective lens, pinhole setting of 20, and electronic zoom of 1 
or 2.5. eYFP was excited using 488 nm argon/krypton laser and detected using a 505 
– 530 nm band pass filter. Alexa 594 label was detected using a 543 nm helium/neon 
laser and detected with a 560 nm long-pass filter. Images acquired using identical 
capture parameters were processed for presentation, off-line, using MetaMorph 
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software (Version 6.1.3: Universal Imaging Corporation, Downing, PA, USA). For 
purposes of clarity, some images are presented at different magnifications. 
2.6.3. Epifluorescence (widefield)  microscopy: Live cells 
CHO-K1 cells expressing recombinant receptors were plated onto sterile poly-D-
lysine coated coverslips and allowed to attach overnight. Coverslip fragments were 
placed into a microscope chamber containing physiological saline solution. 
Fluorescent images of the cells were acquired using a Nikon Eclipse TE2000-E 
fluorescence inverted microscope (Nikon Instruments, Melville, NY) equipped with a 
x40 (numerical aperture 1.3) oil immersion Plan Fluor lens and a cooled digital 
CoolSNAPHQ charge-coupled device camera (Photometrics, Tucson, AZ). The filter 
set used for eYFP (excitation – 500/5 nm; emission – 535/30 nm). Collected images 
were processed off-line, using MetaMorph and MetaFluor imaging software 
(Universal Imaging Corporation, Downing, PA, USA). Images were compared with 
identical image capture parameters. For purposes of clarity, some images are 
presented at different magnifications. 
2.7. Pharmacological assays 
2.7.1. [35S] GTPγS Binding Assay: Filtration 
[35S] GTPγS binding experiments were initiated by the addition 10 μg of membranes 
expressing the receptor of interest to 800 μl of assay buffer (20 mM HEPES, 10 mM 
MgCl2, 100 mM NaCl pH 7.4 supplemented with 10 mg/litre saponin and 10 µM 
GDP) containing the given concentration of agonist. All reactions were performed in 
triplicates. After pre-incubation for 15 minutes at room temperature, 0.1 nM [35S] 
GTPγS was added and assays were incubated for a further 30 minutes at room 
temperature. The reactions were terminated by filtration of the samples onto GF/C 
fibre glass filters followed by three 4 ml washes of ice-cold 1 x T.E. buffer by a 
Brandel cell harvester. Three mls of scintillation fluid was added to the filters, the 
samples were vortexed and the bound [35S] GTPγS was measured by liquid-
scintillation spectrometry. Data were analysed using GraphPad Prism software.  
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2.7.2. [35S] GTPγS Binding Assay: Scintillation proximity 
assay 
[35S] GTPγS binding assays were conducted at room temperature in a 384 well 
format. Membranes (1.5 μg/point) were diluted to 0.3 mg/ml in assay buffer (20 mM 
HEPES, 10 mM MgCl2, 100 mM NaCl pH 7.4) supplemented with 30 μg/ml saponin, 
GDP (10 μM/point) and wheat germ agglutinin SPA beads (90 μg/point) and allowed 
to pre-couple on a roller at room temperature for 30 minutes. The membrane and GDP 
mixture was then mixed with a 0.3 nM of [35S] GTPγS in a 1:1 mix. Then 10 μl of the 
reaction was dispensed into a low volume 384 well plate using a Multidrop dispenser 
and the plates were sealed and centrifuged for one min at 200 g. Bound [35S] GTPγS 
was measured by scintillation counting on a ViewLux 1430 ultraHTS Microplate 
Imager (PerkinElmer). Data were analysed using GraphPad Prism (GraphPad 
Software).  
2.7.3. Pre-treatment 
Monolayers of cells were treated with drug/vehicle for desired time. The reaction was 
stopped on ice and cells were then washed 3 times with ice cold 1 x PBS. Cells were 
harvested and membrane preparations were prepared as normal. 
2.7.4. Data analysis 
Data were analysed using GraphPad Prism software. Concentration response curves 
for ligand effects on [35S] GTPγS binding were analysed by non-linear regression 
using a sigmoidal concentration/response relationship with a Hill coefficient of 1 to 
derive pEC50 values. Where stated, data from at least 3 independent studies were 
grouped and the means ± SEM was presented as per cent stimulation over basal, 
where the baseline values were normalised to 100 %. Where appropriate a one-way 
analysis of variance test followed by a Dunnett post test was completed.  
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3.  Generation of tools to study regulation and 
desensitisation mechanisms of the nicotinic 
acid receptors 
3.1.  Introduction 
The molecular identification of receptors for nicotinic acid has provided the tools to 
further our knowledge of the mechanism of action of this lipid-modulating molecule. 
In order to study these GPCRs in various biochemical and pharmacological assays a 
range of tools were generated and assays were optimised. 
3.1.1. Detection and visualisation of GPCRs 
Detection and visualisation of proteins using fluorescent and epitope tags have greatly 
facilitated the study of GPCR signalling pathways and localisation. The understanding 
of fluorescent proteins has come a long way since Shimomura and co-workers 
purified the green fluorescent protein (GFP) from the jellyfish, Aequoria victoria in 
the 1970s (Morise et al., 1974). Subsequent cloning and sequencing of the GFP gene 
by Prasher and co-workers (Prasher et al., 1992) and demonstration of its expression 
in Escherichia coli (E.coli) by Chalfie and his group (Chalfie et al., 1994) allowed its 
use in cellular assays including reporter gene assays. However, the use of fluorescent 
proteins has now become routine across many research disciplines and is no longer a 
novel technique reserved only for molecular biology laboratories.  
Its popularity is mainly due to its fully functional fluorescent state, in a variety of 
expressions systems, without the need for any substrates or accessory proteins 
(Chalfie et al., 1994). The development of a wide range of variants of GFP, with 
distinct spectral properties, has also increased its appeal especially in the study of 
protein-protein interactions. Due to their relatively small size of 27 kDa, these 
fluorescent proteins have successfully been fused onto the C-terminus of many 
GPCRs without disrupting the ligand binding and signal transduction characteristics 
of the receptors (Milligan, 1999). The fluorescent fusion proteins can then simply be 
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visualised by confocal laser scanning or an epifluorescence microscope; or detected 
by immunoblotting with an antibody raised against the fluorescent protein. 
Like fluorescent proteins epitope tags also serve as useful tools for studying GPCRs. 
The addition of short peptide sequences, usually added at the N- or C-terminus of a 
receptor, makes the protein immunoreactive to a known tag-specific antibody. This 
facilitates the detection of the protein by immunocytochemistry or immunoblotting 
without the need for receptor specific antibodies. This not only provides a cost 
effective and rapid method for protein detection but also avoids cross-reaction of the 
tag-specific antibody with proteins related to the protein of interest (Jarvik & Telmer, 
1998). Again, due to their small size the tags are unlikely to affect the biochemical 
properties of the receptor of interest. 
3.1.2. [35S] GTPγS binding assay 
The [35S] guanosine-5’-O-(3-thio) triphosphate (GTPγS) binding assay measures one 
of the earliest receptor-mediated events. Determining the binding of the poorly 
hydrolysable GTP-analogue [35S] GTPγS to G protein α subunits measures the level 
of G protein activation as a result of agonist occupation of a GPCR. Figure 3.1 is a 
schematic diagram illustrating the principle of this assay, which was first practised in 
1984 with purified β–adrenergic receptors (Asano et al., 1984). Binding of this cell 
impermeable nucleotide is now commonly performed using cell membranes, as 
described by (Hilf et al., 1989). 
The aim of this chapter was to characterise a series of tagged receptor constructs, first 
in a transient and then in a stable expression system. In order to fully characterise the 
recombinant receptors the [35S] GTPγS binding assay was optimised to investigate the 
ability of the tagged receptor constructs to respond to nicotinic acid and display native 
pharmacology. 
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3.2.  Optimisation of [35S] GTPγS binding 
To allow an optimal signal to background window the [35S] GTPγS assay was 
optimised utilising CHO-K1 cell lines stably expressing the HM74A or HM74 
receptor, generated by collaborators at GlaxoSmithKline (GSK), Harlow. The 
optimisation experiments were based around published conditions by this group (Wise 
et al., 2003). To allow a fair comparison between the experiments, a large membrane 
preparation was generated for each of the samples and aliquoted for use. Unless 
stated, HM74A and HM74 expressing membranes were incubated with 1 and 10 mM 
nicotinic acid respectively. Nicotinic acid was prepared in stock buffer and the pH 
was altered to pH 7 with potassium hydroxide. In each experiment a negative control 
of membranes prepared from parental CHO-K1 cells and a positive control of 
membranes prepared from HEK293 cells expressing the α2A-adrenergic receptor was 
also included. The α2A-adrenergic receptor was fused to the α subunit of the pertussis 
toxin-sensitive G protein Gαo which contained a mutation (C351I) making it 
insensitive to pertussis toxin. 
To determine the optimum incubation time, this assay was set up as described in 
section 2.7.1 and incubated for 0.5, 1, 2 and 4 hours at room temperature. The assay 
was terminated by filtration of the samples onto GF/C fibre glass filters followed by 3 
x 4 ml washes of ice-cold 1 x T.E buffer. 
As expected, no increase in [35S] GTPγS binding to parental CHO-K1 membranes was 
observed in the presence of nicotinic acid. However an increase in [35S] GTPγS 
binding was observed in membranes expressing the α2A-adrenergic receptor and Gαo 
fusion protein (α2A-adrenergic-GαoC351I) in the presence of 1 μM UK 14304, a known 
α2-adrenergic receptor agonist (Burt et al., 1998). With respect to membranes 
expressing the HM74A receptor, Figure 3.2 suggests that although [35S] GTPγS 
binding achieved a maximal level by the first time point assessed and did not vary 
subsequently in the presence of nicotinic acid, due to an increase in the basal binding 
of [35S] GTPγS in the absence of ligand, the longer incubation times reduced the 
signal to background window. Although the signal to background ratio for both the 
0.5 and 1 hour incubation conditions was sufficient for further analysis, the 0.5 hour 
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time point was chosen for further experiments as it was also the time point published 
by Wise and co-workers for this particular cell line (Wise et al., 2003). 
Varying concentrations (5, 10, 40 and 100 μM) of guanosine diphosphate (GDP) were 
then tested for their effect on [35S] GTPγS binding on HM74A expressing membranes. 
A reduction in basal [35S] GTPγS binding values in the presence of increasing GDP 
concentration was observed in Figure 3.3. The largest signal to background window 
was observed in conditions with 10 and 5 μM GDP. 10 μM GDP was chosen for 
further experiments as this was also the GDP concentration published by collaborators 
in GSK (Wise et al., 2003). A pEC50 value of 6.2 ± 0.1 M for nicotinic acid was 
calculated from concentration response curves utilising 10 μM GDP (Figure 3.4). 
Three amounts of HM74A expressing membranes (5, 10, and 15 μg) were tested to 
determine the optimal signal to background window for this assay. Increasing 
amounts of protein, as expected, resulted in higher levels of [35S] GTPγS binding both 
in the presence and absence of the ligand. Although a suitable signal to background 
was seen in all conditions, a significant increase in [35S] GTPγS binding over basal 
was observed in samples containing 10 μg of membranes (Figure 3.5), and therefore 
10 μg of protein was utilised for further [35S] GTPγS binding experiments. This was 
also the protein amount utilised by collaborators at GSK (Wise et al., 2003). 
Utilising the optimised conditions established for HM74A expressing CHO-K1 cells, 
a nicotinic acid concentration response curve was employed to test the response of 
nicotinic acid at HM74 (Figure 3.6). Nicotinic acid has been described as a low 
potency ligand at HM74 (Wise et al., 2003). Due to practical limitations, accurate 
pEC50 values can not be calculated in such cases, however pEC50 values can be 
estimated from the available data. In this case, a pEC50 value in excess of 2.9 ± 0.2 M 
was estimated for nicotinic acid. 
3.3.  Generation of tagged receptor constructs 
To allow detection and visualisation of the nicotinic acid receptors, epitope and 
fluorescent protein tagged recombinant receptors were generated and cloned into a 
pcDNA3 plasmid. This plasmid is routinely utilised for expression of recombinant 
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proteins in mammalian cells. It allows efficient expression of proteins of interest 
under the control of the human cytomegalovirus (CMV) promoter. Amongst features 
shared with other plasmids it carries an ampicillin antibiotic resistance gene for 
selection in E.coli bacteria and a neomycin antibiotic resistance gene for selection of 
stable transfects in mammalian cells (Figure 3.7 A). 
Nucleotides encoding the eleven amino acid sequence (YTDIEMNRLGK ) for the 
epitope VSV-G, from the vesicular stomatitis virus glycoprotein, (Kreis, 1986), were 
introduced by PCR at the 5’ end of cDNA encoding both the HM74 and HM74A 
receptors. The appropriate human cDNA template was utilised. HM74 and HM74A 
are highly homologous with only 20 base differences at the cDNA level – mainly at 
the 3’ region (Wise et al., 2003). Therefore the same forward primer sequence was 
utilised for both receptors. The forward primer was designed to introduce a 6 base 
pair Kozak sequence to the 5’ of the VSV-G tag to enhance translation of the protein 
(Kozak, 1987). The primer also incorporated a Hind III recognition sequence; this 
introduced the restriction site at the extreme 5’ end of the receptor cDNA sequence to 
aid cloning of the receptor into expression plasmids. To allow primer recognition, 18 
bases of the nicotinic acid receptor cDNA sequence minus the ATG start codon were 
also incorporated into the primer. To allow efficient binding and digestion by the 
endonuclease, primers were designed with extra bases before the sequence for the 
restriction site. The reverse primer was designed to introduce a Kpn I restriction site 
at the 3’ end of the receptor cDNA sequence; again extra bases were added after the 
restriction site sequence to allow efficient digestion of the receptor. Primer sequence 
information is summarised in Table 3.1. 
The resulting VSV-G tagged receptor cDNA was then sub-cloned into a pcDNA3 
plasmid already engineered to contain the sequence for enhanced yellow fluorescent 
protein (eYFP) as shown in Figure 3.7 B. Enhanced (e) YFP is a red-shifted GFP 
variant with an excitation maximum of 500 nm and an emission maximum of 535 nm. 
3.4.  Characterisation of receptor constructs 
The receptor constructs were then sequenced and tested to confirm that the addition of 
the epitope tag and fluorescent protein did not have any adverse effects on the 
 116 
Sanam Mustafa, 2008  
 
biochemical properties of the receptors. The receptors were transiently transfected 
into HEK293 and CHO-K1 cells. Introduction of the receptor constructs into the host 
cell lines will result in the expression of a fusion protein containing the VSV-G 
epitope and eYFP tagged nicotinic acid receptor. Therefore expression of this receptor 
can be detected by determining the fluorescence from the eYFP fusion protein in the 
cells by direct visualisation by imaging or by immunoblotting techniques. The 
presence of the VSV-G epitope tag can also be detected by these methods however an 
immunostaining step would be required to visualise the VSV-G tag by imaging 
techniques. 
3.4.1. Detection of recombinant receptor constructs 
Membrane preparations of the transfected HEK293 and CHO-K1 cells were prepared. 
The samples were resolved by SDS-PAGE and immunoblotted with anti VSV-G and 
anti GFP antisera as described in chapter 2.5.5. The anti GFP antiserum is able to 
detect eYFP as eYFP differs from GFP by only one amino acid. Figure 3.8, is an 
immunoblot of receptor constructs transiently transfected into HEK293 host cells. A 
VSV-G antibody positive control employed an N-terminally tagged CXCR2 (VSV-G 
CXCR2) receptor. A negative control of the untransfected parental cell line was also 
included. The VSV-G CXCR2 receptor was detected only in the anti VSV-G blot, at 
the expected approximate size of 36 kDa and at around 70 kDa. This larger protein is 
approximately the size at which the VSV-G CXCR2 homodimer would be expected. 
The calculated molecular mass of the VSV-G HM74A eYFP and VSV-G HM74 
eYFP receptors was approximately 66 and 68 kDa respectively. Both were detected 
with anti VSV-G and anti GFP antisera. Compared to the VSV-G HM74A eYFP 
receptor, a very faint band at the expected size was detected for the VSV-G HM74 
eYFP receptor. As equal amounts of protein samples were resolved this suggested this 
receptor was expressed at a lower level. Subsequently, to confirm published data that 
HM74 lacks N-linked glycosylation sites near the N-terminus (Nomura et al., 1993), 
membranes expressing recombinant nicotinic acid receptors were treated with N-
Glycosidase-F. Again, VSV-G CXCR2 receptor was utilised as a control for the 
treatment because this receptor is known to be N-glycosylated (Wilson et al., 2005). 
In samples treated with N-Glycosidase-F, a single polypeptide was detected instead of 
a doublet at around 35 kDa. There was no change in the pattern of proteins observed 
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for the recombinant nicotinic acid receptors. This suggests both nicotinic acid 
receptors are not N-glycosylated or if so, the glycosylation is not susceptible to 
cleavage by this enzyme. As expected, no immunoreactive proteins were detected in 
the parental negative control sample. Similar observations were made when the 
nicotinic acid receptor constructs were transiently expressed in CHO-K1 cell lines 
(data not shown). 
3.4.2. Localisation studies 
Detection of the VSV-G epitope and eYFP tagged forms of the nicotinic acid 
receptors in the membrane preparations by immunoblot suggest the tags have not 
interfered with the translation. Characteristically GPCRs are expressed at the plasma 
membrane with an extracellular N-terminus and intracellular C-terminal domain. This 
allows the receptors to transduce extracellular signals via intracellular messengers. To 
explore if the tagged nicotinic acid receptor constructs were delivered to the plasma 
membrane, a cell surface ELISA assay was adopted to detect cell surface expression 
of the receptors in intact cells. The N-terminal VSV-G tag was utilised in this assay as 
it would only be detected by an anti VSV-G antibody if expressed at the extracellular 
surface. Again, the receptor constructs were transiently transfected into a HEK293 
cell line. Parental HEK293 cells were included as a negative control. When compared 
to the background signal detected from parental HEK293 cells the signal observed 
from cells expressing VSV-G HM74A eYFP receptors was significantly higher (P < 
0.01). Although the signal detected from cells expressing VSV-G HM74 eYFP 
receptors was slightly higher when compared to the signal detected in HEK293 cells, 
it was not significant in a one-way analysis of variance test (Figure 3.9). 
The receptors were initially visualised utilising the eYFP tag by confocal imaging. 
Figure 3.10 A, is a representative image obtained of the VSV-G HM74A eYFP 
receptor transiently expressed in HEK293 cells. An expression pattern consistent with 
cell surface expression was observed. A similar expression pattern was also observed 
when this experiment was repeated in CHO-K1 cells (Figure 3.10 B). Figure 3.10 B 
demonstrates the ability of the VSV-G epitope tag to be detected by 
immunocytochemistry techniques. Although a similar expression pattern was also 
observed for VSV-G HM74 eYFP, due to the very low expression following transient 
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expression it was not possible to obtain high quality images. Taken together with the 
data obtained from the cell surface ELISA assay, it can be summarised that HM74A 
was expressed at the plasma membrane. 
3.5.  Generation and characterisation of CHO-K1 cell 
lines stably expressing recombinant nicotinic acid 
receptors 
Epitope and fluorescent protein tagged versions of the nicotinic acid receptors were 
transfected into CHO-K1 cells using DOTAP, see section 2.4.8.1. The transfected 
cells were then exposed to G418 antibiotic selection, as described in chapter 2.4.8.1, 
resulting in the identification of clones that were resistant to the antibiotic and hence 
potentially expressing the recombinant receptor. Stable expression should allow 
consistent expression levels of the recombinant nicotinic acid receptors and therefore 
also consistency between experiments. CHO-K1 cells were chosen due to their robust 
nature and also to allow comparison with the existing CHO-K1 cell lines stably 
expressing the untagged nicotinic acid receptors described in section 3.2. As this 
method of generating cell lines stably expressing the protein of interest relies upon 
random integration of the cDNA into the genomic DNA of individual CHO-K1 cells, 
clonal selection of the cells was necessary to generate a population of cells with the 
same genetic background. 
3.5.1. Screening and localisation studies 
As mentioned above, transfection and therefore random integration takes place at a 
cellular level. Therefore the expression of a protein in each cell is dependent on the 
transfection efficiency and site of recombination. It is accepted that all cells treated 
with a transfection agent will not have been successfully transfected. Also, it is 
possible that in a successfully transfected cell, the cDNA of the receptor may not be 
integrated in a transcriptionally active locus.  
For this reason, following clonal selection by G418, at least 20 clones per cell line 
were initially tested by confocal microscopy for expression of eYFP and hence the 
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recombinant receptor. Clones where no eYFP fluorescence was detected were 
disregarded. From the remaining clones, although some showed intracellular receptor 
expression, as seen in Figure 3.11 A, seven clones for VSV-G HM74A eYFP 
demonstrated expression patterns indicative of substantial cell surface expression, 
Figure 3.11 B. As mentioned earlier, GPCRs are typically expressed at the cell 
surface. For this reason from the clones displaying predominantly cell surface 
expression, three clones displaying similar levels of fluorescence were chosen for 
further examination (Figure 3.11 C). However, only one clone expressing the VSV-G 
HM74 eYFP receptor was identified (Figure 3.12). Although this clone displayed both 
cell surface and intracellular expression, due to a lack of choice, this clone was 
selected and analysed further. 
3.5.2. Detection of recombinant receptor constructs 
Cell lysates prepared from the chosen clones were resolved by SDS-PAGE and 
immunoblotted to detect the VSV-G epitope and eYFP tags as described in section 
3.4.1. A protein polypeptide of the expected size representing the recombinant 
HM74A or HM74 receptor was detected in all three clones expressing the VSV-G 
HM74A eYFP receptor (Figure 3.13) and the only identified clone expressing the 
VSV-G HM74 eYFP receptor (Figure 3.14). 
3.5.3. Functional analysis 
The ability of the modified receptors stably expressed in CHO-K1 cell lines to 
respond to nicotinic acid was tested in a [35S] GTPγS binding assay. Membrane 
preparations expressing the modified HM74 and HM74A receptors were incubated 
with 1 and 10 mM nicotinic acid respectively. An increase in [35S] GTPγS binding 
over basal was observed for all cell lines and for both receptors (Figure 3.15 A). In 
nicotinic acid concentration response curves, pEC50 values comparable to the native 
nicotinic acid receptors were calculated for all clones expressing VSV-G HM74A 
eYFP (Figure 3.15 B). Clone B5:16 was chosen for further studies of the VSV-G 
HM74A eYFP receptor. Due to a low signal to background window and eventual loss 
of expression of the VSV-G HM74 eYFP receptor, clone D1:12 was disregarded.  
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3.6.  Generation of Flp-In CHO-K1 cell lines stably 
expressing the recombinant nicotinic acid 
receptors 
As mentioned above, a loss of expression of the VSV-G HM74 eYFP receptor was 
observed in the only clone identified with expression of this receptor. Due to an 
extremely low transfection and recombination efficiency experienced with this 
receptor it was decided to make use of the Flp-In CHO-K1 cell line marketed by 
Invitrogen. In this cell line a single stably integrated Flp recombinase target (FRT) 
site has been engineered into a transcriptionally active genomic locus of the CHO-K1 
cell line. Complementary (c) DNA of the protein of interest is delivered via a 
pcDNA5/FRT/T0 expression vector. When transfected together with a Flp 
recombinase vector, pOG44, it allows targeted homologous recombination as opposed 
to random integration relied upon in conventional methods of generating cell lines 
stably expressing proteins of interest. In theory, this should produce an isogenic cell 
line without the need for clonal selection. A Flp-In CHO-K1 was generated for each 
of the modified nicotinic acid receptors as described in the chapter 2.4.9. 
3.6.1. Localisation, detection and functional analysis 
Direct visualisation of eYFP fluorescence using a fluorescence microscope confirmed 
receptor expression and localisation indicative of plasma membrane expression 
(Figure 3.16 A). As before both the VSV-G epitope and eYFP tags were detected by 
immunoblotting (Figure 3.16 B). Membranes expressing either the VSV-G HM74A 
eYFP or the VSV-G HM74 eYFP receptors were tested to confirm their response to 
nicotinic acid in [35S] GTPγS binding assays as described before (Figure 3.17). In 
nicotinic acid concentration response curves, pEC50 values obtained were comparable 
to those obtained with the native nicotinic acid receptors. The Flp-In CHO-K1 cell 
line stably expressing the VSV-G HM74 eYFP receptor was utilised for further 
experiments. 
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3.7.  Receptor expression 
Data presented so far suggests that VSV-G HM74 eYFP is expressed at a lower level 
compared to VSV-G HM74A eYFP following transient expression. Due to the low 
affinity of HM74 for nicotinic acid, binding studies to quantitatively study receptor 
numbers was not feasible. For this reason, to measure and compare the relative 
receptor levels between the CHO-K1 cell line stably expressing VSV-G HM74A 
eYFP and the Flp-In CHO-K1 cell line stably expressing VSV-G HM74 eYFP, eYFP 
fluorescence of lysates prepared from the two cell lines was measured using a Victor2 
plate reader (Figure 3.18). Fluorescence measurements obtained for the VSV-G 
HM74A eYFP receptor were double that for the VSV-G HM74 eYFP receptor. 
To examine receptor expression at the cell surface in these cell lines, cell surface 
biotinylation experiments were utilised as described in chapter 2.5.9. Both cell lines 
were treated with EZ-Link Sulfo-NHS-SS biotin to label the ε-amine of lysine 
residues of proteins expressed at the cell surface. These cells were then lysed and 
streptavidin beads, which have a high affinity for biotin, were used to pulldown the 
biotinylated proteins.  Biotinylated samples eluted from the beads were then analysed 
by immunoblotting with an anti VSV-G antibody to detect receptor specific proteins. 
As only receptors at the cell surface can be biotinylated this assay allowed 
comparison of cell surface expression of the recombinant nicotinic acid receptors. 
Figure 3.19, is an immunoblot comparing cell surface expression of the modified 
receptors. For each of the receptors three samples were analysed. The samples in lane 
1 are aliquots of cell lysates equalised for protein content and represent the total 
receptor population. An aliquot of the supernatant was also saved after the pulldown 
step. This sample containing unbound receptor is represented in lane 2. It is difficult 
to conclude if this represents the intracellular receptor population or unbound 
biotinylated receptor. However it is likely to be a combination of both. Samples in 
lane 3 represent the biotinylated receptors present at the cell surface. Both VSV-G 
HM74A eYFP and VSV-G HM74 eYFP were detected at the anticipated size in all 
three samples, confirming cell surface expression of these receptors. However, a more 
intense signal was detected in samples representing biotinylated VSV-G HM74A 
eYFP compared to the signal corresponding to the biotinylated VSV-G HM74 eYFP. 
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As protein content of the samples were equalised, this supports the observation that 
VSV-G HM74 eYFP receptors are expressed at a lower level at the cell surface. 
3.8.  Generation of Flp-In TREx CHO-K1 
The Flp-In TREx system has been developed by Invitrogen to allow control over the 
expression of a protein from cDNA stably integrated into a cell line (Figure 3.20). It is 
based on the Flp-In system and has been described on many occasions to express one 
protein of interest constitutively while the expression of another protein of interest, 
delivered to the Flp-In locus, is controlled by the experimenter (Lane et al., 2007; 
Milasta et al., 2006). This system allows the study of two different proteins in the 
same cell line with the added benefit of control of expression of the inducible protein. 
In a Flp-In TREx cell line a Tet repressor gene is stably cloned into the host cell 
genome. The gene of interest is introduced into the cell line via a pcDNA5/FRT/T0 
expression vector and its expression is controlled by the human CMV promoter. In the 
absence of tetracycline or doxycycline (a tetracycline derivative) the gene encoding 
the Tet repressor is translated and the resulting protein binds to the Tet operator 
inserted into the CMV promoter. This represses the expression of the gene of interest. 
To express the gene of interest, tetracycline or doxycycline is introduced. This then 
binds strongly to the Tet repressor causing it to undergo a conformational change and 
therefore unable to bind to the Tet operator.  
Invitrogen have developed this system for a number of cell types including HEK293 
cells. However, the Flp-In TREx system is not commercially available in a CHO-K1 
cell background. Invitrogen supply the materials claimed to allow the generation of 
this tetracycline regulated expression system in any cell line. With an aim to allow 
comparison between all cell lines it was decided to generate this system in CHO-K1 
cells so studies could be conducted to analyse any interactions between the highly 
homologous nicotinic acid receptors. 
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3.8.1. Strategy A 
In order to generate the Flp-In TREx system in the CHO-K1 cell line, a pcDNA6/TR 
regulatory vector expressing high levels of the tetracycline repressor was introduced 
into the Flp-In CHO-K1 cells stably expressing the VSV-G HM74 eYFP and VSV-G 
HM74A eYFP receptors (described in section 3.7). These transfected cells were then 
placed on 200 μg/ml hygromycin and 5 μg/ml blasticidin antibiotic selection to select 
for cells expressing both the receptor and repressor respectively. The inducible system 
was tested by analysing the expression of the receptors (by confocal analysis of eYFP 
fluorescence) in the presence and absence of 1 μg/ml doxycycline. In the absence, of 
doxycycline treatment the repressor should be active and therefore no receptor eYFP 
expression should be visualised. However, after a 24 hour doxycycline induction 
receptor expression is expected in a successful inducible system. 
Five clones expressing the VSV-G HM74A eYFP receptor were tested. However, 
none of these cell lines displayed the characteristics of an inducible cell line. Receptor 
expression was observed in non-induced and induced cells at similar levels (Figure 
3.21). However, out of the eight clones tested for the VSV-G HM74 eYFP expressing 
cells no receptor expression was detected in doxycycline treated or non-treated cells 
(Figure 3.22). 
3.8.2. Strategy B 
In another attempt to make a Flp-In TREx CHO-K1 cell line, the tetracycline 
repressor was transfected into parental Flp-In CHO-K1 cells. The transfected cells 
were then placed on zeocin and blasticidin antibiotic selection in accordance with 
Invitrogen’s guidelines. Twenty clones were then screened to identify those with 
stable expression of the tetracycline repressor. Recombinant HM74A receptor cDNA 
was transiently transfected into all the clones and fluorescence of the eYFP was 
visualised in doxycycline treated and non-treated cells. Although receptor expression 
was observed in control and induced cells (data not shown), the clone displaying the 
lowest basal levels and highest inducible levels of VSV-G HM74A eYFP receptor 
expression was chosen to generate two cell lines stably expressing the tagged HM74 
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or HM74A receptors. Again, VSV-G HM74A eYFP expression was not inducible 
(data not shown) and no VSV-G HM74 eYFP expressing clones were identified.  
3.9.  Discussion 
The recent identification of the nicotinic acid receptors as molecular targets for 
nicotinic acid therapy has opened up many opportunities for understanding the 
mechanisms by which it successfully lowers total plasma levels of cholesterol. This 
may allow further understanding of the pathways involved in the side effects 
associated with nicotinic acid use, as well the potential for developing more novel and 
potent drugs. Generating cell lines and developing assays to facilitate our 
understanding of the molecular pharmacology of these receptors was a major 
objective of this study. 
In this chapter, the optimisation of the [35S] GTPγS binding assay has been described 
for the HM74 and HM74A nicotinic acid receptors stably expressed in CHO-K1 cells. 
These cell lines were chosen as they expressed the unmodified, wild type receptor 
proteins and therefore the data obtained from the optimisation experiments could be 
compared with published data. As noted earlier, collaborators at GSK (Harlow) 
generated these cell lines and published the conditions used in a [35S] GTPγS 
scintillation proximity assay (SPA) (Wise et al., 2003). Although the principles of this 
assay are the same, industry favours this low volume high throughput system to 
enable high throughput screening. The details of this assay have been described in 
section 2.7.2. The optimisation experiments were based around published data by 
Wise and co-workers. The optimised conditions of 10 μg membranes, 10 μM GDP 
and an incubation time of 30 minutes time were similar to the published conditions. 
With respect to the GDP concentration, Lorenzen and co-workers have reported 
maximum agonist-induced increases in [35S] GTPγS were observed at 10 μM GDP for 
assays studying these receptors (Lorenzen et al., 2001). As high concentrations of 
GDP have been reported to reduce agonist affinity (Lorenzen et al., 2001), the lower 
GDP concentration of 10 μM was especially important for the low affinity HM74 
receptor. The pEC50 value for nicotinic acid at HM74A was in agreement with 
published data (Lorenzen et al., 2001; Wise et al., 2003; Tunaru et al., 2003). Due to 
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the low potency of nicotinic acid at HM74, it is not possible to calculate accurate 
pEC50 values. However, the estimated pEC50 values were in the mM range described 
in published studies (Lorenzen et al., 2001; Wise et al., 2003; Tunaru et al., 2003).  
Technical difficulties have to be overcome when studying recently identified 
receptors where protein specific antibodies are not available. For this reason 
recombinant receptor constructs expressing the VSV-G epitope and eYFP tags were 
generated for each of the receptors. However, the introduction of N- and C-terminal 
modifications to GPCRs can potentially impact receptor function. Although, the N-
terminal VSV-G epitope tag is not close to the predicted ligand binding sites of the 
nicotinic acid receptors, formed by transmembrane helices (TMH) II, III and VII 
(Tunaru et al., 2005), the C-terminal region of GPCRs are often important in 
regulating receptor endocytosis and G protein interactions. Therefore the addition of a 
fluorescent protein to the C-terminal region of HM74 or HM74A can potentially alter 
its regulation or pharmacology. 
To rule out any detrimental effects of the tagging, the recombinant receptors were first 
characterised in transient then stable expression systems. Plasma membrane 
expression of the receptor was confirmed by confocal analysis, cell surface ELISA 
and biotinylation studies. In [35S] GTPγS binding studies the pEC50 values obtained 
for the tagged receptors were comparable to those for the untagged receptors and also 
the published data. Data presented in this chapter, suggest that the pharmacological 
properties of the nicotinic acid receptors are not disrupted by the presence of the N- 
and C-terminal tags. 
From the studies conducted, it has become apparent that the VSV-G HM74 eYFP 
receptor is difficult to transfect into cells; low transfection efficiency together with 
very low expression made this receptor difficult to work with. Due to very low 
expression of VSV-G HM74 eYFP in a transient system it was difficult to collect data 
about the effects of the tags on this receptor. Even in the presence of antibiotic 
selection pressure during the generation of a CHO-K1 cell line stably expressing this 
receptor, only one clone expressing VSV-G HM74 eYFP was identified.  
Unfortunately this clone lost expression of the receptor at an early stage. More 
success was experienced when a Flp-In CHO-K1 cell line was utilised for stable 
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expression. Characterisation experiments in this cell line confirmed cell surface 
expression and native pharmacology.  
Due to the very low affinity of HM74 for nicotinic acid, receptor numbers could not 
be quantified by binding experiments (Taggart et al., 2005; Wise et al., 2003). 
However, relative receptor levels between the modified HM74 and HM74A 
expressing cell lines were compared by measuring the eYFP fluorescence in cell 
lysates prepared from each of the cell lines. Although VSV-G HM74 eYFP was 
expressed at a lower level compared to VSV-G HM74A eYFP, there were sufficient 
expression levels for receptor detection and receptor activation studies. The relative 
expression levels are consistent with literature reporting lower expression of HM74 
than HM74A in human adipocytes (Semple et al., 2006). 
In order to study both modified HM74 and HM74A receptors together in the same cell 
line it was decided to make use of the well documented inducible Flp-In TREx system 
(Milasta et al., 2006; Lane et al., 2007). As noted, this system was not available in a 
CHO-K1 cell background. With the aim to keep the cell backgrounds for all the cell 
lines stably expressing the nicotinic acid receptors constant, two independent attempts 
were made to generate the Flp-In TREx system in CHO-K1 cells. On both occasions a 
successful inducible system was not achieved. Researchers in Unilever, Netherlands 
have also experienced problems with generating a Flp-In TREx CHO-K1 cell line 
(personal communication, Dr. K. Wieland). As this system is available to purchase in 
a number of cell lines, it is surprising that Invitrogen do not have a Flp-In TREx 
system for one of the most routinely used cell lines. It may be this particular cell line 
poses inherent technical difficulties that make it difficult to generate a successful 
inducible system. 
The data shown in this chapter confirm that the N- and C-terminal modified nicotinic 
acid receptors stably expressed in a CHO-K1 cell background do not possess different 
pharmacological properties to the untagged receptors. 
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Figure 3.1 Schematic diagram illustrating the principle of the [35S] GTPγS assay 
A: In the inactive state the GDP bound G protein α (Gα) subunit associates with the 
β/γ complex to form an inactive heterotrimeric G protein. Upon ligand activation the 
GPCR undergoes a conformational change resulting in increased affinity for the G 
protein; this results in the exchange of GDP for GTP on the Gα subunit, which 
reduces the affinity of the Gα subunit for the β/γ complex and therefore leads to 
dissociation of the heterotrimeric G protein. Both the Gα subunit and the β/γ complex 
can then interact with effectors, transducing the signal. B: The activated state lasts 
until the GTP is hydrolysed to GDP by the intrinsic GTPase activity of the Gα 
subunit. This assay measures the ligand induced activation of the Gα subunit by using 
a radiolabelled analogue of GTP, [35S] GTPγS. The binding of the poorly 
hydrolysable [35S] GTPγS to the Gα subunit can then be measured by liquid-
scintillation spectrometry. 
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Figure 3.2 Optimisation of [35S] GTPγS assay: Incubation time 
10 μg of CHO-K1 membranes stably expressing HM74A were incubated in the 
presence (red) and absence (blue) of 1 mM nicotinic acid in a [35S] GTPγS assay. 
Assays were incubated for 0.5, 1, 2 and 4 hours at room temperature. Membranes 
prepared from parental CHO-K1 cells were utilised as a negative control and were 
incubated with (red) or without (blue) 1 mM nicotinic acid. HEK293 membranes 
expressing α2A-adrenergic-GαoC351I served as a positive control and were incubated 
with (red) or without (blue) 1 μM UK 14304. Assays were terminated by filtration of 
the samples onto GF/C fibre glass filters. Bound [35S] GTPγS was measured by 
liquid-scintillation spectrometry. Assays were performed in triplicate and are 
representative of three experiments. Data points represent means ± SEM. A: Binding 
of [35S] GTPγS. B: HM74A expressing membranes.  
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Figure 3.3 Optimisation of [35S] GTPγS assay: GDP concentration 
GDP concentrations of 5, 10, 40 and 100 μM were tested using 10 μg of HM74A 
expressing CHO-K1 membranes in a [35S] GTPγS assay. Membranes were incubated 
with (red) or without (blue) 1 mM nicotinic acid for 30 minutes at room temperature. 
A negative control of membranes generated from parental CHO-K1 cells were 
incubated with (red) or without (blue) 1 mM nicotinic acid. HEK293 membranes 
expressing α2A-adrenergic-GαoC351 were utilised as a positive control and were 
incubated in the presence (red) and absence (blue) of 1 μM UK 14304. Assays were 
terminated by filtration of the samples onto GF/C fibre glass filters. Bound [35S] 
GTPγS was measured by liquid-scintillation spectrometry. Experiments were 
performed in triplicate and data points represent means ± SEM. Data shown is 
representative of three experiments. A: Binding of [35S] GTPγS. B: HM74A 
expressing membranes. A reduction in the binding of [35S] GTPγS was observed in 
the presence of increasing concentrations of GDP.  
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Figure 3.4 Optimisation of [35S] GTPγS assay: Nicotinic acid concentration response 
curve utilising optimised GDP concentration  
A nicotinic acid concentration response curve was employed using 10 μg of HM74A 
expressing CHO-K1 membranes in a [35S] GTPγS assay containing 10 μM GDP. 
Following 30 minutes incubation at room temperature the assay was terminated by 
filtration of the samples onto GF/C fibre glass filters. Bound [35S] GTPγS was 
measured by liquid-scintillation spectrometry. pEC50 = 6.2 ± 0.1 for nicotinic acid 
was calculated. Experiments were performed in triplicate and data were analysed 
using GraphPad Prism software. Data points represent means ± SEM from a single 
experiment, representative of three independent experiments. 
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Figure 3.5 Optimisation of [35S] GTPγS assay: Protein amount 
The optimal protein amount was determined by testing 5, 10 and 15 μg of HM74A 
expressing CHO-K1 membranes in a [35S] GTPγS assay containing 10 μM GDP. The 
membranes were incubated in the presence (red) or absence (blue) of 1 mM nicotinic 
acid for 30 minutes at room temperature. Membranes prepared from parental CHO-
K1 cells were utilised as a negative control and were incubated as HM74A expressing 
membranes. α2A-adrenergic-GαoC351 expressing HEK293 membranes were incubated 
with (red) or without (blue) 1 μM UK 14304 and were utilised as a positive control. 
Assays were terminated by filtration of the samples onto GF/C fibre glass filters and 
bound [35S] GTPγS was measured by liquid-scintillation spectrometry. Assays were 
performed in triplicate and data points represent means ± SEM, representative of three 
experiments. A: Binding of [35S] GTPγS. B: HM74A expressing membranes. An 
increase in the binding of [35S] GTPγS was observed in the presence of increasing 
protein amount. 
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Figure 3.6 Nicotinic acid concentration response curve: HM74 
A nicotinic acid concentration response curve was set up to test the response of 
nicotinic acid at HM74 stably expressed in CHO-K1 cells utilising the optimised 
conditions. Following 30 minutes incubation at room temperature the assay was 
terminated by filtration of the samples onto GF/C fibre glass filters and bound [35S] 
GTPγS was measured by liquid-scintillation spectrometry. pEC50 = 2.9 ± 0.2 for 
nicotinic acid was estimated. Experiments were performed in triplicate and data were 
analysed using GraphPad Prism software. Data points represent means ± SEM from a 
single experiment, representative of three independent experiments. 
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Figure 3.7 Schematic map of pcDNA3 vector and schematic diagram of the HM74 and 
HM74A receptor constructs generated 
A: pcDNA3 has been engineered to contain a multiple cloning site comprising DNA 
sequences recognised by the restriction enzymes detailed in the map. This allows 
introduction of a cDNA sequence of interest which is expressed under the control of 
the human cytomegalovirus (CMV) promoter. Amongst other features, it carries an 
ampicillin antibiotic resistance gene for selection in E.coli bacteria and a neomycin 
antibiotic resistance gene for selection of stable transfects in mammalian cells. 
(pcDNA3 map, Invitrogen) B: The VSV-G epitope tag was engineered at the 5’ 
region of the HM74 and HM74A cDNAs by PCR. The Hind III and Kpn I restriction 
sites also generated by PCR, at the indicated sites, were utilised for sub-cloning the 
epitope tagged receptors into a pcDNA3 expression vector already possessing eYFP 
cDNA sequence.   
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Primer cDNA template Introduce Sequence 
Forward HM74 
or 
HM74A 
Hind III restriction 
site 
Kozak sequence 
VSV-G epitope tag 
At 5’ end 
5’ GTA CGT CCA AGC 
TTG CCA CCA TGT ACA 
CCG ATA TCG AAA TGA 
ACC GCC TTG GTA AGA 
ATC GGC ACC ATC TGC 
AG 3’ 
Reverse HM74 Kpn I restriction site 
At 3’ end 
5’ GTA CGT CCG GTA 
CCA GGA GAG GTT GGG 
CCC AG 3’ 
Reverse HM74A Kpn I restriction site 
At 3’ end 
5’ GTA CGT CCG GTA 
CCC TCG ATG CAA CAG 
CCC AAC TG 3’ 
Table 3.1 Primer sequences 
Primer sequences designed to introduce the Hind III restriction site and VSV-G 
epitope at the 5’ end and the Kpn I restriction site at the 3’ end of human HM74 and 
HM74A receptor cDNA. 
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Figure 3.8 Immunoblot detecting VSV-G epitope and eYFP-tagged forms of the 
nicotinic acid receptors 
VSV-G HM74A eYFP and VSV-G HM74 eYFP cDNAs were transiently transfected 
separately into HEK293 cells. 10 μg of membrane preparations prepared from each 
were resolved by SDS-PAGE and immunoblotted to detect the VSV-G (A) and eYFP 
(B) tags. A VSV-G antibody positive control used VSV-G CXCR2 receptor expressed 
in HEK293 cells and detected a band at the expected size of 36 kDa. A negative 
control of the untransfected parental cell line was also included. VSV-G HM74A 
eYFP was detected by both anti VSV-G and anti GFP antisera at its anticipated size of 
66 kDa. VSV-G HM74 eYFP was also detected by both antisera at around 68 kDa but 
a weak signal was detected, suggesting lower expression of this receptor. A: N-
Glycosidase-F treatment (+) of membranes expressing recombinant nicotinic acid 
receptors did not alter the pattern of proteins detected compared with samples not 
treated with N-Glycosidase-F (-). VSV-G CXCR2 receptor was utilised as a positive 
control for N-Glycosidase-F treatment. Results shown are of a single experiment, 
representative of three individual experiments.  
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Figure 3.9 Cell surface receptor measurement by ELISA 
Cell surface expression of the recombinant nicotinic acid receptors was measured in 
transiently transfected HEK293 cells in a whole cell ELISA assay utilising an anti 
VSV-G antibody. A negative control of the parental HEK293 cell line was included. 
When compared to parental HEK293 cells, the signal detected from HEK293 cells 
expressing VSV-G HM74A eYFP was significantly higher (* = P < 0.01). The signal 
detected from HEK293 cells expressing VSV-G HM74 eYFP was not significantly 
different in a one-way analysis of variance test (p > 0.05). Data points represent 
means ± SEM. Results are representative of three independent experiments.  
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Figure 3.10 Localisation of VSV-G HM74A eYFP receptors 
VSV-G HM74A eYFP cDNA was transiently transfected into (A) HEK293 and (B) 
CHO-K1 cells. (A) HEK293 cells expressing VSV-G HM74A eYFP receptor were 
directly visualised for eYFP fluorescence (green) by confocal imaging. (B) Detection 
by confocal imaging of the VSV-G tag (red) in permeabilised and immunostained 
cells, direct visualisation of eYFP fluorescence (green) and a merge of the two images 
(yellow).
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 Clone B5:16 Clone B5:4 Clone B5:13 
Figure 3.11 Identification of CHO-K1 cell lines stably expressing the VSV-G HM74A 
eYFP receptor 
CHO-K1 cells were transfected with VSV-G HM74A eYFP cDNA and subjected to 
G418 antibiotic selection. Clones resistant to G418 antibiotic selection were screened 
by direct visualisation by confocal imaging utilising the eYFP tag to identify VSV-G 
HM74A eYFP expression. A: These two images are representative of clones that were 
disregarded due to intracellular receptor expression. B and C: Representative of 
clones with cell surface receptor localisation. C: Clones chosen for further analysis. 
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Clone D1:12 
 
Figure 3.12 Identification of a CHO-K1 cell line stably expressing the VSV-G HM74 eYFP 
receptor 
CHO-K1 cells were transfected with VSV-G HM74 eYFP cDNA and placed under 
G418 antibiotic selection. Clones resistant to G418 antibiotic selection were screened 
by direct visualisation by confocal imaging utilising the eYFP tag to identify VSV-G 
HM74 eYFP expression. Only one clone expressing VSV-G HM74 eYFP was 
identified and therefore analysed further. 
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Figure 3.13 Detection of VSV-G and eYFP tagged forms of the HM74A receptor stably 
expressed in CHO-K1 cells 
The three clones described in Figure 3.11 stably expressing VSV-G HM74A eYFP 
were compared to confirm receptor expression and detection of tags. 20 μg of cell 
lysates prepared from these clones were resolved by SDS-PAGE and immunoblotted 
with anti VSV-G (A) and anti GFP (B) antibodies. Protein bands representing the 
tagged receptor were detected at the anticipated size in immunoblots against the VSV-
G tag and eYFP protein in each clone. 
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Figure 3.14 Detection of VSV-G and eYFP tagged forms of the HM74 receptor stably 
expressed in CHO-K1 cells 
20 μg of cell lysates prepared from cells stably expressing VSV-G HM74 eYFP 
(described in figure 3.12) were resolved by SDS-PAGE and immunoblotted to detect 
the VSV-G (A) and eYFP (B) tags. In each immunoblot, protein bands representing 
the VSV-G HM74 eYFP receptor were detected at the expected size. 
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Nicotinic acid 
pEC50  
B5:4 6.3 ± 0.1 
B5:13 6.6 ± 0.1 
B5:16 6.3 ± 0.2 
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Figure 3.15 Functional analysis of CHO-K1 cell lines stably expressing modified 
versions of the nicotinic acid receptors 
[35S] GTPγS binding assays were employed to test the response of tagged nicotinic 
acid receptors to nicotinic acid. The assays were terminated after 30 minutes at room 
temperature by filtration of the samples onto GF/C fibre glass filters. Bound [35S] 
GTPγS was measured by liquid-scintillation spectrometry. A: Modified HM74A and 
HM74 were incubated in the presence (red) and absence (blue) of 1 and 10 mM 
nicotinic acid respectively. Membranes prepared from parental CHO-K1 cells were 
utilised as a negative control and were incubated with (red) or without (blue) 10 mM 
nicotinic acid. Membranes expressing α2A-adrenergic-GαoC351 served as a positive 
control and were incubated with (red) or without (blue) 1 μM UK 14304.  B: 
Nicotinic acid concentration response curves (final concentrations ranging from 1 nM 
to 1 mM) on the tagged HM74A receptors (summary of pEC50 values).  Results 
shown are of an individual experiment and are representative of three individual 
experiments. Data were analysed using GraphPad Prism software. Data points 
represent means ± SEM. 
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Figure 3.16 Localisation and detection of modified nicotinic acid receptors stably 
expressed in Flp-In CHO-K1 cells 
Flp-In CHO-K1 cells were transfected with VSV-G HM74A eYFP or VSV-G HM74 
eYFP cDNA and placed under 200 μg/ml hygromycin selection. For each transfected 
cell line, cells resistant to hygromycin antibiotic selection were pooled and screened 
by direct visualisation by fluorescence imaging utilising the eYFP tag to identify 
receptor expression (A). VSV-G epitope and eYFP tagged forms of the HM74 (A1) 
and HM74A (A2) receptors. B: 20 μg of cell lysates prepared from these cells were 
resolved by SDS-PAGE. Proteins representing the modified receptors were detected 
at the expected size, in immunoblots against the VSV-G tag (B1) and eYFP (B2) 
protein.
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Figure 3.17 Functional analysis of Flp-In CHO-K1 cell lines stably expressing 
recombinant nicotinic acid receptors 
A: [35S] GTPγS binding assays were employed to test the response of the tagged 
nicotinic acid receptors to nicotinic acid. A: Modified HM74A and HM74 were 
stimulated with 1 and 10 mM nicotinic acid respectively. Membranes prepared from 
parental CHO-K1 cells were utilised as a negative control and were incubated with 
(red) or without (blue) 10 mM nicotinic acid. Membranes expressing α2A-adrenergic-
GαoC351 served as a positive control and were incubated with (red) or without (blue) 1 
μM UK 14304. The assays were terminated after 30 minutes incubation at room 
temperature by filtration of the samples onto GF/C fibre glass filters. Bound [35S] 
GTPγS was measured by liquid-scintillation spectrometry. B: Nicotinic acid 
concentration response curves on the tagged (B1) HM74A (pEC50 = 6.9 ± 0.1) and 
(B2) HM74 (pEC50 = 2.9 ± 0.1) receptors. Results shown are representative of three 
individual experiments. Data were analysed using GraphPad Prism software. Data 
points represent means ± SEM. 
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Figure 3.18 VSV-G HM74A eYFP expression compared to VSV-G HM74 eYFP  
Whole cell lysates prepared from CHO-K1 and Flp-In CHO-KI cell lines stably 
expressing either the modified HM74A or HM74 receptor, respectively, were 
equalised for protein concentration and the eYFP fluorescence was measured with a 
Victor2 plate reader. Negative controls of lysates prepared from parental CHO-K1 
cells and a reading from an empty well (labelled blank) were also included. VSV-G 
HM74A eYFP stably expressed in CHO-K1 cells has a higher expression level than 
VSV-G HM74 eYFP stably expressed in a Flp-In CHO-K1. 
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Figure 3.19 Biotin labelling of cell surface expressed nicotinic acid receptors 
Cell lines stably expressing VSV-G HM74A eYFP (CHO-K1 background) or VSV-G 
HM74 eYFP (Flp-In CHO-K1 background) were treated with EZ-Link Sulfo-NHS-SS 
biotin to label proteins expressed at the cell surface. Cells were then lysed and an 
equal amount of protein was rotated with 100 μl of streptavidin beads at 4 oC for 1 
hour, to pulldown biotinylated proteins. Biotinylated samples were eluted from the 
beads with 100 μl of Laemmli buffer containing 5% beta-meracaptoethanol by 
incubating at 37 oC for 1 hour. 30 μl of the samples were resolved by SDS-PAGE and 
analysed by immunoblotting with an anti VSV-G antibody to detect receptor proteins. 
The samples in lane 1 are aliquots of cell lysates equalised for protein content. An 
aliquot of the supernatant was also saved after the pulldown step. This sample 
containing unbound receptor is represented in lane 2. Samples in lane 3 represent the 
biotinylated receptors present at the cell surface. VSV-G HM74A eYFP (A) and 
VSV-G HM74 eYFP (B) expression detected at the anticipated size, confirming cell 
surface expression of this receptor. Results shown are of an individual experiment and 
are representative of three independent experiments. 
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Figure 3.20 Flp-In TREx system 
Schematic diagram illustrating the principle behind the inducible system (Invitrogen 
Flp-In. TREx Core Kit manual).  
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Figure 3.21 Flp-In TREx CHO-K1 cell line stably expressing VSV-G HM74A eYFP   
Flp-In TREx CHO-K1 cells stably expressing VSV-G HM74A eYFP receptors were 
transfected with a pcDNA6/TR vector carrying a tetracycline repressor gene. The 
cells were then placed on hygromycin and blasticidin antibiotic selection to select for 
cells expressing both the receptor and repressor respectively. Following clonal 
selection, the inducible function of the clones was tested. Clones were treated with 1 
μg/ml of doxycycline overnight and visualised for eYFP fluorescence by confocal 
imaging using the same settings. Receptor expression was observed in both the 
control and treated samples. Images are representative of all the clones tested. 
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Figure 3.22 Flp-In TREx CHO-K1 cell line not expressing VSV-G HM74 eYFP   
Flp-In TREx CHO-K1 cells stably expressing VSV-G HM74 eYFP receptors were 
transfected with a pcDNA6/TR vector carrying a tetracycline repressor gene. The 
cells were then placed on hygromycin and blasticidin antibiotic selection to select for 
cells expressing both the receptor and repressor respectively. Following clonal 
selection, the inducible function of the clones was tested. Clones were treated with 1 
μg/ml of doxycycline overnight and visualised for eYFP fluorescence by confocal 
imaging using the same settings. Receptor expression was not observed in either the 
control or treated samples. Images are representative of all the clones tested. 
 
Sanam Mustafa, 2008  
 
4.  Regulation and desensitisation studies on 
the nicotinic acid receptors 
4.1.  Introduction 
Many mechanisms have evolved for regulating GPCR signalling. Mechanisms operate 
at the receptor level to prevent or block initiation of the signalling cascade in the 
presence of continuous agonist stimulation. These phenomena, termed desensitisation, 
prevent over-stimulation of the receptor.  
The first stage of this regulatory pathway for many GPCRs involves phosphorylation 
of serine and threonine residues within the third intracellular loop or C-terminal 
domain of the receptor. GRK and second messenger-dependent protein kinases, such 
as PKA or PKC are known to phosphorylate GPCRs. GRK family members 
selectively phosphorylate agonist-occupied receptors marking them for further 
desensitisation by arrestin proteins.  
β-arrestin 1 and 2 are expressed widely and therefore have relatively broad receptor 
specificity. Following agonist stimulation these cytoplasmic proteins undergo a 
substantial conformational change into a high-affinity receptor binding state and 
translocate rapidly to the plasma membrane where they bind to phosphorylated 
GPCRs (Lohse et al., 1990; Gurevich & Benovic, 1993). By binding to the receptor 
the arrestin protein prevents G protein coupling by steric hindrance (Kuhn & Wilden, 
1987; Krupnick et al., 1997). The arrestin protein can then interact with various other 
proteins of the endocytotic machinery and internalise the GPCR (Goodman, Jr. et al., 
1996).  
The aim of this chapter was to study regulation of the nicotinic acid receptors. These 
highly homologous receptors share 96 % identity at the protein level with the main 
differences in the C-terminal tail region (Zellner et al., 2005). A five base-pair 
insertion at the 3’end of the gene encoding the HM74A receptor ultimately results in 
HM74A possessing a shorter C-terminal tail compared to HM74 (Wise et al., 2003). 
As the C-terminal tail of GPCRs often plays a key role in the regulation of receptor 
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signalling, the aim of this study was to identify any potential differences in the 
regulation of these receptors. 
4.2.  Basic pharmacology  
Nicotinic acid receptors have been reported to couple to the Gi class of G proteins 
(Wise et al., 2003; Aktories et al., 1983b; Tunaru et al., 2003). The conserved cysteine 
residue at position 351, in the α-subunits of the Gi class of G proteins act as a 
substrate for ADP-ribosylation catalysed by pertussis toxin (Burns, 1988). ADP-
ribosylation prevents effective information transfer between the receptor and G 
protein by steric hindrance. To confirm published work, CHO-K1 cell lines stably 
expressing HM74 or HM74A receptors were incubated in the presence and absence of 
25 ng/ml pertussis toxin for 16 hours. Membrane preparations were generated and 
[35S] GTPγS binding assays were utilised to test the response of the nicotinic acid 
receptors to nicotinic acid (Figure 4.1). When incubated in the presence of nicotinic 
acid, an increase in [35S] GTPγS binding above basal was observed in non-treated 
samples. However, nicotinic acid-mediated stimulation of [35S] GTPγS binding was 
abolished following pertussis toxin treatment supporting previous reports that 
nicotinic acid receptors couple to the Gi family of G proteins. A reduction in basal 
[35S] GTPγS binding was also observed in membranes prepared from pertussis toxin 
treated CHO-K1 cells stably expressing HM74A. This suggests HM74A displays Gi 
mediated constitutive activity. 
To confirm basic pharmacology of the nicotinic acid receptors, [35S] GTPγS binding 
assays were utilised to confirm the potency of agonists at HM74 and HM74A (Tables 
4.1 and 4.2). As shown previously, (Wise et al., 2003), acifran was a more potent 
agonist at HM74 than nicotinic acid. Acifran was also an agonist at HM74A (Wise et 
al., 2003). Agonist activity of acipimox and 5-methyl pyrazole-3-carboxylic acid 
(MPCA) at HM74A were also confirmed (Wise et al., 2003), with the rank order of 
potencies nicotinic acid > MPCA > acifran > acipimox. Two novel compounds, GSK 
1 and GSK 2, developed by GSK, displayed similar potencies to nicotinic acid at 
HM74A (Table 4.2). Published reports have identified β-hydroxybutyrate as the 
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endogenous ligand for HM74A (Taggart et al., 2005). The observed low potency of β-
hydroxybutyrate at HM74A was in agreement with published studies. 
4.3.  Nicotinic acid stimulates ERK1/2 phosphorylation 
The ability of nicotinic acid to activate ERK1/2 phosphorylation via the nicotinic acid 
receptors was determined by treating CHO-K1 cell lines stably expressing HM74 or 
HM74A with or without of 10 mM nicotinic acid for 5 minutes (Figure 4.2). In both 
cases, a significant increase in phosphorylated ERK1/2 was detected in samples 
treated with nicotinic acid. Such experiments were repeated with CHO-K1 cell lines 
stably expressing the N- and C-terminally modified forms of the nicotinic acid 
receptors (Figure 4.2). The addition of the VSV-G epitope tag and fluorescent protein 
did not interfere with the receptor’s ability to transduce this signal. In the case of both 
HM74 and HM74A, wild type and tagged receptors, the observed signal was 
abolished by pertussis toxin treatment suggesting nicotinic acid-stimulated ERK1/2 
phosphorylation was mediated via a pertussis toxin sensitive G protein. Nicotinic 
acid-mediated ERK1/2 phosphorylation at HM74A was concentration-dependent with 
a response detectable at 100 nM nicotinic acid (Figure 4.3). However, 10 mM 
nicotinic acid was required to induce ERK1/2 phosphorylation via HM74 (Figure 
4.3). With respect to HM74A, time courses of nicotinic acid treatment showed rapid 
and sustained stimulation of nicotinic acid-induced ERK1/2 phosphorylation (Figure 
4.3). However, in the case of ERK1/2 phosphorylation via HM74, nicotinic acid-
induced ERK1/2 phosphorylation was delayed and more transient (Figure 4.3). Foetal 
bovine serum has been reported to induce ERK1/2 phosphorylation and therefore 
served as a positive control in every experiment. It is not known which components of 
serum activate ERK1/2 phosphorylation and by which mechanism. However, the 
numerous peptides and growth factors naturally found in serum are likely to act, at 
least partly, through various endogenously expressed receptors such as sphingosine-1-
phosphate or epidermal growth factor receptors. The slight reduction in serum-
stimulated ERK1/2 phosphorylation as a result of pertussis toxin treatment suggests 
one such mechanism is via pertussis toxin sensitive G proteins. Total levels of 
ERK1/2, detected in parallel studies, served as loading controls.  
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4.4.  Desensitisation studies on the nicotinic acid 
receptors 
In order to determine if prolonged exposure of HM74 to nicotinic acid caused 
desensitisation of the receptor, in an initial experiment a CHO-K1 cell line stably 
expressing HM74 was treated with 10 mM nicotinic for 0 and 15 minutes. A high 
concentration of nicotinic acid was chosen at approximately ten times the estimated 
pEC50 value at this receptor. Membrane preparations generated from these samples 
were then exposed to increasing concentrations of nicotinic acid in a [35S] GTPγS 
binding assay (Figure 4.4). Although no change in the pEC50 value was observed in 
control and nicotinic acid pre-treated samples, a significant reduction (p < 0.03) in the 
maximum binding of [35S] GTPγS was observed in the presence of 10 mM nicotinic 
acid. To examine effects of longer pre-treatments, membrane preparations were 
generated from cells pre-treated with nicotinic acid for 0, 15, 30, 45 and 60 minutes 
(Figure 4.4). In a [35S] GTPγS binding assay, these membrane preparations were 
incubated in the presence or absence of 10 mM nicotinic acid. Although when 
compared to non-treated samples, a trend towards a reduction in [35S] GTPγS binding 
was observed in all pre-treated samples challenged with nicotinic acid, this was only 
statistically significant (p < 0.05) in samples pre-treated for 60 minutes with nicotinic 
acid. 
In a similar study, a CHO-K1 cell line stably expressing HM74A was pre-treated with 
10 μM nicotinic acid, a maximally effective concentration at this receptor (based on 
previous [35S] GTPγS binding studies), for 0, 15, 30 and 60 minutes. Membrane 
preparations generated from these cells were then incubated in the presence or 
absence of 10 μM nicotinic acid in a [35S] GTPγS binding assay (Figure 4.5). When 
compared to control samples, no statistically significant change in [35S] GTPγS 
binding was observed in pre-treated samples incubated with nicotinic acid. 
4.5.  Regulation studies on the nicotinic acid receptors 
The studies described above suggest HM74, but not HM74A displays desensitisation 
characteristics. In order to investigate regulation of the nicotinic acid receptors, 
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including the mechanism by which HM74 was desensitised following exposure to 
nicotinic acid the studies detailed below were conducted. 
4.5.1. Study of Gαi expression level 
First the potential role of downregulation of Gαi G proteins in the desensitisation 
observed in nicotinic acid pre-treated HM74 samples was examined. This was 
investigated by studying the expression level of Gαi G protein in control and nicotinic 
acid pre-treated samples. 
No change in Gαi G protein expression level was detected in membrane preparations 
generated from CHO-K1 cells stably expressing HM74 and pre-treated with 10 mM 
nicotinic acid for 0, 15 minutes and 24 hours (Figure 4.6). Nicotinic acid pre-
treatment also had no effect on the expression of Gαq/11 class of G protein. Equal 
loading of the control and nicotinic acid pre-treated samples was confirmed by 
immunoblotting with an anti tubulin antiserum. Membranes prepared from Flp-In 
HEK293 cells expressing Gαi1 G protein as described by (Lane et al., 2007) were 
included as positive antibody control for the Gαi 1and 2 antibody. In a similar manner, 
membranes prepared from HEK293 cells transiently expressing G protein Gα11 served 
as an antibody control for the Gαq/ll antibody. 
4.5.2. Internalisation studies on the nicotinic acid receptor 
A number of assays were used to determine whether HM74 desensitisation was due to 
nicotinic acid-dependent internalisation of HM74. In parallel studies, internalisation 
of HM74A as a regulatory mechanism for HM74A signalling was also examined. Mu-
opioid receptor, which is known to internalise by a β-arrestin dependent pathway 
(Milasta et al., 2005), was utilised as a positive control in these studies (data not 
shown). 
4.5.2.1. Mouse embryo fibroblast (MEF) cells 
Wild type and β-arrestin 1 and 2 knock out MEF cells (kindly gifted by Robert J. 
Lefkowitz) (Kohout et al., 2001) were utilised to study nicotinic acid-induced 
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internalisation of the nicotinic acid receptors and to determine if β-arrestins 1 and 2 
played a role in this.  
Receptor cDNA was introduced into wild type and β-arrestin 1 and 2 knock out MEF 
cells by nucleofection as described in section 2.4.7.2. Nucleofected cells incubated in 
the presence and absence of 10 mM nicotinic acid were fixed and eYFP fluorescence 
was visualised by confocal microscopy (Figure 4.7). In the absence of nicotinic acid, a 
distribution pattern indicative of cell surface expression was observed in both wild 
type and knock out cells. Following nicotinic acid treatment no change in distribution 
pattern was observed. 
4.5.2.2. CHO-K1 cells 
As nicotinic acid desensitisation studies were conducted in a CHO-K1 cell 
background, internalisation studies were repeated in these cells to rule out any cell 
type specific effects. A CHO-K1 cell line stably expressing VSV-G HM74 eYFP was 
incubated in the presence or absence of 10 mM nicotinic acid. Live cells were then 
imaged by fluorescence microscopy (Figure 4.8). Again, an expression pattern 
consistent with plasma membrane expression was visualised in the presence and 
absence of nicotinic acid. 
When similar studies were adopted for HM74A, VSV-G HM74A eYFP did not 
internalise in response to 10 μM or even a higher concentration of 10 mM nicotinic 
acid treatment (Figures 4.8 and 4.9). To assess if longer nicotinic acid treatments 
induced internalisation, cells were incubated up to 1 hour, however this also did not 
result in detectable receptor internalisation (Figure 4.9). 
4.5.2.3. Cell surface biotinylation 
To confirm the above observations, a cell surface labelling technique was adopted (as 
described in sections 2.5.9 and 3.7). Figure 4.10 A is a schematic diagram illustrating 
the application of the cell surface biotin labelling technique to study receptor 
internalisation. For each cell line stably expressing either VSV-G HM74 eYFP or 
VSV-G HM74A eYFP, biotin labelling of cell surface receptors was compared in 
ligand treated and non-treated cells. Compared to non-treated samples, receptor 
internalisation as a result of ligand treatment would result in a reduction in the amount 
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of biotinylated protein detected. However, in the absence of ligand-dependent 
internalisation similar amounts of biotinylated protein would be detected in both 
treated and untreated samples. In the case of both receptors, nicotinic acid failed to 
induce receptor internalisation even at a 10 mM concentration (Figure 4.10). To 
examine if the lack of internalisation detected was nicotinic acid specific, these 
studies were repeated with β-hydroxybutyrate (Figure 4.10 C2). Again, internalisation 
of VSV-G HM74A eYFP was not detected. 
4.5.2.4. Cell surface ELISA 
In another attempt to study agonist-induced receptor internalisation, a cell surface 
ELISA assay, as described in section 3.4.2, was adopted. CHO-K1 cell lines stably 
expressing either VSV-G HM74 eYFP or VSV-G HM74A eYFP were incubated in 
the presence or absence of nicotinic acid, as described in chapter 2.5.11 (Figure 4.11). 
No significant change in cell surface expression of either receptor was observed in the 
presence of nicotinic acid. Receptor function was confirmed in these cell lines by 
nicotinic acid-induced phosphorylation of ERK1/2 via VSV-G HM74 eYFP and 
VSV-G HM74A eYFP (Figure 4.11).  
4.5.2.5. β-arrestin 2 GFP translocation study 
Although the pharmacology of the tagged receptor constructs were shown, in chapter 
3, to be comparable to wild type receptors in both transient and stable expression 
systems, to rule out any detrimental effects of the N-terminal VSV-G and more 
importantly the C-terminal eYFP tag on the internalisation characteristics of this 
receptor, β-arrestin translocations studies, utilising CHO-K1 cell lines stably 
expressing either the wild type HM74 or HM74A receptor, were performed. β-arrestin 
is a cytosolic protein; agonist-mediated translocation from the cytoplasm to the 
plasma membrane would provide evidence of receptor internalisation mechanisms 
being engaged. If, however translocation of β-arrestin is not detected, in isolation 
these studies would not provide definitive evidence for a lack internalisation as 
GPCRs have been reported to internalise by β-arrestin-independent pathways (Claing 
et al., 2000; Teixeira et al., 1999), however taken together with the other studies 
presented, it would support previous observations.  
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A GFP C-terminal tagged β-arrestin 2 fusion protein was utilised for these studies. 
Bovine β-arrestin 2 GFP cDNA was transiently introduced into CHO-K1 cell lines 
stably expressing HM74 or HM74A and translocation of the arrestin protein in 
response to nicotinic acid was examined (Figure 4.12). β-arrestin 2 GFP demonstrated 
a cytoplasmic distribution pattern which remained unchanged following nicotinic acid 
treatment.  
4.5.3. Nicotinic acid-induced phosphorylation of the 
nicotinic acid receptors 
Data presented so far suggest nicotinic acid receptor signalling is not regulated by 
receptor sequestration and β-arrestin involvement has also been ruled out. As receptor 
phosphorylation by a GRK is considered to be the ‘trigger’ for β-arrestin recruitment 
the ability of the nicotinic acid receptors to be phosphorylated in an agonist-dependent 
manner was investigated.  
In [32P] orthophosphate assays, as described in section 2.5.10, CHO-K1 cells 
expressing VSV-G HM74A eYFP were incubated with vehicle or 10 mM nicotinic 
acid for 15 or 30 minutes. An increase in phospho-HM74A was observed in samples 
treated with nicotinic acid after only 15 minutes of nicotinic acid treatment (Figure 
4.13). Phosphorylation of HM74A was concentration dependent with the biggest 
increase in phosphorylation observed with 10 mM nicotinic acid treatment however 
10 μM nicotinic acid was sufficient to phosphorylate HM74A to detectable levels 
(Figure 4.13). HM74 was also phosphorylated in an agonist dependent manner 
(Figure 4.15 A).  
4.5.4. Kinase inhibitor study 
NetPhos phosphorylation prediction software was utilised to identify possible 
phosphorylation sites. This application predicts serine, threonine and tyrosine 
phosphorylation sites in eukaryotic proteins. As both receptors are highly homologous 
and were phosphorylated in an agonist-dependent manner it was not surprising many 
common sites were identified. However, the longer C-terminal region of HM74 
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contained a predicted PKC phosphorylation site not present in HM74A (Figure 4.14). 
To investigate which kinase(s) was responsible for phosphorylating HM74, selective 
kinase inhibitors were utilised. RO318220 is a known PKC inhibitor shown to block 
PKC dependent phosphorylation (Beltman et al., 1996). H89 is a known PKA 
inhibitor documented to block PKA dependent phosphorylation (Chijiwa et al., 1990). 
When [32P] orthophosphate experiments were performed in the presence of either 
RO318220 or H89, although nicotinic acid-stimulated phosphorylation of VSV-G 
HM74A eYFP was not abolished a reduction in nicotinic acid-induced 
phosphorylation was observed (Figure 4.15 A). In the presence of RO318220, a 
reduction in the basal phosphorylation was also observed. However, when similar 
experiments were performed with VSV-G HM74A eYFP expressing cells, no 
reduction in HM74A phosphorylation was observed in samples treated with either 
inhibitor (Figure 4.15 B).  
In parallel studies, cell lines stably expressing VSV-G HM74 eYFP or VSV-G 
HM74A eYFP were each treated with phorbol 12-myristate 13-acetate (PMA), a 
known PKC activator (Niedel et al., 1983) or forskolin, known to activate PKA via 
adenylate cyclase (de Souza et al., 1983) in the presence and absence of the 
corresponding kinase inhibitor. In each case, controls of vehicle and nicotinic acid 
treatment were also included. RO318220 and H89 were shown to inhibit ERK 1/2 and 
CREB phosphorylation, respectively (Figure 4.16). 
4.6.  Discussion 
Regulation of GPCR signalling is vital in order to avoid receptor over-stimulation as a 
result of prolonged exposure to agonist. With respect to this, regulation of the 
nicotinic acid receptors was examined in this study.  
First, published data describing the basic pharmacology of the receptors was 
confirmed. Nicotinic acid receptors have been reported to couple to the Gi class of G 
proteins (Wise et al., 2003; Aktories et al., 1983b; Tunaru et al., 2003). Studies 
utilised pertussis toxin, which catalyses the ADP-ribosylation of a conserved cysteine 
residue in the α-subunits of the Gi class of G proteins and therefore prevents effective 
information transfer between receptor and G proteins (Burns, 1988). In the case of 
 165 
Sanam Mustafa, 2008  
 
both HM74 and HM74A, nicotinic acid stimulated [35S] GTPγS binding was 
abolished following pertussis toxin treatment. This confirms that these receptors 
mediate nicotinic acid-induced signal transduction via Gi G proteins. With respect to 
HM74A, a reduction in basal [35S] GTPγS binding was also observed in pertussis 
toxin treated samples. This suggests a degree of Gi mediated constitutive activity at 
HM74A. 
In [35S] GTPγS binding assays, in agreement with published data, acifran 
demonstrated higher potency at HM74 than nicotinic acid (Wise et al., 2003). Agonist 
activity of acifran, acipimox and MPCA at HM74A was also confirmed however, the 
rank order of potencies obtained was nicotinic acid > MPCA > acifran > acipimox. 
Published data suggest MPCA is least potent at HM74A (Wise et al., 2003). β-
hydroxybutyrate, which has been described as the endogenous ligand for HM74A, 
was less potent than nicotinic acid (Taggart et al., 2005). Two novel compounds, GSK 
1 and GSK 2, with similar molecular structures to nicotinic acid were developed by 
GlaxoSmithKline. These compounds were more potent at HM74A than nicotinic acid 
and are now in trials for their suitability as drug compounds.  
The ability of nicotinic acid to stimulate ERK1/2 phosphorylation via the nicotinic 
acid receptors was examined next. Data published by Mahboubi and co-workers 
detected nicotinic acid-induced ERK1/2 phosphorylation via HM74A but not HM74 
(Mahboubi et al., 2006). However they utilised 1 μM nicotinic acid, which from 
nicotinic acid concentration response experiments presented in Figure 4.3, is not 
sufficient for ERK1/2 phosphorylation via HM74. As reported, nicotinic acid-
stimulated ERK1/2 phosphorylation was Gi mediated (Mahboubi et al., 2006; Tunaru 
et al., 2003) and the addition of N or C-terminal tags did not affect this response. 
Nicotinic acid-induced ERK1/2 phosphorylation via HM74A was rapid and sustained. 
However, nicotinic acid-induced ERK1/2 phosphorylation via HM74 was slower and 
transient. Although sustained ERK1/2 phosphorylation suggests β-arrestin-mediated 
signalling (Ahn et al., 2004), as pertussis toxin treatment abolished ERK1/2 
phosphorylation this suggested G protein involvement. Also, in β-arrestin 
translocation studies, there was no evidence of β-arrestin 2 GFP translocation to the 
plasma membrane or interaction with HM74A in response to nicotinic acid.  
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In nicotinic acid pre-treatment studies of HM74, a reduction in [35S] GTPγS binding 
was observed in samples incubated with nicotinic acid. Although there was no change 
in the pEC50 values estimated from nicotinic acid concentration curves, the reduction 
in the maximum binding of [35S] GTPγS was significant in a one way analysis of 
variance statistical test and therefore suggested desensitisation of HM74 signalling. 
However, no desensitisation of HM74A as a result of prolonged exposure to nicotinic 
acid was detected. Studies conducted by Green and co-workers in 1992, before the 
identification of the nicotinic acid receptors, suggest prolonged incubation of 
adipocytes with nicotinic acid reduced sensitivity of the cells to nicotinic acid in a 
subsequent lipolysis assay (Green et al., 1992). Published data also confirmed the 
observations made in this study, that nicotinic acid does not induce Gαi G protein 
down-regulation (Green et al., 1992). 
To investigate this further, nicotinic acid-induced internalisation of the nicotinic acid 
receptors was examined utilising various tools and techniques. In the case of each 
receptor, there was no convincing evidence of receptor internalisation in response to 
nicotinic acid and in the case of HM74A, β-hydroxybutyrate treatment. In β-arrestin 
translocation studies, no change in the localisation of β-arrestin 2 GFP was detected in 
cells treated with nicotinic acid. This, taken together with observations from the 
internalisation studies, suggests nicotinic acid receptors do not recruit β-arrestin or 
sequester in response to agonist treatment. However, recent findings by Richman and 
co-workers not only suggest nicotinic acid-induced internalisation of HM74A 
(Richman et al., 2007) but also co-localisation with β-arrestin 2 (personal 
communication, Professor G. Milligan). Differences in the findings may be addressed 
by the tools utilised in the studies. For example, in the studies by Richman and co-
workers, COS-7 cells were utilised and both HM74A and β-arrestin were transiently 
introduced into these cells. It can be argued that CHO-K1 and COS-7 cells inherently 
possess different ‘internalisation machinery’ and therefore this can result in the 
different internalisation characteristics observed. One such example has been 
described by Barlic and co-workers. In this study, CXCR1 has been described to 
internalise in rat basophilic leukemia 2H3 (RBL-2H3) cells but not in HEK 293 cells 
(Barlic et al., 1999). Closer examination revealed that endogenous β-arrestin 2 
expression in HEK 293 cells was not sufficient for CXCR1 internalisation. Another 
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plausible explanation may implicate the addition of the N- or C-terminal tags utilised 
in the studies outlined in this chapter. Studies conducted by Richman and co-workers 
utilised an N-terminus epitope tagged HM74A receptor. It could be argued, especially 
in the case of the C-terminus, that the tags are interfering or preventing effective 
receptor/β-arrestin binding and therefore receptor internalisation. This issue was 
addressed in the study by utilising wild type HM74A in the β-arrestin translocation 
studies. Despite this, no translocation of β-arrestin 2 GFP was visualised in response 
to nicotinic acid. Human β-arrestin 2 was utilised in the study by Richman and co-
workers whereas studies described here utilised bovine β-arrestin 2, therefore it could 
be argued that a β-arrestin protein from a different species was unable to interact with 
human HM74A. However, bovine and human β-arrestin 2 share 94.8 % identity at the 
protein level (Figure 4.17). The region (amino acids 24 – 330) in which the receptor 
activation recognition and the secondary receptor binding domains fall (Gurevich et 
al., 1995) are highly conserved between the two species. Taken together with reports 
of bovine β-arrestin 2 interaction with other human GPCRs, this is unlikely to be an 
issue (Milasta et al., 2005). Personal communication with Professor Stefan 
Offermanns has also addressed many of the above concerns. Experimental studies by 
his group have also failed to detect internalisation of the nicotinic acid receptors in 
response to nicotinic acid. Studies utilised N-terminal tagged receptors in a variety of 
cell types including COS-7 and CHO-K1 cell lines. 
When phosphorylation of the nicotinic acid receptors was examined, an increase in 
receptor phosphorylation as a result of nicotinic acid treatment was observed for both 
HM74 and HM74A. As these receptors are highly homologous and are both 
phosphorylated in an agonist-dependent manner, it is possible that both HM74 and 
HM74A share the same phosphorylation sites. Phosphorylation prediction software 
programmes predict several common phosphorylation sites for the nicotinic acid 
receptors, however there are two extra predicted phosphorylation sites, serines in both 
cases, on the C-tail region of HM74, as indicated in Figure 4.14. The serine at 
position 366 is predicted to be phosphorylated by PKC as it conforms to the 
determined consensus PKC phosphorylation motif. This motif is comprised of three 
amino acids where a serine/threonine residue is followed by any amino acid and then 
either an arginine or lysine (Hocevar et al., 1993). However, this region does not 
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contain a GRK consensus motif, a diacidic sequence upstream of serine residues 
(Berrada et al., 2000). GRK, PKA and PKC are expressed in adipocytes and therefore 
they play a potential role in the nicotinic acid-dependent phosphorylation of the 
nicotinic acid receptors (Usui et al., 2004; Zhou et al., 2006; Li et al., 2008). Kinase 
inhibitor studies have implicated both PKC and PKA in the agonist-dependent 
phosphorylation of HM74. However, other kinases are also likely to play a role as 
phosphorylation was not completely abolished. An increase in phosphorylation as a 
result of nicotinic acid treatment was observed despite the presence of these kinase 
inhibitors. Also, due to the poor immunoprecipitation qualities of this receptor it is 
important to verify the role of both PKC and PKA through other means. For example, 
it can be examined if over-expression of PKC or PKA results in an increase in 
agonist-dependent HM74 phosphorylation. The role of both PKC and PKA in the 
agonist-dependent phosphorylation of HM74A was ruled out.   
The role of GRKs in the phosphorylation of the nicotinic acid receptors could not be 
investigated due to a lack of suitable tools. GRK2 dominant negative mutants that can 
be transfected into cell lines are available (Kong et al., 1994), however due to the poor 
transfection efficiency experienced with cell lines stably expressing the nicotinic acid 
receptors, this avenue was not explored. As the hamster genome has not been 
sequenced, gene silencing approaches utilising GRK siRNA to explore the role of 
GRK in the existing CHO-K1 cell lines, could not be exploited. At present human 
GRK2 siRNA is available and although in preliminary studies hamster GRK2 
expression was knocked down (Figure 4.18), this level of knock down was not 
consistent from experiment to experiment as with HEK293 cells. Also, with 
knockdown studies as not all endogenous protein expression is silenced it is possible 
that remaining expression is sufficient for phosphorylation. Therefore, studies of this 
sort would not be conclusive on their own but would complement other findings. The 
role of GRKs can also be studied by over expressing these proteins and then 
examining if this results in an increase in receptor phosphorylation. Again, results 
from a study like this would not be compelling on their own but would require further 
evidence. 
In summary, key differences in the signalling and regulation of the nicotinic acid 
receptors were identified in this study. HM74 and HM74A display differential 
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kinetics with respect to nicotinic acid-stimulated ERK 1/2 phosphorylation. Also 
studies in this chapter identified the desensitisation of HM74 but not HM74A as a 
result of prolonged nicotinic acid exposure. An increase in HM74 and HM74A 
phosphorylation was detected in samples treated with nicotinic acid. In the case of 
HM74, both PKC and PKA may play a partial role in this. However, both nicotinic 
acid receptors failed to internalise in response to nicotinic acid and in the case of 
HM74A, also in response to β-hydroxybutyrate. 
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Figure 4.1 Nicotinic acid stimulated [35S] GTPγS binding is abolished by pertussis toxin 
treatment 
CHO-K1 cell lines stably expressing HM74 or HM74A were treated with 25 ng/ml 
pertussis toxin for 16 hours at 37 oC and membranes were prepared from treated (+) 
and untreated cells (-). 10 μg of membranes were incubated in the presence (red) and 
absence (blue) of 1 mM (HM74) or 1 μM (HM74A) nicotinic acid in [35S] GTPγS 
binding assays containing 0.3 nM [35S] GTPγS. The assay was terminated by filtration 
of the samples onto GF/C fibre glass filters and bound [35S] GTPγS was measured by 
liquid-scintillation spectrometry. In both cases, nicotinic acid stimulated [35S] GTPγS 
binding was abolished by pertussis toxin treatment. Experiments were performed in 
triplicate and data points represent means ± SEM. 
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Ligand pEC50 
Nicotinic acid 3.0 ± 0.2 
Acifran 4.1 ± 0.1 
 
Table 4.1 HM74 basic pharmacology 
[35S] GTPγS binding scintillation proximity assays were employed to test the response 
of HM74 stably expressed in CHO-K1 cells to nicotinic acid (blue) and acifran (red) 
at final concentrations ranging from 1 nM to 1 mM. Bound [35S] GTPγS was 
measured by scintillation counting. Data were analysed using GraphPad Prism 
software. pEC50 values are means ± SEM calculated from three independent 
experiments. 
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Ligand pEC50 
Nicotinic acid 5.9 ± 0.3 
Acifran 4.4 ± 0.2 
Acipimox 3.7 ± 0.1 
MPCA 4.6 ± 0.2 
GSK 1 6.0 ± 0.2 
GSK 2 5.6 ± 0.3 
β-hydroxybutyrate 2.9 ± 0.2 
  
Table 4.2 HM74A basic pharmacology 
[35S] GTPγS binding assays were employed to test the response of HM74A stably 
expressed in CHO-K1 cells to various ligands at final concentrations ranging from 1 
nM to 1 mM. Bound [35S] GTPγS was measured by scintillation counting. Data were 
analysed using GraphPad Prism software. pEC50 values are means ± SEM obtained 
from three independent experiments. 
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Figure 4.2 Nicotinic acid stimulates ERK1/2 phosphorylation. ERK1/2 phosphorylation 
was abolished by pertussis toxin treatment 
CHO-K1 cell lines stably expressing wild type or modified nicotinic acid receptors 
were serum starved and treated in the presence (+) and absence (-) of 25 ng/ml 
pertussis toxin for 16 hours at 37 oC. Cells were then incubated with 10 mM nicotinic 
acid (lane 2) for 5 minutes in an ERK1/2 phosphorylation assay. A negative control of 
vehicle (lane 1) and positive control of 10 % foetal bovine serum treatment (lane 3) 
were included in all experiments. Cell lysates prepared from the samples were 
equalised for protein content, resolved by SDS-PAGE and immunoblotted with anti 
ERK1/2 antiserum to determine equal loading of samples (42/44 kDa) and anti 
phospho-ERK1/2 antibody to study ERK1/2 phosphorylation (42/44 kDa). Nicotinic 
acid stimulated ERK1/2 phosphorylation via HM74 (A1), VSV-G HM74 eYFP (A2), 
HM74A (B1) and VSV-G HM74A eYFP (B2). ERK1/2 phosphorylation by nicotinic 
acid was abolished by pertussis toxin treatment. Immunoblots shown are 
representative of at least three independent experiments.  
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Figure 4.3 Nicotinic acid induced ERK1/2 activation via HM74A was rapid and 
sustained. Nicotinic acid induced ERK1/2 activation via HM74 was slower and more 
transient 
A: CHO-K1 cell lines stably expressing HM74A (A1) or HM74 (A2) were exposed to 
varying concentrations of nicotinic acid for 5 minutes in an ERK1/2 phosphorylation 
assay. A negative control of vehicle (-) and positive control of 10 % foetal bovine 
serum (+) were included in each experiment. B: CHO-K1 cell lines stably expressing 
HM74A (B1) or HM74 (B2) were incubated with 10 mM nicotinic acid for varying 
lengths of time in an ERK1/2 phosphorylation assay. Cell lysates prepared from these 
samples were equalised for protein content, resolved by SDS-PAGE and 
immunoblotted with anti ERK1/2 antiserum to determine equal loading of samples 
and anti phospho-ERK1/2 antibody to study ERK1/2 phosphorylation. A1: 100 nM 
nicotinic acid was sufficient to activate ERK1/2 phosphorylation via HM74A. A2: 10 
mM nicotinic acid activated ERK1/2 phosphorylation via HM74. B1: Nicotinic acid 
induced ERK1/2 phosphorylation via HM74A was rapid and sustained. B2: Nicotinic 
acid induced ERK1/2 phosphorylation via HM74 was slower and transient. 
Immunoblots shown are representative of at least three independent experiments.
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Figure 4.4 Nicotinic acid pre-treatment causes desensitisation of HM74 mediated 
activation of Gαi 
CHO-K1 cells stably expressing HM74 were pre-treated with 10 mM nicotinic acid 
for 0 or 15 minutes and membranes were prepared. A: Nicotinic acid concentration 
curves of control (blue) and 15 minute nicotinic acid pre-treated (red) samples were 
compared in a [35S] GTPγS binding assay. Binding of [35S] GTPγS: Group data of 
n=3. The reduction in the nicotinic acid stimulated maximum binding of [35S] GTPγS 
observed in pre-treated samples was significant in a one way analysis of variance test 
(** = p < 0.03). B: Samples prepared from cells pre-treated with nicotinic acid for 0, 
15, 30, 45 and 60 minutes were incubated in the presence (red) and absence (blue) of 
10 mM nicotinic acid in a [35S] GTPγS binding assay. Binding of [35S] GTPγS: Group 
data of n=4. When compared to control samples, the reduction in the binding of [35S] 
GTPγS observed in samples pre-treated with nicotinic acid for 60 minutes and then 
challenged with nicotinic acid was significant in a one way analysis of variance test (* 
= p < 0.05). Data were analysed using GraphPad Prism software. Data points 
represent means ± SEM. 
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Figure 4.5 Nicotinic acid pre-treatment does not cause desensitisation of HM74A 
mediated activation of Gαi 
Membrane preparations were generated from CHO-K1 cells stably expressing 
HM74A and  pre-treated with 10 μM nicotinic acid for 0, 15, 30, 45 and 60 minutes. 
Samples were incubated in the presence (red) and absence (blue) of 10 μM nicotinic 
acid in a [35S] GTPγS binding assay. Binding of [35S] GTPγS: Group data of n=3. 
When compared to control samples, no significant reduction (p > 0.05) in either basal 
or nicotinic acid stimulated binding of [35S] GTPγS was observed in pre-treated 
samples in a one way analysis of variance test. Data points represent means ± SEM. 
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Figure 4.6 No change in Gαi 1 and 2 G protein expression level in control and nicotinic 
acid pre-treated HM74 samples 
Membrane preparations, generated from CHO-K1 cells stably expressing HM74 and 
pre-treated with 10 mM nicotinic acid for 0, 15 minutes and 24 hours, were resolved 
by SDS-PAGE (lanes 1, 2 and 3 respectively). A positive antibody control employed 
HEK293 membranes expressing Gαi1 G protein (lane 4). Membranes prepared from 
HEK293 cells transiently expressing G protein Gα11 (lane 5) were also included. An 
anti Gαi 1and 2 antiserum was utilised to detect Gαi1 G proteins (40 kDa), anti Gαq/11 
antiserum to detect Gα11 G protein (40 kDa) and anti tubulin antiserum to detect 
tubulin (57 kDa), a loading control for HM74 expressing membranes. No change in 
Gαi 1 and 2 and Gαq/11 G protein expression levels were detected.  Results shown are of 
a single experiment, representative of three independent experiments. 
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Figure 4.7 Lack of detectable internalisation of the nicotinic acid receptors transiently 
expressed in mouse embryonic fibroblasts when challenged with nicotinic acid 
VSV-G HM74 eYFP (A) or VSV-G HM74A eYFP (B) cDNA was introduced into 
mouse embryonic fibroblast (MEF) wild type (1) and β–arrestin 1 and 2 knock out (2) 
cells by nucleofection. Transfected cells were incubated in the presence (+) or 
absence (-) of 10 mM or 10 μM nicotinic acid, respectively, for 30 minutes. Cells 
were fixed and eYFP fluorescence visualised by confocal microscopy. In both cases, 
no substantial change in receptor localisation was observed following nicotinic acid 
treatment in wild type or β-arrestin 1 and 2 knock out cells. Results are representative 
of at least three experiments. 
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Figure 4.8  Lack of detectable internalisation of the nicotinic acid receptors stably 
expressed in CHO-K1 cells when challenged with nicotinic acid 
CHO-K1 cells stably expressing VSV-G HM74 eYFP (A) or VSV-G HM74A eYFP 
(B) were incubated with (+) or without (-) 10 mM  or 10 μM nicotinic acid, 
respectively, for 30 minutes and live cells were imaged by fluorescence microscopy. 
Based on examination of the eYFP tag, receptor localisation was unchanged by 
treatment with nicotinic acid. Results are representative of at least three experiments. 
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Figure 4.9 Nicotinic acid does not internalise VSV-G HM74A eYFP  
CHO-K1 cells stably expressing VSV-G HM74A eYFP were incubated with 10 μM 
nicotinic acid for 0 (A), 15, 30, 45 and 60 minutes (B). CHO-K1 cells stably 
expressing VSV-G HM74A eYFP were treated with 10 mM nicotinic acid for 0 (A) 
and 30 minutes (C). Cells were fixed and imaged by confocal microscopy to visualise 
the eYFP tag. Receptor localisation was unchanged with nicotinic acid treatment. 
Results are representative of at least three experiments.  
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Figure 4.10 Lack of internalisation of the nicotinic acid receptors  
A: Schematic diagram illustrating the application of the cell surface biotinylation 
assay to study receptor internalisation. In the absence of ligand treatment (1), 
receptors at the cell surface are labelled with biotin (indicated as red) and can be 
detected by immunoblotting (4, lane 1). Receptor internalisation as a result of ligand 
treatment (2) would result in little or no labelling, therefore in an immunoblot, when 
compared to non-treated samples, a reduced amount of protein would be detected (4, 
lane 2). No internalisation as a result of ligand exposure (3) would result in equivalent 
labelling of cell surface expressing receptors as in non-treated samples and therefore 
detection of protein in an immunoblot (4, lane 3) would be similar to that of non-
treated samples. CHO-K1 cells stably expressing either VSV-G HM74 eYFP (B) or 
VSV-G HM74A eYFP (C) were incubated in the absence (-) or presence of nicotinic 
acid (B, C1) or β-hydroxybutyrate (C2) for 30 minutes and treated with EZ-Link 
Sulfo-NHS-SS biotin. Resulting samples were then resolved by SDS-PAGE and 
analysed by immunoblotting with an anti VSV-G antibody to detect receptor proteins. 
Samples in the lower panels are cell lysates equalised for protein content. Samples in 
the upper panels represent receptors at the cell surface. In all cases, receptor 
internalisation was not detected. Results shown are representative of at least 3 
independent experiments.  
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Figure 4.11 Nicotinic acid does not internalise either VSV-G HM74 eYFP or VSV-G 
HM74A eYFP 
CHO-K1 cells stably expressing VSV-G HM74 eYFP (A) or VSV-G HM74A eYFP 
(B) were incubated in the presence (red) or absence (blue) of 10 mM nicotinic acid for 
30 minutes. Cell surface expression of each receptor (A1, B1) was measured in an 
intact cell ELISA assay utilising an anti VSV-G antibody. Negative controls of no 
primary antibody (control 1) and no primary and secondary antibody (control 2) were 
incubated in the presence (red) or absence (blue) of 10 mM nicotinic acid. In a two-
tailed t test, p values of 0.8 (A1) and 0.4 (B1) were calculated. Nicotinic acid 
receptors did not internalise in response to nicotinic acid. Grouped data of n=4 shown. 
Data points represent means ± SEM. In an ERK1/2 phosphorylation assay these cells 
were incubated with 10 mM nicotinic acid (lane 2) for 5 minutes (A2, B2). A negative 
control of vehicle (lane 1) and positive control 10 % foetal bovine serum (lane 3) 
were also included. Cell lysates prepared from the samples were equalised for protein 
content, resolved by SDS-PAGE and immunoblotted with anti ERK1/2 antiserum, to 
determine equal loading of samples and an anti phospho-ERK1/2 antibody to study 
ERK1/2 phosphorylation. Immunoblots shown are representative of at least three 
independent experiments. Internalisation of VSV-G HM74 eYFP or VSV-G HM74A 
eYFP in response to nicotinic acid was not detected. Nicotinic acid induced ERK1/2 
phosphorylation via VSV-G HM74 eYFP and VSV-G HM74A eYFP. 
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Figure 4.12 No change in β-arrestin 2 GFP distribution in CHO-K1 cells stably 
expressing either HM74 or HM74A following nicotinic acid treatment 
β–arrestin 2 GFP was transiently transfected into CHO-K1 cells stably expressing 
HM74 (A) or HM74A (B). Cells were incubated for 30 minutes in the presence (+) 
and absence (-) of 10 mM or 10 μM nicotinic acid, respectively. Cells were fixed and 
GFP fluorescence visualised by confocal microscopy. Translocation of β–arrestin 2 
GFP to the cell surface was not observed at this time point in response to nicotinic 
acid. Results are representative of at least three experiments. 
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Figure 4.13 VSV-G HM74A eYFP was phosphorylated in an agonist-dependent manner 
CHO-K1 cells stably expressing VSV-G HM74A eYFP were pre-incubated with 0.2 
mCi/ml [32P] orthophosphate for 90 minutes. A: Cells were incubated in the presence 
or absence (-) of 10 mM nicotinic acid for 15 and 30 minutes. Cell lysates were 
prepared and equalised for protein content and volume before immunoprecipitating 
with an anti VSV-G antiserum to isolate the receptor. Samples were resolved by SDS-
PAGE and phospho-proteins visualised by autoradiography. 15 minutes was sufficient 
for nicotinic acid induced phosphorylation of VSV-G HM74A eYFP. B: Cells were 
incubated for 15 minutes in the presence of increasing concentrations of nicotinic 
acid. Control of cells treated with vehicle (-) were also included. Nicotinic acid 
dependent phosphorylation was concentration dependent. Results are representative of 
three independent experiments. 
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HM74A T S P 
Figure 4.14 Schematic diagram illustrating predicted phosphorylation sites on the C-
terminus of HM74 
HM74A has a 24 amino acid shorter C-terminus than HM74. Common predicted 
phosphorylation sites in the C-terminal region of the nicotinic acid receptors are in 
blue. Sites in red are predicted phosphorylation sites exclusive to HM74; SKK is a 
predicted PKC phosphorylation site. Phosphorylation sites were predicted with 
NetPhos phosphorylation prediction software. 
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Figure 4.15 VSV-G HM74 eYFP was phosphorylated in an agonist-dependent manner. 
PKC and PKA inhibitors did not abolish nicotinic acid induced phosphorylation 
CHO-K1 cells stably expressing VSV-G HM74 eYFP (A) or VSV-G HM74A eYFP 
(B) were pre-incubated with 0.2 mCi/ml [32P] orthophosphate supplemented with 
vehicle, 1 μM RO318220 or 10 μM H89 for 90 minutes. Cells were then incubated for 
a further 15 minutes in the presence (+) and absence (-) of 10 mM nicotinic acid and 
where appropriate, in the presence of the indicated kinase inhibitor. Cell lysates were 
prepared and equalised for protein content before immunoprecipitating with an anti 
VSV-G antiserum to isolate the receptor. 1: Samples were resolved by SDS-PAGE 
and phospho-proteins visualised by autoradiography. 2: Quantification of signal 
intensity represented as per cent phosphorylation over basal. Results shown are 
representative of three independent experiments. 
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Figure 4.16 RO318220 inhibits ERK1/2 phosphorylation. H89 inhibits CREB 
phosphorylation 
In an ERK1/2 phosphorylation assay, Flp-In CHO-K1 and CHO-K1 cells stably 
expressing VSV-G HM74 eYFP (A1) or VSV-G HM74A eYFP (B1), respectively, 
were serum starved overnight. Next day, cells were incubated with vehicle (-), 10 mM 
nicotinic acid, 1 μM PMA or 1 μM PMA in the presence of 1 μM RO318220 for 15 
minutes. Samples treated with RO318220 were pre-incubated with 1 μM RO318220 
for 30 minutes. Cell lysates were prepared and resolved by SDS-PAGE and 
immunoblotted with anti ERK1/2 antiserum to determine equal loading of samples 
and an anti phospho-ERK1/2 antibody to study ERK1/2 phosphorylation. After an 
overnight serum starvation step, CHO-K1 cells stably expressing VSV-G HM74 
eYFP (A2) or VSV-G HM74A eYFP (B2) were incubated with vehicle (-), 10 mM 
nicotinic acid, 50 μM forskolin or 50 μM forskolin in the presence of 10 μM H89 for 
15 minutes. Samples treated with H89 were pre-incubated with the PKA inhibitor for 
30 minutes. Cell lysates were prepared and resolved by SDS-PAGE and 
immunoblotted with an anti GAPDH antibody to demonstrate equal loading of 
samples (36 kDa) and an anti phospho-CREB ser133 antibody to study CREB 
phosphorylation (45 kDa). Both PKC and PKA inhibitors were biologically active.  
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Figure 4.17 Alignment of human and bovine β-arrestin 2 amino acid sequences 
Human and bovine β-arrestin 2 share a 94.8 % identity at the protein level. Protein 
sequence alignment using SIM alignment software. 
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Figure 4.18 Knockdown of GRK2 in CHO-K1 and HEK293 cells 
CHO-K1 (A) and HEK293 (B) cells were transiently transfected with either GRK2 
siRNA or pcDNA3 cDNA. 48 hours after transfection, cell lysates were prepared 
from transfected and non-transfected (-) cells. Samples, equalised for protein content, 
were resolved by SDS-PAGE and immunoblotted with anti GRK2 antiserum to detect 
reduction in the expression of GRK2 protein (80 kDa). Total levels of tubulin (57 
kDa), detected in parallel studies, served as loading controls. Compared to non-
transfected cells, a greater reduction in GRK2 expression was observed in HEK293 
cells. No change in GRK2 expression was observed in cells transfected with pcDNA3. 
Immunoblot presented displays the greatest knockdown of GRK2 in CHO-K1 cells 
observed from three independent experiments. 
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5.  Nicotinic acid receptor chimeras as tools to 
study desensitisation 
5.1.  Introduction 
Advances in molecular biology have allowed for creative methods to study protein 
function. One such method is the use of chimeric proteins. The use of chimeric 
GPCRs to study G protein-coupling was first reported in 1998 (Kobilka et al., 1988; 
Kubo et al., 1988). GPCR chimeras have been used to help define domains within 
receptors critical for roles such as, ligand recognition, receptor activation, 
downstream signalling and receptor trafficking. For example, C-terminal regions of 
homologous receptors, such as the α1A- and α1B-adrenergic receptors have 
successfully been exchanged and as a result downstream signalling of the receptors 
studied. In this study it was shown that by introducing the C-terminal tail of the α1B-
adrenergic receptor, it’s phosphorylation characteristics were then adopted by the α1A-
adrenergic receptor (Vazquez-Prado et al., 2000). 
The nicotinic acid receptors are highly homologous and differ by only 20 base-pairs at 
the cDNA sequence level corresponding to the open reading frame (Wise et al., 2003). 
The gene encoding HM74A has a 5 base-pair insertion at the 3’end which results in 
HM74A possessing a shorter C-terminal tail than HM74 (Wise et al., 2003). 
Cytoplasmic domains of GPCRs are implicated in G protein interaction and are 
important for post-translational modifications such as phosphorylation. As the C-
terminal region of GPCRs is often important in the regulation of receptor signalling, it 
was hypothesised that the differences in the desensitisation characteristics of HM74 
and HM74A, identified in chapter 4, could be due to the differences in the C-terminal 
region of the nicotinic acid receptors. To explore this hypothesis, chimeric nicotinic 
acid receptors were generated. Here the intracellular C-terminal region of HM74 and 
HM74A were exchanged and the resulting ‘nicotinic acid receptor C- terminal tail 
chimeras’ were expressed in a stable expression system. Nicotinic acid pre-treatment 
studies were then conducted on these cell lines to explore the characteristics of 
desensitisation.  
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By exchanging domains of related GPCRs, chimeric receptors have been reported to 
take on the properties and characteristics of the donor or host receptor (Yin et al., 
2004). For example, when the C-terminal regions of the gonadotrophin-releasing 
hormone (GnRH) receptors type I and type II were exchanged, GnRH type I adopted 
the desensitisation properties of GnRH type II and exhibited phosphorylation and 
desensitisation characteristics (McArdle et al., 2002). If the C-terminal region of 
HM74 is important for nicotinic acid-induced desensitisation, then by truncating this 
region to resemble the C-terminal region of HM74A, desensitisation may be altered. 
In a similar fashion, by introducing the HM74 C-terminal tail to HM74A, HM74A 
may then display the desensitisation characteristics of HM74. This hypothesis was 
examined in this study. 
5.2.  Generation of nicotinic acid receptor chimera 
constructs 
Nicotinic acid receptor chimeras, where the C-terminal tails of HM74 and HM74A 
were exchanged, were engineered by digesting VSV-G HM74 eYFP and VSV-G 
HM74A eYFP constructs with the restriction enzymes indicated in Figure 5.1. The 
resulting DNA fragments, representing the N- and C-termini of the receptors, were 
then swapped in a DNA ligation reaction, as illustrated in Figure 5.1. The chimeric 
HM74A receptor engineered to possess the longer C-terminal tail of HM74 will be 
referred to as VSV-G HM74A/HM74 eYFP. In a similar fashion, the chimeric HM74 
receptor modified to incorporate the HM74A C-terminal region will be referred to as 
VSV-G HM74/HM74A eYFP. 
5.3.  Generation of Flp-In CHO-K1 cell lines stably 
expressing the chimeric nicotinic acid receptors 
Two Flp-In CHO-K1 cell lines each stably expressing one of the chimeric receptors 
were generated as described in section 2.4.9.  
 198 
Sanam Mustafa, 2008  
 
5.3.1. Localisation, detection and functional analysis 
There is a possibility chimeric receptors may not function due to misfolding or 
problems with targeting of the chimeric receptor to the plasma membrane. For this 
reason, the localisation and pharmacology of the chimeric nicotinic acid receptors was 
investigated. 
Direct visualisation of eYFP fluorescence using a fluorescence microscope confirmed 
receptor expression and localisation consistent with cell surface expression (Figure 
5.2 A). Both VSV-G epitope and eYFP tags were also detected by immunoblotting 
(Figure 5.2 B). Relative receptor levels were compared by measuring eYFP 
fluorescence of cell lysates prepared from the two cell lines (Figure 5.2 C). VSV-G 
HM74A/HM74 eYFP was expressed at a higher level than VSV-G HM74/HM74A 
eYFP.  
Membrane preparations generated from the two cell lines stably expressing the 
chimeric receptors were incubated in the presence and absence of nicotinic acid and 
[35S] GTPγS binding measured as previously described (Figure 5.3 A1). Both 
chimeric receptors responded to nicotinic acid and an increase in [35S] GTPγS binding 
was observed in the presence of the drug. As mentioned previously, β-
hydroxybutyrate has been described as the endogenous ligand for HM74A but not 
HM74 (Taggart et al., 2005). To confirm the basic pharmacological properties of the 
nicotinic acid receptors had not been swapped by introducing the C-terminal region of 
either HM74A or HM74 to the corresponding receptor, membranes expressing the 
chimeric receptors were incubated in the presence and absence of β-hydroxybutyrate 
in a [35S] GTPγS binding assay (Figure 5.3 A2). In the presence of β-hydroxybutyrate, 
an increase in [35S] GTPγS binding was only observed in membranes expressing the 
chimeric VSV-G HM74A/HM74 eYFP receptor. When membranes generated from 
each cell line were incubated with increasing concentrations of nicotinic acid or 
acifran (Figure 5.3 B and C), pEC50 values obtained were comparable to those 
calculated for the host wild type receptor (Tables 4.1 and 4.2). 
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5.3.2. Internalisation studies 
No agonist-induced internalisation of the nicotinic acid receptors was detected in 
previous studies detailed in chapter 4.  Based on this, neither chimeric receptor was 
expected to internalise in response to nicotinic acid treatment. This was examined 
utilising a cell surface ELISA assay, as described in section 4.5.2.4. CHO-K1 cell 
lines stably expressing VSV-G HM74A/HM74 eYFP or VSV-G HM74/HM74A 
eYFP were incubated in the presence and absence of nicotinic acid, as described in 
chapter 2.5.11 (Figure 5.4 A). No significant change in cell surface expression of 
either chimeric receptor was observed in the presence of nicotinic acid. Samples 
incubated only with a secondary antibody or in the absence of both primary and 
secondary antibodies served as negative controls. 
To test the above observations did not reflect a lack of biological activity of the 
nicotinic acid utilised, the ability of nicotinic acid to induce ERK1/2 phosphorylation 
via the chimeric receptors was tested. Figure 5.4 B confirmed that nicotinic acid was 
able to induce ERK1/2 phosphorylation via the chimeric receptors and the lack of 
detectable internalisation of the chimeric receptors was not an artefact due to the use 
of inactive nicotinic acid. Total levels of ERK1/2, detected in parallel studies, served 
as loading controls. 
5.4.  Desensitisation studies 
In order to determine if the C-terminal region of the nicotinic acid receptors played a 
role in the desensitisation characteristics of HM74 and HM74A, nicotinic acid pre-
treatment studies similar to those detailed in chapter 4 were conducted with CHO-K1 
cell lines stably expressing the chimeric nicotinic acid receptors. 
5.4.1.  VSV-G HM74/HM74A eYFP 
A CHO-K1 cell line stably expressing VSV-G HM74/HM74A eYFP was treated with 
10 μM (Figure 5.5) or 10 mM (Figure 5.6) nicotinic acid for 0, 30, 60 minutes and 24 
hours. The selected concentrations of nicotinic acid were approximately ten times the 
estimated pEC50 value at either the host or donor receptors which formed the chimeric 
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receptor. Membrane preparations generated from these samples were then exposed to 
increasing concentrations of nicotinic acid, acifran or GSK 1 in [35S] GTPγS binding 
assays (Figures 5.5 A and 5.6 A respectively). For each of the pre-treatments, pEC50 
values for the ligands have been summarised in Figures 5.5 B and 5.6 B. In all cases, 
no significant change in the pEC50 value was observed in control and nicotinic acid 
pre-treated samples and no significant change in the maximum binding of [35S] 
GTPγS was observed. In the same study, a significant reduction in [35S] GTPγS 
binding was observed in nicotinic acid pre-treated membranes prepared from CHO-
K1 cells stably expressing wild type HM74 receptor when compared to membranes 
prepared from non-treated control cells.   
5.4.2. VSV-G HM74A/HM74 eYFP 
In a similar study, a CHO-K1 cell line stably expressing VSV-G HM74A/HM74 
eYFP was treated with 10 mM nicotinic for 0 and 24 hours. Membrane preparations 
generated from these samples were then exposed to increasing concentrations of 
nicotinic acid in [35S] GTPγS binding assays (Figure 5.7). Although no significant 
change in the pEC50 value was calculated in control and nicotinic acid pre-treated 
samples, a small reduction in [35S] GTPγS binding in samples pre-treated for 24 hours 
was observed (Figure 5.7). However this was not statistically significant. 
5.5.  Discussion 
Studies conducted in chapter 4 suggest HM74 and HM74A share many characteristics 
including nicotinic acid-induced receptor phosphorylation, a lack of β-arrestin 2 
recruitment and no detectable receptor internalisation. However, desensitisation of 
Gαi mediated signalling was only observed as a result of prolonged nicotinic acid 
exposure to HM74 but not HM74A.  
HM74 and HM74A are highly homologous, sharing 96 % identity at the protein level. 
As mentioned previously, the main structural difference between the two receptors is 
the longer C-terminal tail of HM74. As the C-terminal region of GPCRs is often 
important for receptor regulation, to test the hypothesis that the C-terminal region of 
 201 
Sanam Mustafa, 2008  
 
HM74 may play a role in the desensitisation characteristics of this receptor, ‘nicotinic 
acid receptor C-terminal tail chimeras’ were generated. 
Due to the highly homologous nature of the receptors, exchanging the C-terminal 
regions of HM74 and HM74A did not disrupt the protein folding or targeting to the 
plasma membrane. The chimeras displayed wild type characteristics of cell surface 
expression. Despite the modification in the C-terminal region of the receptors, the 
relative expression levels of the receptors did not change; VSV-G HM74A/HM74 
eYFP was expressed at a higher level than VSV-G HM74/HM74A eYFP. In cell lines 
stably expressing the original tagged receptor constructs, VSV-G HM74A eYFP was 
expressed at a higher level than VSV-G HM74 eYFP. This suggests that the protein 
domains upstream of the C-terminal region may be implicated in regulating receptor 
expression level.  
The C-terminal chimeras were generated without disturbing the predicted ligand 
binding site formed by transmembrane helices II, III and VII (Tunaru et al., 2005). 
Therefore the exchange of the C-terminal region did not change the pharmacology of 
the host receptors. Furthermore, both chimeric receptors retained their ability to 
mediate ERK1/2 phosphorylation and did not internalise in response to nicotinic acid 
treatment.  
To investigate the role of the C-terminal region of the nicotinic acid receptors in the 
regulation of these receptors, nicotinic acid pre-treatment studies were repeated with 
the CHO-K1 cell lines stably expressing the chimeric receptors. Membrane 
preparations generated from these samples were exposed to increasing concentrations 
of nicotinic acid, acifran and GSK 1 in [35S] GTPγS binding assays. In nicotinic acid 
pre-treatment studies of VSV-G HM74/HM74A eYFP, the desensitisation of HM74 
observed in chapter 4 was abolished. This suggests the C-terminal tail of HM74 may 
be implicated in the regulation of this receptor. However, when these studies were 
repeated with the VSV-G HM74A/HM74 eYFP receptor chimera the reduction in 
[35S] GTPγS binding in samples pre-treated with nicotinic acid was not significant in a 
one way analysis of variance test.  
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From the data presented for the VSV-G HM74A/HM74 eYFP receptor chimera, 
although a trend indicative of desensitisation is observed, the errors are large. In an 
ideal situation, these studies should have been repeated until satisfactory and reliable 
results were obtained. Due to time constraints this was not possible. Since the 
reduction in the maximum binding of [35S] GTPγS observed in nicotinic pre-treated 
samples was not significant, firm conclusions cannot be drawn from such data. 
Thus it can only conclude that although the C-terminal region may play a role in the 
desensitisation of HM74 it is not clear at this present time if this region is sufficient or 
crucial for desensitisation of the HM74 receptor. 
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Figure 5.1 Schematic diagram of C-terminal tail nicotinic acid receptor chimeras 
generated 
A: Alignment of HM74 and HM74A C-terminal sequences illustrating the longer C-
terminal tail of HM74. B: Schematic figure illustrating the strategy designed to 
generate ‘C-tail’ chimeras of the nicotinic acid receptors. VSV-G HM74 eYFP (B1) 
and VSV-G HM74A eYFP (B2) receptor constructs were digested with the restriction 
enzymes indicated in B1 and B2. The resulting receptor fragments were ligated to 
generate chimeric receptor constructs, VSV-G HM74/HM74A eYFP (B3) and VSV-G 
HM74A/HM74 eYFP (B4). 
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Figure 5.2 Localisation and detection of chimeric nicotinic acid receptors stably 
expressed in Flp-In CHO-K1 cells 
Flp-In CHO-K1 cells were transfected with VSV-G HM74/HM74A eYFP or VSV-G 
HM74A/HM74 eYFP cDNA and subjected to 200 μg/ml hygromycin selection. For 
each transfected cell line, cells resistant to hygromycin antibiotic selection were 
pooled and screened by fluorescence imaging utilising the eYFP tag to identify 
receptor expression (A). VSV-G epitope and eYFP tagged forms of the 
HM74/HM74A (A1) and HM74A/HM74 (A2) receptors. B: 20 μg of cell lysates 
prepared from these cells were resolved by SDS-PAGE. Proteins representing the 
chimeric receptors were detected at the expected size (66 kDa); VSV-G 
HM74/HM74A eYFP (lane 1) and VSV-G HM74A/HM74 eYFP (lane 2). C: Whole 
cell lysates prepared from these cell lines were equalised for protein concentration and 
the eYFP fluorescence was measured with a Victor2 plate reader. Negative controls of 
lysates prepared from parental CHO-K1 cells and a reading from an empty well 
(labelled blank) were also included. VSV-G HM74A/HM74 eYFP has a higher 
expression level than VSV-G HM74/HM74A eYFP. 
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Figure 5.3 Functional analysis of Flp-In CHO-K1 cell lines stably expressing chimeric 
nicotinic acid receptors 
A: A [35S] GTPγS binding assay was employed to test the response of the chimeric 
nicotinic acid receptors. The assays were terminated after 30 minutes incubation at 
room temperature by filtration of the samples onto GF/C fibre glass filters. Bound 
[35S] GTPγS was measured by liquid-scintillation spectrometry. Membrane 
preparations generated from cell lines expressing either the chimeric HM74A or 
chimeric HM74 receptor were incubated in the presence (red) and absence (blue) of 
(A1) 1 and 10 mM nicotinic acid respectively or (A2) 10 mM β-hydroxybutyrate. B: 
[35S] GTPγS binding scintillation proximity assays were employed to investigate 
native receptor pharmacology. Bound [35S] GTPγS was measured by scintillation 
counting. Nicotinic acid concentration response curves on membranes expressing 
(B1) VSV-G HM74/HM74A eYFP (estimated pEC50 = 2.8 ± 0.5) and (B2) VSV-G 
HM74A/HM74 eYFP (pEC50 = 5.9 ± 0.2) receptors. C: Acifran concentration 
response curves on membranes expressing (C1) VSV-G HM74/HM74A eYFP (pEC50 
= 4.2 ± 0.1) and (C2) VSV-G HM74A/HM74 eYFP (pEC50 = 4.6 ± 0.1) receptors. 
Data were analysed using GraphPad Prism software. Grouped data of n=3 shown. 
Data points represent means ± SEM. 
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Figure 5.4 Nicotinic acid does not internalise the chimeric receptors 
A: CHO-K1 cells stably expressing VSV-G HM74/HM74A eYFP or VSV-G 
HM74A/HM74 eYFP were incubated in the presence (red) and absence (blue) of 10 
mM nicotinic acid for 30 minutes. Cell surface expression of the chimeric receptors 
was measured in an intact cell ELISA assay utilising an anti VSV-G antibody. 
Negative controls of no primary antibody (control 1) and no primary and secondary 
antibody (control 2) were incubated in the presence (red) and absence (blue) of 10 
mM nicotinic acid. In a two-tailed t test, a p value of 0.5 was calculated in both cases; 
no significant change in cell surface expression was detected. Grouped data of n=4 
shown. Data points represent means ± SEM. B: CHO-K1 cell line stably expressing 
VSV-G HM74/HM74A eYFP (B1) or VSV-G HM74A/HM74 eYFP (B2) were 
incubated with 10 mM nicotinic acid (lane 2) for 5 minutes in an ERK1/2 
phosphorylation assay. A negative control of vehicle (lane 1) and positive control of 
10 % foetal bovine serum treatment (lane 3) was included. Cell lysates prepared from 
the samples were equalised for protein content, resolved by SDS-PAGE and 
immunoblotted with anti ERK1/2 antiserum, to determine equal loading of samples 
and an anti phospho-ERK1/2 antibody to study ERK1/2 phosphorylation. 
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Immunoblots shown are representative of at least three independent experiments. 
Nicotinic acid induced ERK1/2 phosphorylation via the chimeric receptors.
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A1 
B 
A2
A3 
10 μM nicotinic 
acid pre-
treatment (time) 
Nicotinic acid
pEC50  
Acifran 
pEC50  
GSK 1 
pEC50  
0 2.8 ± 0.5 4.2 ± 0.1 5.2 ± 0.1 
30 mins 2.2 ± 2.8 3.9 ± 0.3 5.3 ± 0.1 
60 mins 2.2 ± 1.8 4.2 ± 0.2 5.3 ± 0.2 
24 hours 2.9 ± 0.4 4.1 ± 0.2 5.0 ± 0.1 
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Figure 5.5 Nicotinic acid pre-treatment does not cause desensitisation of VSV-G 
HM74/HM74A eYFP mediated activity of Gαi  
CHO-K1 cells stably expressing VSV-G HM74/HM74A eYFP receptor were 
incubated for 24 hours, 10 μM nicotinic acid was present for  0, 30, 60 minutes and 24 
hours. Membrane preparations generated were incubated in the presence of increasing 
concentrations of nicotinic acid (A1), acifran (A2) and GSK 1 (A3) in [35S] GTPγS 
binding assays. Bound [35S] GTPγS was measured by scintillation counting. When 
compared to control samples, no significant change in the maximum binding of [35S] 
GTPγS was observed in pre-treated samples in a one way analysis of variance test. (B) 
Summary of pEC50 values. Data were analysed using GraphPad Prism software. 
Grouped data of n=3 shown. Data points represent means ± SEM. 
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A1 
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A2
A3 
10 mM nicotinic 
acid pre-
treatment (time) 
Nicotinic acid 
pEC50  
Acifran 
pEC50  
GSK 1 
pEC50  
0 2.8 ± 0.5 4.2 ± 0.1 5.2 ± 0.1 
30 mins 3.4 ± 0.3 3.7 ± 0.3 4.9 ± 0.1 
60 mins 3.0 ± 0.2 4.1 ± 0.1 5.0 ± 0.1 
24 hours 2.9 ± 0.3 3.9 ± 0.1 4.9 ± 0.1 
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Figure 5.6 Nicotinic acid pre-treatment does not cause desensitisation of VSV-G 
HM74/HM74A eYFP mediated activity of Gαi  
CHO-K1 cells stably expressing VSV-G HM74/HM74A eYFP receptor were pre-
treated with 10 mM nicotinic acid for 0, 30, 60 minutes and 24 hours. Membrane 
preparations generated were incubated in the presence of increasing concentrations of 
nicotinic acid (A1), acifran (A2) and GSK 1 (A3) in [35S] GTPγS binding assays. 
Bound [35S] GTPγS was measured by scintillation counting. When compared to 
control samples, no significant change in the maximum binding of [35S] GTPγS was 
observed in pre-treated samples in a one way analysis of variance test. (B) Summary 
of pEC50 values. Data were analysed using GraphPad Prism software. Grouped data of 
n=3 shown. Data points represent means ± SEM. 
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10 mM nicotinic 
acid pre-
treatment (time) 
Nicotinic acid 
pEC50  
0 6.2 ± 0.3 
24 hours 6.0 ± 0.4 
 
Figure 5.7 No significant reduction in the maximum binding of [35S] GTPγS observed in 
nicotinic acid pre-treated samples 
CHO-K1 cells stably expressing the VSV-G HM74A/HM74 eYFP chimeric receptor 
were pre-treated with 10 mM nicotinic acid for 0 (black) and 24 hours (green). 
Membrane preparations generated were incubated in the presence of increasing 
concentrations of nicotinic acid in [35S] GTPγS binding assays (A). Bound [35S] 
GTPγS was measured by scintillation counting. When compared to control samples, 
no significant change in nicotinic acid stimulated binding of [35S] GTPγS was 
observed in pre-treated samples (p > 0.7) in a one way analysis of variance test. (B). 
Data were analysed using GraphPad Prism software. Grouped data of n=3 shown. 
Data points represent means ± SEM. 
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6. Discussion 
For nearly 50 years nicotinic acid has been successfully prescribed by clinicians to 
prevent cardiovascular disease and its associated mortality (Altschul et al., 1955). A 
greater understanding of the roles of different lipids, especially high levels of LDL 
cholesterol and low levels of HDL cholesterol as a risk factor for cardiovascular 
disease, has fostered a new enthusiasm for nicotinic acid therapy. To date, nicotinic 
acid is the only drug on the market proven to successfully raise HDL cholesterol 
levels to higher, protective concentrations. Nicotinic acid’s molecular mechanism of 
action, however, still remains elusive. In order to address issues such as the gram 
quantities required to observe its lipid-modulating qualities and the main side effect, 
the so called ‘niacin flush’ it is critical to understand the basis by which nicotinic acid 
is able to lower total plasma levels of cholesterol and raise levels of protective lipids 
(Altschul et al., 1955; Morrow et al., 1989; Sakai et al., 2001). The recent 
identification of the nicotinic acid receptors as molecular targets for nicotinic acid has 
allowed these issues to be explored (Soga et al., 2003; Tunaru et al., 2003; Wise et al., 
2003).   
The gene encoding the high affinity nicotinic acid receptor, HM74A, is located in 
close proximity on chromosome 12 to the gene encoding its low affinity counterpart 
HM74 and to a more distantly related receptor, GPR81 (Zellner et al., 2005). 
Comparison of these homologues revealed a high degree of similarity, with HM74 
and HM74A sharing the highest homology (Zellner et al., 2005). The main structural 
difference between these receptors is the extended C-terminal tail of HM74 (Wise et 
al., 2003). As the C-terminal tail of GPCRs is often implicated in receptor regulation 
it was hypothesised that the differences in this region may result in the differential 
regulation of HM74 and HM74A. This hypothesis was tested by examining the 
regulation and desensitisation characteristics of each receptor in a heterologous 
expression system and then, based on any differences identified, the importance of the 
C-terminal region was further analysed by the use of chimeric nicotinic acid receptors, 
where the C-terminal tail of HM74 and HM74A were exchanged.   
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The tools required for this study were generated; N- and C-terminus tagged HM74 
and HM74A receptor constructs were engineered. The introduction of N- and C-
terminal tags can potentially impact receptor localisation or function, for example, by 
disrupting protein folding. In the case of the β2-adrenergic receptor, a single amino 
acid change in the C-terminal tail is sufficient to disrupt interactions with intracellular 
endocytic machinery and influence GPCR trafficking (Cao et al., 1999; Hall et al., 
1998). The possibility of generating a non-functional or ‘faulty’ protein by 
introducing both N- and C-terminal tags should not be overlooked and for this reason 
the recombinant receptors were thoroughly characterised in transient and stable 
expression systems.  
Localisation studies confirmed expression of the tagged nicotinic acid receptor 
constructs at the plasma membrane, however some intracellular expression was also 
observed. The cell surface expression pattern suggested that the N- and C-terminus 
tags did not interfere with trafficking of the receptor to the plasma membrane. The 
intracellular expression observed may be due to over-expression of the recombinant 
receptors, which is not unusual in heterologous expression systems where there is 
limited control over protein expression levels. Another possibility is that the long half-
life of the fluorescent proteins contributed to the maintained presence of the GFP 
tagged receptors within the intracellular vesicles (McLean & Milligan, 2000). 
Published studies have reported plasma membrane expression of the nicotinic acid 
receptors, however additional intracellular expression has also been observed (Tunaru 
et al., 2005; Zhang et al., 2005). Again, these studies were also utilising receptors 
tagged with fluorescent proteins in a heterologous expression system.  
The ligand binding sites of the nicotinic acid receptors is predicted to be formed by 
TM II, III and VII (Tunaru et al., 2005). Although, the N-terminal VSV-G epitope tag 
is not close to this predicted ligand binding site and studies have reported that the 
addition of N-terminal epitope tags has no effect on ligand binding, the ability of the 
modified receptors to respond to nicotinic acid was examined (Terrillon et al., 2004). 
As the C-terminal region of GPCRs are important for G protein interactions, G protein 
coupling was also assessed in this study. It was shown that the presence of the N- and 
C-terminal tags did not disrupt the pharmacological properties of the nicotinic acid 
receptors by altering the ligand binding site or preventing G protein coupling. The 
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pEC50 values determined in this study were consistent with values obtained from both 
endogenously expressed receptors and recombinant expression systems (Lorenzen et 
al., 2001; Tunaru et al., 2003; Wise et al., 2003). Recombinant nicotinic acid receptors 
displayed native pharmacology and therefore were shown to be useful and reliable 
tools to study the regulation of the nicotinic acid receptors. 
In desensitisation studies, HM74 but not HM74A displayed desensitisation as a result 
of prolonged exposure to nicotinic acid. Although, in nicotinic acid concentration 
response curves there was no change in pEC50 values estimated for membranes 
prepared from control and pre-treated cells expressing HM74, there was a significant 
reduction in the maximum binding of [35S] GTPγS. This suggested desensitisation of 
HM74 signalling. This observation was in agreement with studies conducted by Green 
and co-workers in 1992, which reported that prolonged incubation of adipocytes with 
nicotinic acid reduced sensitivity of the cells to nicotinic acid in lipolysis assays 
(Green et al., 1992). However, as these studies were published before the 
identification of the nicotinic acid receptors the mechanism behind the desensitisation 
could not be explored. Green and co-workers also confirmed the observations made in 
this study, that nicotinic acid does not induce Gαi G protein downregulation (Green et 
al., 1992). Therefore studies presented in this thesis build upon the work by Green and 
co-workers and suggests a potential role for HM74 in the reduced sensitivity 
observed. 
To examine the potential role of the C-terminal tail of HM74 in the desensitisation 
characteristics of this receptor, nicotinic acid C-terminal tail chimeras were generated; 
the C-terminal region of HM74 and HM74A receptor were exchanged. With respect 
to basic pharmacology, these receptor chimeras were shown to behave as their wild 
type counterparts. As the ligand binding site was not modified in the generation of the 
chimeric receptors a change in the basic pharmacological properties was not expected. 
With the use of a HM74A selective agonist, β-hydroxybutyrate, results obtained from 
[35S] GTPγS binding assays confirmed this. β-hydroxybutyrate was only active at the 
chimera with the HM74A N-terminal region. When nicotinic acid pre-treatment 
studies were conducted on cell lines stably expressing the HM74 receptor modified to 
possess the HM74A C-terminal region, the desensitisation of HM74 observed in 
previous studies was abolished. This suggests the C-terminal region of HM74 may be 
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implicated in the desensitisation of HM74. As no firm conclusions could be drawn 
from studies of the HM74A chimera possessing the HM74 C-terminal region, it is not 
possible to conclude whether the C-terminal region of HM74 alone is crucial for 
desensitisation or required in combination with other regions. If however, 
HM74A/HM74 C-terminal chimera was shown to desensitise a more conclusive 
observation could have been drawn. For this reason, to understand the role of the C-
terminal region in the regulation of the nicotinic acid receptors, nicotinic acid pre-
treatment studies should be repeated with this cell line. 
If the presence of the C-terminal region of HM74, results in desensitisation of 
HM74A, then in future experiments HM74A chimeras possessing truncated forms of 
the HM74 C-terminal region should be engineered and the nicotinic acid pre-
treatments studies repeated. These studies should highlight the important regions of 
the C-terminal tail. Once the crucial region has been identified, the key amino acid(s) 
can then be determined by site directed mutagenesis studies. 
The ability of nicotinic acid to stimulate ERK1/2 phosphorylation via the nicotinic 
acid receptors was examined and differential kinetics were identified. Nicotinic acid 
was able to stimulate ERK1/2 phosphorylation rapidly via HM74A and signalling was 
sustained at least until 60 minutes. However, signalling via HM74 was slower and 
more transient. The mechanisms behind these kinetic differences can be investigated 
by utilising the C-terminal chimeras. It is possible the C-terminal region of the 
nicotinic acid receptors play a role and if the characteristics of ERK1/2 
phosphorylation are switched in the chimeras then this would provide strong evidence 
for this. Key players at the amino acid level could then be identified by site-directed 
mutagenesis studies similar to those described above.  
Alternatively, if the kinetics of ERK1/2 phosphorylation remain unchanged in the 
studies utilising the chimeric receptors, then it is possible that the difference observed 
is due to the different ligand (nicotinic acid) on/off rate at each receptor. The ligand 
on/off rate at each receptor can be calculated by performing association and 
dissociation binding assays. However, due to the relatively low potency of nicotinic 
acid at both HM74 and HM74A, these experiments would require huge amounts of 
radiolabelled ligand and therefore were not considered viable. However, it can be 
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hypothesised that nicotinic acid has a slower on rate at HM74 than HM74A and 
therefore this translates as slower ERK1/2 phosphorylation via HM74. It would be 
interesting to perform ERK1/2 phosphorylation assays with acifran, which has a 
similar potency at both HM74 and HM74A. Acifran, which has been shown to 
stimulate ERK1/2 phosphorylation (Mahboubi et al., 2006), may have a similar on/off 
rate at both receptors, and therefore it can be further hypothesised similar ERK1/2 
phosphorylation kinetics. 
With the increasing interest in examining GPCR signalling at different levels of the 
downstream pathway, if time had permitted, the nicotinic acid pre-treatment studies 
described in this thesis to study receptor desensitisation would have been investigated 
with respect to ERK1/2 phosphorylation. These findings could then be compared to 
those obtained from [35S] GTPγS binding assays. It would not be inconceivable that 
prolonged nicotinic acid exposure results in desensitisation of receptor signalling in 
one pathway but not in another. Should this be the case, it would add to the many 
published reports of biased agonism or ‘agonist-directed trafficking’ (Kenakin, 1995; 
Berg et al., 1998; Backstrom et al., 1999; Richman et al., 2007). As nicotinic acid-
stimulated ERK1/2 phosphorylation was demonstrated to be G protein mediated any 
agonist bias with respect to ERK1/2 phosphorylation is likely to be post G protein 
activation. 
The regulation of the nicotinic acid receptors was investigated further by examining 
nicotinic acid-induced internalisation of both HM74 and HM74A. However, there was 
no convincing evidence of receptor internalisation or β-arrestin 2 interactions in 
response to nicotinic acid treatment.  
These findings were not consistent with published work which demonstrated nicotinic 
acid-induced internalisation of HM74A in a β-arrestin dependent fashion (Richman et 
al., 2007). Potentially these opposing findings may be related to differences in the 
experimental set up, such as cell background or species of β-arrestin utilised, or the 
possible detrimental effects of N- or C-terminal tagging of the receptors, as detailed in 
section 4.6. However, as discussed previously, these issues are unlikely to explain the 
differences. For example, by utilising wild type nicotinic acid receptors in the β-
arrestin translocation studies any detrimental effect of the C-terminal eYFP tagging on 
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the receptor/β-arrestin binding was avoided. However, β-arrestin 2 GFP did not 
translocate to the cell surface in response to nicotinic acid in cells expressing the 
unmodified receptors. Although, this observation on its own is not sufficient to 
conclude that the nicotinic acid receptors do not internalise in response to nicotinic 
acid, a lack of β-arrestin translocation is supportive of the observations made in 
various internalisation studies.  
To add value to the observations made from the β-arrestin translocation experiments, 
β-arrestin trapping experiments can also be performed. β-arrestin internalises GPCRs 
via a clathrin-dependent pathway (von Zastrow & Kobilka, 1994; Ferguson et al., 
1996). Sucrose inhibits clathrin recruitment and interferes with coated-pit formation 
and therefore endocytosis (Ashworth et al., 1995; Hansen et al., 1993). Therefore 
hypertonic concentrations of sucrose would prevent β-arrestin from internalising the 
receptor. It could be argued that the lack of translocation observed actually is a lack of 
detectable translocation and does not necessarily equate to no translocation. In the 
case that the nicotinic acid receptors only interact with β-arrestin in a rapid and 
transient fashion, experiments where high concentrations of sucrose are included 
would ‘trap’ β-arrestin at the cell surface. The use of high affinity β-arrestin mutants 
would complement this study. By introducing two mutations (R404E, R406E) into the 
amino acid sequence of β-arrestin 2, it has been shown that β-arrestin 2 gains higher 
affinity for GPCRs (Heding, 2004). If the nicotinic acid receptors interact with β-
arrestin 2 then by using the mutant protein this interaction would be more stable and 
therefore more likely to be detected. 
As mentioned previously, unpublished studies by Offermanns and co-workers have 
also failed to detect internalisation of HM74A in response to nicotinic acid. These 
studies utilised N- terminal tagged receptors in a variety of cell types including COS-7 
and CHO-K1 cell lines (personal communication, Professor S. Offermanns). This 
further supports the observations made in this thesis.  
As receptor phosphorylation can play a role in the regulation of receptor signalling, 
the ability of the nicotinic acid receptors to be phosphorylated in an agonist-dependent 
manner was examined. In both cases, an increase in receptor phosphorylation was 
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observed following nicotinic acid treatment. As agonist-dependent phosphorylation is 
often considered to be one of the first stages of β-arrestin interaction and receptor 
sequestration, at this moment the function or the downstream implication of receptor 
phosphorylation is unclear. In any case, it is possible that the nicotinic acid receptors 
can undergo dephosphorylation and therefore resensitisation at the plasma membrane, 
much like the thyrotropin-releasing hormone receptor which has been reported to 
dephosphorylate at the cell surface without the need to be internalised (Jones & 
Hinkle, 2005).  
GRK, PKA and PKC are expressed in adipocytes and therefore it was hypothesised 
they may play a role in the agonist-dependent phosphorylation of the nicotinic acid 
receptors. Through kinase inhibitor studies both PKC and PKA were implicated, to 
some degree, in HM74 but not HM74A phosphorylation. However, as PKC and PKA 
selective inhibitors failed to completely abolish nicotinic acid-induced 
phosphorylation of HM74, other kinases are anticipated to be involved. It would be 
interesting to repeat these studies with the C-tail chimeras to examine if PKC and 
PKA inhibitors have an effect on the phosphorylation of the HM74A chimera with the 
HM74 C-tail and vice versa. A note of caution should be highlighted here with respect 
to studying receptor regulation in recombinant systems (as used in this study) as 
receptors may be differentially regulated from those that are endogenously expressed. 
For example, the M3 muscarinic receptor can be differentially phosphorylated 
depending on whether it is heterologously expressed in CHO cells or endogenously 
expressed in cerebellar granule neurons (Torrecilla et al., 2007). This highlights the 
importance of studying receptor function/regulation in native cell types where 
possible. 
Due to the lack of robust tools, the role of GRKs in the phosphorylation of the 
nicotinic acid could not be investigated. Although a gene silencing approach was 
attempted, due to an inconsistency with the level of knockdown achieved from 
experiment to experiment, this approach could not be pursued.   
Although existing evidence supports the role of HM74A as the mediator of nicotinic 
acid’s lipid-modulating effects, the potential importance of HM74 can not be ignored 
(Tunaru et al., 2003; Zhang et al., 2005; Taggart et al., 2005). As mentioned in section 
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1.6, the high doses of nicotinic acid required to produce a pharmacological response 
suggest HM74 may mediate some of the anti-lipolytic effects. It has, however, been 
reported that 90 % of nicotinic acid administered is eliminated from the body as 
unchanged nicotinic acid or nicotinuric acid (Gille et al., 2008). The remaining 10 % 
has a half-life of only 20 – 45 minutes in the plasma, so there is a possibility that the 
vitamin may not be able to maintain the concentrations required to activate HM74.  
Based on current evidence, a role for HM74 in nicotinic acid-mediated lipolysis 
inhibition can not be fully ruled out. For example of the three studies reporting 
HM74A as the clinical target for nicotinic acid, two have been conducted in mouse 
model systems where there is no HM74 orthologue (Taggart et al., 2005; Tunaru et 
al., 2003). Therefore the role of HM74 could not be investigated. In studies by Zhang 
and colleagues, although it was demonstrated that nicotinic acid was unable to inhibit 
lipolysis in 3T3 L1 cells expressing human HM74 cDNA, this conclusion was drawn 
from data obtained from a heterologous expression system examining HM74 in 
isolation (Zhang et al., 2005).  
In humans, due to the presence of both HM74A and HM74, deduction of the clinical 
target is more complicated and therefore only studies conducted in native cell lines in 
a physiologically relevant context can be conclusive. For example, there is the 
possibility that an individual’s response to nicotinic acid may be dependent on which 
HM74 and HM74A haplotype they carry. At least two non-synonymous nucleotide 
changes that fall within the coding regions of HM74 have been identified (Zellner et 
al., 2005). These changes in amino acid sequence may impact receptor function. 
Studies examining receptors in isolation do not allow for these types of issues to be 
addressed. It may also be possible that HM74 requires the expression of HM74A to 
mediate anti-lipolytic effects. Given the high homology between these receptors it 
would not be surprising if they form heterodimers. It would be interesting to examine 
this by utilising co-immunoprecipitation and various biophysical techniques such as 
resonance energy transfer (RET) based methods, including fluorescence resonance 
energy transfer (FRET) and bioluminescence resonance energy transfer (BRET). RET 
based techniques are highly sensitive and enable protein-protein interactions to be 
analysed in real time, in living cells. Briefly, RET is the energy transfer from a donor 
molecule to an acceptor molecule as a result of dipole-dipole coupling in a non-
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radiative manner. In the case where the donor molecule is a fluorescent molecule, 
exposure to light of a characteristic wavelength will result in excitation and 
subsequent energy transfer is then referred to as a FRET signal. Where the donor is 
the enzyme Renilla luciferase (Rluc), oxidation of a suitable substrate releases energy 
and the resultant energy transfer to a fluorescent acceptor molecule is referred to as 
BRET signal. These RET based techniques have been summarised in Figure 6.1 
(Pfleger & Eidne, 2005). 
The physiological relevance of the desensitisation of HM74 has yet to be determined. 
At this moment it is not known if this level of desensitisation could be translated into 
a significant response in a physiological system. Although, studies by Green and co-
workers suggested reduced sensitivity of nicotinic acid pre-treated adipocytes to 
nicotinic acid, this was a measurement of lipolysis by quantification of glycerol 
release (Green et al., 1992). An examination of HDL and LDL cholesterol levels 
would be more informative and these studies would have to be conducted with the 
knowledge that HM74A does not desensitise and therefore could compensate for 
HM74. Keeping in mind the importance of endogenously expressed receptors, further 
studies, if possible, should be conducted in cells which endogenously express the 
nicotinic acid receptors, such as adipocytes or human epidermoid A431 cells (Zhou et 
al., 2007). The identification of selective agonists for HM74A and HM74 should help 
clarify the roles of each receptor in lipolysis and lipid-modulation. 
Currently, there are limited published studies highlighting GPCRs which do not 
desensitise in response to prolonged agonist exposure. However, the α2-adrenergic 
subtype α2C10, β3-adrenergic and GnRH type I receptors are examples of such 
GPCRs (Kurose & Lefkowitz, 1994; Jewell-Motz & Liggett, 1996; Liggett et al., 
1993; McArdle et al., 2002). As it is generally accepted that HM74A is likely to be 
the clinical target for nicotinic acid it will be of great interest to pharmaceutical 
companies that this receptor did not display any desensitisation characteristics 
(Tunaru et al., 2003; Zhang et al., 2005). Patients on nicotinic acid therapy develop 
tolerance to the nicotinic acid-induced flushing response, however do not develop 
tolerance to the lipid-modifying effects of this drug (Stern et al., 1991; Offermanns, 
2006). In this context, a lack of desensitisation of HM74A could begin to explain the 
lasting effects of nicotinic acid treatment. Once the mechanism(s) by which nicotinic 
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acid acts is fully understood, novel, more potent drugs which do not cause 
desensitisation or the uncomfortable flushing response may be designed. 
As expected, many pharmaceutical companies are already in the process of 
developing such compounds. Arena and Merck, for example, have reported 
compounds which have anti-lipolytic qualities but apparently do not cause the 
flushing normally associated with the use of nicotinic acid (Richman et al., 2007; 
Shen et al., 2007a; Shen et al., 2007b). Published studies by Richman and co-workers 
show these non-flushing compounds do not internalise HM74A or induce ERK1/2 
phosphorylation via this receptor (Richman et al., 2007). Recent communication 
suggests the beneficial effects of these compounds did not translate in their entirety in 
human trials (personal communication, Prof. G. Milligan). It seems the beneficial rise 
in HDL levels was not observed in humans, therefore nicotinic acid remains the only 
drug in the market capable of this.  
GlaxoSmithKline have developed similar compounds that also do not cause flushing 
(unpublished data). One such compound, a xanthine derivative (GSK 3), is a selective 
agonist at HM74A (SmithKline Beecham Corporation., 2005). GSK 3 is more potent 
than nicotinic acid in [35S] GTPγS assays of HM74A activation (Figure 6.2). Unlike 
the compounds described by Richman and co-workers, this ligand does induce 
ERK1/2 phosphorylation in a pertussis toxin-sensitive manner (Figure 6.3). GSK 3-
induced ERK1/2 phosphorylation was not as sustained as that observed with nicotinic 
acid (Figure 4.3) but could be detected at a lower level for up to 60 minutes (Figure 
6.3). Preliminary [32P] orthophosphate experiments suggest 10 μM GSK 3 is required 
to stimulate HM74A phosphorylation (Figure 6.4). However, the ability of GSK 3 to 
induce internalisation of HM74A has not been examined thus far. 
Studies by Benyo and co-workers have implicated HM74A receptors, expressed on 
Langerhans cells, as the mediators of nicotinic acid-induced flushing (Benyo et al., 
2005; Benyo et al., 2006). It is currently thought that HM74A mediates this flushing 
response via the prostanoids, especially prostaglandin D2 (PGD2), which are produced 
after nicotinic acid administration (Morrow et al., 1989; Stern et al., 1991). Merck’s 
attempt to capitalise on this knowledge and introduce Cordaptive, the brand name for 
a novel drug combining extended-release nicotinic acid and a selective prostaglandin 
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antagonist, laropiprant, has recently been rejected by the FDA. Although the reasons 
behind the rejection are not clear, it can be speculated that the use of selective 
inhibitors of prostaglandin function may result in other unknown or unwanted 
biological effects.  
Although, a lack of available tools and the low affinity of the nicotinic acid receptors 
has made the characterisation of both HM74 and HM74A difficult, the identification 
of selective agonists at either HM74 (Skinner et al., 2007a; Semple et al., 2006) or 
HM74A (Taggart et al., 2005; Skinner et al., 2007b; Shen et al., 2007a; Shen et al., 
2007b) will be beneficial for future studies. The studies described in this thesis have 
generated many tools and identified differences between HM74 and HM74A which 
can be exploited to further investigate the mechanisms by which the nicotinic acid 
receptors are regulated. 
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Figure 6.1 Diagram illustrating principles of RET based techniques 
A: FRET is the result of the energy transfer from a donor fluorophore excited with 
light at specific wavelength. B: Oxidation of coelenterazine to coelenteramide by the 
donor Rluc results in an energy transfer to a fluorescent molecule, resulting in a 
BRET signal. C: Example illustrating how the RET based techniques can be adopted 
to study dimerisation of receptors. Figure from (Pfleger & Eidne, 2005). 
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Figure 6.2 GSK 3: A novel and potent HM74A agonist that does not induce flushing 
A [35S] GTPγS binding assay was employed to compare the response of HM74A 
expressing CHO-K1 membranes to increasing concentrations of GSK 3 (black: pEC50 
= 7.1 ± 0.1) and nicotinic acid (red: pEC50 = 6.4 ± 0.2). Bound [35S] GTPγS was 
measured by liquid-scintillation spectrometry. Results are representative of three 
independent experiments. Data points represent means ± SEM. Data were analysed 
using GraphPad Prism software.  
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Figure 6.3 GSK 3 stimulated ERK1/2 phosphorylation. ERK1/2 phosphorylation was 
abolished by pertussis toxin treatment 
A: CHO-K1 cells stably expressing HM74A were serum starved and treated in the 
presence (+) and absence (-) of 25 ng/ml pertussis toxin for 16 hours at 37 oC. Cells 
were then incubated with 100 nM GSK 3 (lane 2) for 5 minutes in an ERK1/2 
phosphorylation assay. A negative control of vehicle (lane 1) and positive control of 
10 % foetal bovine serum treatment (lane 3) were included. In similar assays, cells 
were exposed to increasing concentrations of GSK 3 for 5 minutes (B) or 100 nM 
GSK 3 for varying lengths of time (minutes) (C). A negative control of vehicle (-) and 
positive control of 10 % foetal bovine serum treatment (+) was included in every 
experiment. Cell lysates prepared from the samples were equalised for protein 
content, resolved by SDS-PAGE and immunoblotted with anti ERK1/2 antiserum to 
determine equal loading of samples (42/44 kDa) and anti phospho-ERK1/2 antibody 
to study ERK1/2 phosphorylation (42/44 kDa). GSK 3 induced ERK1/2 
phosphorylation via HM74A was detected at low levels up until 60 minutes and was 
abolished by pertussis toxin treatment. 1 nM GSK 3 was sufficient to stimulate 
ERK1/2 phosphorylation. Results shown are representative of three independent 
experiments. 
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Figure 6.4 GSK 3-induced phosphorylation of VSV-G HM74A eYFP  
CHO-K1 cells stably expressing VSV-G HM74A eYFP were pre-incubated with 0.2 
mCi/ml [32P] orthophosphate for 90 minutes. Cells were incubated for 15 minutes in 
the presence of increasing concentrations of GSK 3. Control of cells treated with 
vehicle (-) were also included. Cell lysates were prepared and equalised for protein 
content and volume before immunoprecipitating with an anti VSV-G antiserum to 
isolate the receptor. A: Samples were resolved by SDS-PAGE and phospho-proteins 
visualised by autoradiography. B: Quantification of signal intensity represented as per 
cent phosphorylation over basal. VSV-G HM74A eYFP was phosphorylated by 10 
μM GSK 3. Results are representative of three independent experiments. 
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